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Abstract 
Background 
Present study deals with development of an oral controlled release system to deliver anti-
angina drug “nicorandil” at predetermined and reproducible rate over a desired period of 
time. To achieve these goal different crosslink polymeric networks were formulated and 
their competence of delivering drug at predefined rate over desired period was evaluated. 
Objective 
The basic purpose of study was to formulate and evaluate such oral drug delivery system 
for anti-angina drug “nicorandil” which can deliver drug at desired sustained rate. As 
nicorandil has shorter elimination half-life of 1 hour so that frequent daily dosing can be 
replaced with once sustained dose. 
Experimental design and methods 
Free radical solution polymerization technique was used to prepared pH sensitive crosslink 
polymeric networks using different polymer, monomer and crosslinker concentrations. 
Four different combinations i.e. HEMA-co-AA, HPMC-co-AA, HPMC-co-AA-co-HEMA 
and CMC-co-MAA-co-AMPS hydrogels were developed and their responsiveness to 
buffer solutions of different pH i.e. pH 1.2, pH5.8 and pH 7.4 was evaluated. Crosslinking 
structure of all formulations were confirmed by FTIR, XRD and SEM. For thermal 
stability formulations were also subjected to TGA and DSC studies. In-vitro drug release 
studies of all formulations were conducted moreover in-vivo evaluation of the best 
formulations was also performed. 
Results 
HEMA-co-AA hydrogels were prepared by using MBA as crosslinker. HEMA-co-AA 
hydrogels showed pH responsiveness as they showed maximum swelling at pH 7.4 as 
compared to pH 1.2. This property was used as a key factor to design sustained release 
 xxv 
 
drug delivery system that deliver drug in gastrointestinal tract in response of different pH 
environment. Among combination HEMA-co-AA hydrogels F1 was found to be the best 
as it showed maximum cumulative drug release i.e. 92.878% at pH 7.4. Desired release 
profile was noticed to be greatly affected by varying concentrations of polymer, monomer 
or crosslinker.  
HPMC-co-AA hydrogels had good pH sensitivity as these showed better and maximum 
swelling at pH 7.4 and minimum swelling at pH 1.2. Among this combination F1 depicted 
better desired properties regarding pH sensitivity, greater swelling ratio and desired 
sustained drug release profile etc. Swelling ratio, gel fraction and cumulative percent drug 
release was noted to be decreased with increasing crosslinker concentration i.e. MBA 
while these parameters were noted to be increased with increasing AA and HPMC 
concentrations. Desired sustained release profile could be attained by adjusting polymer, 
monomer and crosslinker ratio. 
HPMC-co-AA-co-HEMA hydrogels were developed by free radical polymerization 
technique using MBA as crosslinker. Formulations were subjected to swelling (at pH 1.2, 
pH 5.8 and pH 7.4) and in-vitro drug release studies (at pH 1.2 and pH 7.4). Swelling and 
percent drug release was noted to be decreased with increasing MBA and HEMA 
concentration while it was noted to be increased with increasing AA and HPMC 
concentrations. More over swelling ratio and percent drug release was also increased 
gradually with increasing pH from acidic to alkaline i.e. pH 1.2 to pH 7.4. All 
formulations were noted to be stable and intact during swelling and in-vitro drug release 
studies. Among this combination F24 was found to be the best as it gave best results for 
swelling and cumulative percent drug release i.e. 82.820%. It also showed better 
pharmacokinetic profile as well. 
Developed CMC-co-MAA-co-AMPS showed less pH sensitivity as compared to all other 
three combinations as difference in swelling ratio and cumulative percent drug release at 
acidic and alkaline pH was negligible. Formulations were noted to be unstable and broken 
during swelling and in-vitro drug release studies. 
 xxvi 
 
HEMA-co-AA (F1), HPMC-co-AA (F12) and HPMC-co-AA-co-HEMA (F24) hydrogels 
were selected for in-vivo evaluation using animal model rabbits as these showed better in-
vitro sustained drug release profile. After oral administration of these formulations Cmax 
was noted to be 60.608 ± 2.816 ng/mL, 108.388 ± 2.338 ng/mL and 92.322 ± 3.667 ng/mL 
respectively. MRT was noted to be 12.790 ± 0.310 hrs, 13.1786 ± 0.468 hrs and 13.600 ± 
0.245 hrs for HEMA-co-AA (F1), HPMC-co-AA (F12) and HPMC-co-AA-co-HEMA 
(F24) hydrogels. On behalf of these in-vivo findings it can be concluded that these 
crosslink polymeric networks can be used as good sustain release drug delivery system. 
Conclusion 
From results of present study it could be concluded that among four different crosslink 
polymeric networks prepared, HPMC-co-AA (F12) hydrogel could be considered as 
superior as it gave better in vitro/in vivo release profile and thus proven suitable for 
desired sustained release effect at predetermined rate over prolong period of time. 
However these findings are preliminary and studies can proceed to further investigations. 
Key Words: Hydrogel, Nicorandil, Polymeric networks, Crosslinker, Monomer, 
Swelling ratio, In vitro and in vivo evaluation 
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1.0. Introduction 
Polymers have become marvelous icon of interest in many areas, such as the 
pharmaceutical industry, therapeutic innovation and others. Spreads in polymer science 
have open new gates to expansion of novel drug delivery systems (Veeran and Guru, 
2011). Advances in polymers impart unique properties of interest to carrier system. Both 
natural and synthetic polymers are stand-in an auspicious tool for drug delivery, 
especially in oral administration therapeutic drugs having challenging issues like poor 
absorption or short half-life etc. (Chandel et al., 2013). Because of unique properties like 
compatibility, degradation and nontoxic behavior of bio-composite polymers, these are 
becoming a tool of tremendous interest for controlled drug delivery. By suitable physical 
or chemical modification in polymers, properties of interest can be attained or enhanced 
(Sonia and Sharma, 2011). 
Among polymers, natural ones are of enormous custom for manhood, as natural polymers 
offer attractive properties of interest and desired attributes (viz. low density, mechanical 
properties) (Ashish and Balbir, 2012). On earth cellulose (a polydispersed, linear 
homopolymer composed of D-glucopyranose units, linked together by β-(1→4) 
glycosidic bonds) as natural polymer is the utmost plentiful renewable polymer (Gilberto 
et al., 2010), offering enormous striking physical and chemical attributes like 
biodegradability, biocompatibility, stereo regularity, hydrophilicity, reactive hydroxyl 
groups and ability to form supra structures (Heinze and Liebert, 2001). Cellulose and 
cellulose derivatives have many uses in different areas such as fibers, films, coatings, 
laminates, optical films and sorption media, additives, building materials, 
pharmaceuticals, foodstuffs and cosmetics (Dieter et al., 2005). 
As far as water soluble polymers are concerned they dissolve, disperse or swell in water 
providing base to alter the physical properties of aqueous systems as gelation, thickening 
or emulsification/stabilization. These polymers are usually constituted from repeating 
units or blocks of units of hydrophilic groups those are substituted or attached the basic 
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backbone of structure. These hydrophilic groups could possess nonionic, anionic, cationic 
or amphoteric properties (Veeran and Guru, 2011). 
In view of health related dysfunctions, reaching drug at site of action in appropriate 
concentration over a sufficiently prolong period of time is the main task. But the action of 
pharmaceutical agents is confined by enormous factors including degradation of agent, 
interaction with cells and inability to infiltrate tissues. These facts provide the basic to 
develop carrier systems of higher interest with desired profile as these systems act as 
right tool for time and distribution controlled drug delivery (Gemma et al., 2012). For 
oral controlled release drug delivery systems hydrophilic gel forming polymeric systems 
are in extensive use to acquire an anticipated drug release profile, cost effectiveness and 
broad regulatory acceptance (Kamel et al., 2008). Hydroxypropylmethylcellouse 
(HPMC) and sodium carboxymethylcellulose (CMC) are hydrophilic polymers attaining 
prominence in this regard as these approaches anticipated attributes of an ideal polymer. 
More over both hydrophilic and hydrophobic variants with different viscosity grades are 
also available making them more and more suitable candidate for desired release profile 
(Kajal et al., 2011). 
This polymeric area invites various modifications in properties of polymer viz. blending, 
grafting and curing to achieve targeted action. Among these graft copolymers have been 
extensively used to formulate a number of controlled release systems like hydrogels, 
microspheres or matrix tablets etc. „Grafting‟ refers to a technique in which monomers 
are covalently bonded (modified) onto the polymer chain. Graft copolymerization mends 
the properties of polymers to stretch them a new anticipated property. These are gaining 
great attention in various areas like dyeing, printing, fiber strength, chemical resistance, 
water repellency, crease resistance and abrasion resistance etc. (Susheel et al., 2011). On 
grafting, host polymer/monomer advances to looked-for properties. These grafted 
copolymeric systems are of inordinate status to mature into various stimuli-dependent 
controlled release systems such as pH sensitive hydrogels (Sabyasachi et al., 2010). 
Nicorandil, a nicotinamide derivative is an efficacious remedy in management of 
hypertension and angina pectoris. As a potassium channel opener it causes vasodilatation 
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of arterioles and large coronary arteries. Venous vasodilatation is attributed to its nitrate 
component. Chemically it has its place to organic nitrate groups. Nitrate moiety is 
considered responsible for its pharmacologic activities as it stimulates production of 
cyclic GMP in smooth muscle cells causing vasodilatation (Kukovetz and Holzmann, 
1987). Opening of ATP sensitive K
+
 channels attribute to dilatation of peripheral and 
coronary resistant arterioles. Moreover, it encompasses NO2 group, responsible for 
dilation of systemic veins and epicardial coronary arteries (Markham et al., 2000). 
The study was planned to appraise graft polymeric carrier systems for sustained or 
controlled delivery of potassium channel opener “Nicorandil”. With an elimination half-
life of almost 1 hour it is a likely agent for development of controlled release 
formulations for treatment of hypertension and angina pectoris. Nicorandil is available in 
tablet form having dose 5 to 40 mg twice daily. To lessen frequency of administration 
and to improve patient compliance, once daily sustained release formulation of nicorandil 
is anticipated. With all these obvious truths Nicorandil is an appropriate applicant for 
development of controlled release dosage form. As study was proposed to account for the 
pharmaceutical features of nicorandil with superior emphasis on its suitable delivery 
system, cellulose based graft copolymeric system using different concentrations have 
been achieved with looked for controlled release of nicorandil. 
Whole work flow chart has been given on the next page. 
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2.0 Literature Review 
2.1 Introduction of polymers 
Polymeric hydrogels have captured great attention of researchers in view of their 
biocompatibility (Jun et al., 2003). Highly swelling hydrogels and polymers being three 
dimensional networks are capable of absorbing large amounts of water as compared to 
their dry weight. Depending upon the structure of final product and nature of 
components, hydrogels can absorb water ranging from 10 % to thousands of times of 
their dry weight (Mohammad, 2010). Modification of natural polymers by using various 
means like grafting of polymer has become of great importance. Copolymerization of 
natural polymers with variety of monomers is useful in achieving final formulation with 
desired and different physicochemical properties as that of individual components. Many 
natural polymers like chitin, cellulose, functionalized cellulose; hydroxypropyl methyl 
cellulose, methyl cellulose and other natural fibers are frequently studied for graft 
copolymer by using redox system as initiator. 
2.2 Cellulose 
Cellulose an organic compound having formula (C6H10O5)n is actually a polysaccharide. 
Cellulose is composed of β (1→4) linked D-glucose repeated units linked together in 
linear fashion from hundreds to thousands (Updegraff, 1969). Being the most abundant 
organic polymer on earth (Klemm et al., 2005) it is found as primary cell wall component 
of green plants, present in many forms of algae, accounts for 90% of cotton fibers, 40-
50% of wood and 45% of dried hemp. 
2.2.1 History 
Cellulose first isolated from plant matter was discovered by a French chemist Anselme 
Payen. He also discovered its chemical formula (Payen, 1838). Celluloid was first 
thermoplastic polymer successfully produced from cellulose by Hyatt Manufacturing 
Company in 1870.  Later on in 1890 and 1912 two derivatives rayon and cellophane was 
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produced, respectively (Kobayashi et al., 1992). Structure of plant cell wall illustrating 
arrangement of cellulose and other poly saccharide is given in figure 2.1. 
 
Figure 2.1. Arrangement of cellulose and other polysaccharide in plant cell wall 
(http://en.wikipedia.org/wiki/Cellulose) 
2.2.2 Physicochemical properties 
Cellulose is tasteless, odorless hydrophilic compound, insoluble in water and most of 
organic solvents. It is biodegradable in nature. With the help of acids at high temperature, 
chemically it can be converted into glucose units. 
2.2.3 Structure 
Structure of cellulose is given in figure 2.2. 
 
Figure 2.2. Structure of cellulose 
 
http://en.wikipedia.org/wiki/Cellulose 
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Cellulose consisting of β (1→4) linked D-glucose units is a straight chain polymer. It has 
no coiling or branching, rather extended stiff rod-like conformation is found. Hydroxyl 
groups present on one chain shows hydrogen bonding with oxygen atoms present on 
same chain or other chain resulting in micro fibrils with high tensile strength. A 
temperature of 320°C and 25 MPa pressure is required for conversion of cellulose into 
amorphous state in water (Deguchi et al., 2006).  
On the bases of presence of hydrogen bonding between and within strands, various 
crystalline structures of cellulose are recognized. Natural cellulose is referred as cellulose 
I. It contains Iα and Iβ strands. Bacterial cellulose is augmented in Iα while higher plants 
cellulose mainly contains Iβ. Cellulose I can be converted into cellulose II. Similarly, 
cellulose III and cellulose IV are also reported at different conditions of temperature and 
pressure (Sherif, 2014). 
Many properties of cellulose are attributed by various factors like chain length, degree of 
polymerization and number of glucose units etc. e.g. 300 and 1700 units are 
characteristics of wood pulp while cotton, plant fibers and bacterial cellulose have 800 to 
10,000 units (Klemm et al., 2005). Break down of cellulose into very small chain lengths 
results in structures referred cellodextrins. These are soluble in water and organic 
solvents as compared to long-chain cellulose. 
Cellulose that is derived from plants is typically present in a mixture with pectin, lignin, 
hemicellulose   and other substances. As far as bacterial cellulose is concerned it is quite 
pure, with greater water content and tensile strength attributed to longer chain lengths 
(Klemm et al., 2005). 
Cellulose contains crystalline and amorphous regions. Upon treating with strong acids, 
breakdown of amorphous region takes place resulting in nanocrystalline cellulose. 
Nanocrystalline cellulose is a novel material having looked-for attributes (Peng et al., 
2011). 
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2.2.4 Derivatives 
Upon reaction with various reagents, hydroxyl groups (-OH) of cellulose reacts partially 
or fully and produce various derivatives having desired properties. For example many 
types of cellulose esters and cellulose ethers (-OR) are produced in this way. 
Among ester derivatives cellulose acetate and cellulose triacetate are film forming 
derivatives with numerous uses. Nitrocellulose is regarded as early film forming 
substantial and used as an explosive. 
Table 2.1. Ester derivatives 
Cellulose ester Example Functional Group “R” 
Organic esters Cellulose triacetate  -(C=O)CH3   
 Cellulose acetate H or -(C=O)CH3 
 Cellulose propionate H or -(C=O)CH2CH3 
 Cellulose acetate butyrate (CAB) 
H or -(C=O)CH3 or -
(C=O)CH2CH2CH3 
 
Cellulose acetate propionate 
(CAP) 
H or -(C=O)CH3 or -
(C=O)CH2CH3 
Inorganic esters Cellulose sulfate H or -SO3H 
 Nitrocellulose (cellulose nitrate) H or -NO2 
Table 2.2. Ether derivatives 
Cellulose ethers Example Functional Group “R” = H or 
Alkyl Ethyl cellulose -CH2CH3 
 Methylcellulose -CH3 
 Ethyl methyl cellulose -CH3 or -CH2CH3 
Hydroxyalkyl Hydroxypropyl cellulose (HPC) -CH2CH(OH)CH3 
 Hydroxyethyl cellulose -CH2CH2OH 
 Hydroxyethyl methyl cellulose -CH3 or -CH2CH2OH 
 Ethyl hydroxyethyl cellulose -CH2CH3 or—CH2CH2OH 
 
Hydroxypropyl methyl cellulose 
(HPMC) 
-CH3 or -CH2CH(OH)CH3 
Carboxyalkyl Carboxymethyl cellulose (CMC) -CH2COOH 
http://en.wikipedia.org/wiki/Cellulose 
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2.2.5 Applications 
i. Paper products: Paper, card stock and paper board are mainly obtained from 
cellulose. 
ii. Fibers: Cellulose is main constituent of linen and cotton textile industry. From it 
―rayon‖ can also be produced which is an important fiber for textile since start of 
20th century. 
iii. Consumables: A lot of uses of cellulose are found in pharmaceutical industry. In 
tablet manufacturing powdered cellulose (E460ii) and microcrystalline 
cellulose (E460i) are consumed as inactive fillers. Cellulose also has its role as 
thickener and stabilizer in processed food industry. Some cellulose powders are 
used to prevent caking inside package. 
iv. Science: In research labs cellulose has many uses like stationary phase for (TLC) 
thin layer chromatography, filtration media either in combination with 
diatomaceous earth or alone, fillers, thickening agent and preservative etc. 
v. Building material: Environment friendly building insulation obtained from 
recycling of paper is becoming popular. Cellulose materials which are alternative 
of plastics and resins and offer water and fire resistance are also becoming 
popular as these possess sufficient strength too. 
vi. Miscellaneous: Thin transparent film cellophane can be made from cellulose. 
Nitrocellulose consumed as smokeless gunpowder, as base of photographic 
material celluloid, water soluble adhesives and binders come under some of its 
miscellaneous applications. 
2.3 Graft Polymers  
Graft copolymers are basically segmented copolymers residing linear back bone of one 
configuration and arbitrarily dispersed branches of other composite as represented in 
10 
 
figure 2.3. Grafted side chain though structurally different from main chain could be 
homopolymer/s or copolymer/s. 
 
Figure 2.3. Graft copolymer 
http://en.wikipedia.org/wiki/Graft_polymer 
2.3.1 General properties 
Being branched copolymer, graft copolymers are capable to form wormlike conformation 
and thus possessing confined and fit structures. Use of graft copolymers has its roots 
decade behinds. Various methods of preparation can be used to acquire various desired 
properties. They can be used in production of impact resistant materials, as 
compatibilizers or emulsifiers for stable blends or alloys and as thermoplastics elastomers 
(McNaught and Wilkinson, 1996). Grafting of copolymer generally results in more 
thermostable materials than that of their respective homopolymers (Jenkins et al., 1996). 
2.3.2 Methods of preparation 
Three different methods have been reported for preparation of graft copolymers as 
depicted diagrammatically in figure 2.3 i.e. 
a) Grafting onto 
b) Grafting from 
c) Grafting through 
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Figure 2.4. Grafting onto (top left), Grafting from (middle right), Grafting through 
(bottom left) and their generalized reaction scheme 
2.3.2.1 Grafting onto 
This method involves use of such backbone chain which bears functional groups ―A‖. 
These functional groups have random distribution along chain. When functional groups 
present on main backbone and end groups of branches undergo coupling reaction graft 
polymer originates. These coupling reactions can be induced by chemical modification of 
backbone by various reaction mechanisms like atom-transfer radical-polymerization, 
free-radical polymerization, anionic polymerization and living polymerization. Grafting 
onto method usually use anionic polymerization technique. Without generation of 
reactive groups on polymer backbone this method could not be possible. 
2.3.2.2 Grafting from 
In this method macromolecular backbone is subjected to chemical modification to 
produce active sites which are capable of initiating functionality. These initiating sites 
can be incorporated in a post polymerization reaction or can previously be a portion of 
polymer backbone. Though number of branches along backbone can be controlled by 
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number of active sites along backbone but length of each chain may be different 
depending upon kinetic and steric hindrance effects. For grafting from synthesis of 
polymers various techniques like cationic grafting, anionic grafting, free radical 
polymerization and atom transfer radical-polymerization are employed.  
2.3.2.3 Grafting through 
To synthesize graft copolymer, monomer with lower molecular weight is copolymerized 
with macromonomer having an acrylate functionalized group using free radicals 
polymerization technique. Number of grafted chains is determined by aspects like ratio of 
monomer to macromonomer molar concentrations and copolymerization behavior. With 
change in concentrations of monomer to macro-monomer, random placement of branches 
occurs. Addition of these branches could be either heterogonous or homogenous 
depending upon reactivity ratio of terminal functional group to monomer (Koichi et al., 
1985). Though this method can utilizes any of known polymerization technique but living 
polymerization offers good control over the molecular weight and weight distribution. 
2.3.3 Approaches of synthesis  
For synthesis of graft copolymers, different approaches are there. These include; 
a) Ring-opening metathesis polymerization (ROMP) 
b) Atom transfer radical polymerization (ATRP) 
c) Free radical living polymerization (FRLP) 
d) Anionic and cationic polymerizations (ACP) 
Some less common polymerization include; 
a) Ring-opening olefin metathesis polymerization 
b) Radiation-induced polymerization 
c) Polycondensation reactions (Bellas and Rehahn, 2007).  
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2.3.4 Types of copolymers 
As copolymers are composed of at least two different types of structural units, these can 
be classified on the basis of arrangement of these units (Jenkins et al., 1996). Some 
important types are listed below: 
a. Alternating copolymers: These have regular repeating alternative units e.g., A-
B-A-B-A-B-A-B-A-B. 
b. Periodic copolymers: In this type structural units are present in repeated 
sequence e.g., (A-B-A-B-B-A-A-A-A-B-B-B)n 
c. Statistical copolymers: In this type, structural units follow a statistical rule for 
sequence i.e., probability of presence of any type of monomer on a typical point 
of main chain is equal to mole fraction of that monomer. Thus units are randomly 
arranged and referred as truly random copolymer. 
d. Block copolymers: These consist of two or more homopolymer units which are 
linked together by covalent bonds. There may be an intermediate non-repeating 
subunit, which is referred as a junction block. If block polymers have two distinct 
blocks then it is referred as di-block and if it possesses three then referred as tri-
block copolymers. 
On the bases of existence of or arrangement of branches, these can also be classified 
as; 
a. Linear copolymers: It comprises of a single main chain. 
b. Terpolymer: It comprises of three distinct monomers. (Origin, Latin word “ter‖ 
meaning thrice) 
c. Branched copolymers: It comprises of a single main chain having one or more 
polymeric side chains. Other special types of branched copolymers include:  
 Star copolymers 
 Brush copolymers 
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 Comb copolymers 
2.3.5 Applications of graft copolymers in pharmaceutical industry 
Due to unique structure of graft copolymers as compared to copolymers, these have 
various applications in pharmaceutical industry. 
Common applications include: 
 Membranes for the separation of gases or liquids 
 Polymeric emulsifiers 
 Drug deliverers 
 Thermoplastic elastomers 
 Hydrogels 
 Compatibilizers for polymer blend 
2.4 Gel 
Gel was first made by Thomas Graham, Scottish chemist in 19th-century. According to 
IUPAC definition of gel it is non-fluid colloidal network which enlarges throughout its 
entire volume by a fluid. Gel can be described as jelly like solid material which covers 
properties of soft and weak to hard and tough materials. Gels are considerably 
dilute crosslink system presenting no flow in steady state. It is crosslinking structure 
within gel that imparts hardness (Sing, 1985). 
2.4.1 Types of gels 
Following are some important types of gels 
 Hydrogels 
 Organogels 
 Xerogels 
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2.4.2 Hydrogels 
2.4.2.1 Introduction 
Term hydrogel was first described in 1894. Hydrogels are hydrophilic polymeric chains 
network often found in colloidal gel where water acts as dispersion medium (Enas et al., 
2013). Over the years, researcher has used many days to define hydrogels. Most common 
definition of hydrogel is that it is water swollen polymeric crosslink network simply 
formed by reaction of one or more monomers. In other way it can be defined as 
polymeric network capable to swell and hold ample portion of water but importantly will 
not dissolve in water. Over past 50 years, hydrogels have gained considerable attention 
because of their wide range of applications (Brannon and Harland, 1991; Yuhui et al., 
2013).  Hydrogels are highly absorbent in nature and can hold over 90% of water which 
possess degree of flexibility near to natural tissues (Peppas and Khare, 1993). 
Water absorption ability of hydrogels can be attributed to hydrophilic functional groups 
present on polymeric backbone while their resistance to dissolution is attributed to 
crosslinking between polymeric network chains. Both naturally occurring and synthetic 
materials fit definition of hydrogels. During past two decades, synthetic hydrogels have 
replaced natural Hydrogels because of their various preferable quality attributes like 
longer service life, greater water absorption capacity and greater gel strength. Actually 
synthetic polymers possess well defined polymer network structures that can be modified 
to attain desired degradation and functional profile. Moreover, synthetic hydrogels are 
stable over sharp and strong variations of temperatures. 
Now a days hydrogels fit definition of two or multi component systems containing three-
dimensional polymer network and water which fills spaces present between 
macromolecules. On the basis of polymer properties and nature and density of network 
joints, hydrogels can retain various amounts of water. In swollen state this water 
absorption and retention capacity is greater as compared to non-swollen state. Water 
soluble polymers are preferable for synthesis of synthetic hydrogels. Hydrogels can 
contain chemical crosslink via covalent bonds, physically crosslinking via non-covalent 
interactions or may contain combination of both. Its water retaining capacity can be 
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attributed to capillaries action or osmotic and hydration forces created by polymer chain 
network (Roorda et al., 1986). 
Various ―classical‖ chemical ways to synthesize hydrogels are there. One way involves 
one-step procedures i.e. polymerization with parallel crosslinking of multifunctional 
monomers. Other way involves multiple step procedures which involve synthesis of 
polymer molecules with reactive groups and then their subsequent crosslinking usually 
by suitable crosslinking agents. By synthetic hydro gels good controlled over desired 
properties like biodegradation, mechanical strength and response to chemical/biological 
stimuli can be attained (Sina et al., 2007). 
2.4.2.2 Classification 
Hydrogels can be classified in different ways detailed below: 
a) Classification based on source 
Hydrogels can be classified on the bases of source of constituent polymer/monomer as; 
 Natural hydrogels, consisting of natural polymers/monomer 
 Synthetic hydrogels, containing synthetic polymer/monomer 
 Hybrid hydrogels, having combination of both natural and synthetic 
polymer/monomer (Zhao et al., 2013). 
b) Classification according to polymeric composition 
On the bases of polymeric composition, hydrogels can be classified as: 
i. Homopolymer hydrogels: Polymeric network arisen from single species of 
monomer is referred as homopolymers. It is basic structural unit of any polymer 
network. Structure of crosslink network depends upon factors like nature of 
monomer and polymerization technique (Takashi et al., 2007). 
ii. Copolymer hydrogel: These consist of two or more different monomers having 
at least one hydrophilic component. These are arranged randomly or in blocks or 
alternating configuration along polymer backbone (Yang et al., 2002). 
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iii. Multipolymer Interpenetrating polymeric hydrogel (IPN): These consist of 
two independent crosslink synthetic and/or natural polymer networks. In case of 
semi-IPN, one polymer is a crosslink and other is a noncrosslink (Maolin et al., 
2000). 
c) Classification based on configuration 
On the basis of physical or chemical composition, hydrogels can be classified as follows: 
i. Amorphous (non-crystalline) 
ii. Semi-crystalline (combination of amorphous and crystalline states) 
iii. Crystalline 
d) Classification based on type of crosslinking 
On the bases of nature of crosslinking, hydrogels can be classified into two classes. 
i. Chemically crosslink hydrogels: having permanent network junctions 
ii. Physical crosslink hydrogels: having transient network junctions arising from 
either polymer chain entanglements or physical interactions. 
e) Classification based on physical appearance 
By virtue of technique of polymerization, hydrogels could appear as matrix, film or 
microsphere. 
f) Classification according to network electrical charge 
By virtue of presence or absence of electrical charge, hydrogels can be classified as; 
i. Nonionic (neutral) 
ii. Ionic (anionic or cationic) 
iii. Amphoteric electrolyte (containing both acidic and basic groups) 
iv. Zwitterionic (having both anionic and cationic groups in each structural repeating 
unit) 
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2.4.2.3 Hydrogel product sensitive to environmental conditions 
Being three dimensional crosslink structure, hydrogels can swell or deswell in water 
reversibly and in swollen state can entrap large volume of water. Hydrogels can be 
designed in such a way that their responsiveness to change in external environment can 
be controlled by reversible swelling and deswelling. There is variety of physical and 
chemical stimuli in response to which hydrogels show dramatic volume transition. 
Among physical stimuli there is temperature, pressure, electric or magnetic field, light 
and sound. While solvent composition, pH, ionic strength and molecular species enlisted 
under chemical stimuli (Jinsub et al., 2010). Response of hydrogels to various stimuli is 
represented in figure 2.5. 
 
 
Figure 2.5. Response of hydrogel to various stimuli 
Synthetic hydrogels have gained great attention in research field from last four decades 
and still is of great focus. 
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2.4.2.4 Uses of hydrogel products 
First synthetic hydrogel was formulated by Wichterle and Lim in 1954 (Wichterle and 
Lim, 1960) after that hydrogel found their application in many field, like; 
 Hygienic products (Singh et al., 2010) 
 Agriculture (Amulya, 2010) 
 Drug delivery systems (Mehrdad et al., 2009) and sealing (Singh et al., 2010) 
 Coal dewatering (Sun et al., 2002) 
 Artificial snow (Singh et al., 2010) 
 Food additives (Chen et al., 1995). 
  Pharmaceuticals (Kashyap et al., 2005) 
 Biomedical applications (Sachiko et al., 2008; Dimitrios et al., 2008) 
 Tissue engineering and regenerative medicines (Ling et al., 20011) 
 Diagnostics (Van et al., 2003) 
 Wound dressing (Panprung et al., 2011) 
 Separation of biomolecules or cells (Feng et al., 2010) 
 Barrier materials to regulate biological adhesions (Debashish et al., 2010) 
 Biosensor (Peter et al., 2009) 
2.4.2.5 Techniques adopted in hydrogel preparation 
Both natural and synthetic polymers can be used for preparation of hydrogels. Synthetic 
polymers are chemically stronger compared to natural polymers and possess greater 
mechanical strength but results in slow degradation (Tabata, 2009). So optimal designed 
should be preferred by using either natural or synthetic polymers with suitable functional 
groups (Shantha and Harding, 2002). 
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As hydrogel is a hydrophilic polymeric crosslink network, so any method that can create 
crosslink network can be employed to formulate hydrogel. Most commonly 
copolymerization/crosslinking free-radical polymerizations are used.  
Various polymerization approaches listed as below: 
1. Chemical reaction polymerization 
2. Radiation polymerization 
3. Physical interactions like entanglements and electrostatics 
For the formation of gel, any polymerization techniques can be used including bulk, 
solution and suspension polymerization. 
Generally, hydrogel preparation involves three integral components i.e. monomer, 
initiator, and crosslinker. Various types of diluents like water or other aqueous solutions 
are employed to have control over heat of polymerization and final hydrogels properties. 
Process impurities including non-reacted monomer, initiators, crosslinkers, and unwanted 
products needed to be washed. General representation of hydrogel preparation is shown 
in figures 2.6. 
 
Figure 2.6. General method of hydrogel preparation 
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Acrylamide, acrylic acid and its salts based hydrogels were prepared by inverse-
suspension polymerization (Raju and Raju, 2001). Solution polymerization of highly 
concentrated acrylic monomers solution was prepared (Takeda and Taniguchi, 1985). In 
2000 Chen formulated acrylic acid sodium acrylate superabsorbent hydrogels via 
concentrated solution polymerization technique (Chen and Zhao, 2000). 
Major polymerization methods have been stated below: 
a) Bulk polymerization 
One or more types of monomers can be employed for bulk hydrogel preparation. Wide 
variety of monomers is available to form a range of hydrogel with desired profile. For 
hydrogel preparation usually very small amounts of crosslinkers are needed. 
Polymerization can be initiated with ultraviolet radiation or chemical catalysts. Selection 
of appropriate initiator depends upon type of monomers and solvents being employed. 
Polymerized hydrogel can be prepared in the form of films, membranes, particles, rods 
and emulsions. 
It is regarded as one of the simplest technique involving monomer and monomer soluble 
initiators. As concentration of monomer/s increases rate of polymerization increases 
while viscosity increases with conversion that generates heat. The problem can be 
overcome by continuing reaction at low conversion rates (Kiatkamjornwong et al., 2007). 
As a result of bulk polymerization, homogenous glassy, transparent and hard hydrogels 
are produced which swell in water resulting in soft and flexible product. 
b) Solution polymerization 
In solution copolymerization/crosslinking reactions, the ionic or neutral monomers are 
mixed with multifunctional crosslinking agent. The polymerization is initiated thermally 
by UV-irradiation or by a redox initiator system. The presence of solvent serving as a 
heat sink is the major advantage of the solution polymerization over the bulk 
polymerization. The prepared hydrogels need to be washed with distilled water to remove 
the monomers, oligomers, crosslinking agent, the initiator, the soluble and extractable 
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polymer, and other impurities. Phase separation occurs and the heterogeneous hydrogel is 
formed when the amount of water during polymerization is more than the water content 
corresponding to the equilibrium swelling. 
Typical solvents used for solution polymerization of hydrogels include water, ethanol, 
water–ethanol mixtures, and benzyl alcohol. The synthesized solvent may then be 
removed after formation of the gel by swelling hydrogels in water. 
c) Suspension polymerization 
It is an advantageous method as products are obtained in the form of powder or 
microspheres (beads) where no grinding is needed. In this method, dispersion of 
monomers and initiator in the hydrocarbon phase is formed as a homogenous mixture. In 
this technique particle size depends upon various factors like viscosity of monomer 
solution, rotor design, agitation speed and dispersant type (Tomonari et al., 2006). 
d) Grafting to a support 
In this method free radicals are generated on the surface of stronger support, then chain of 
monomers are covalently attached on this surface. Thus, mechanical properties of 
hydrogel are improved. Various types of polymer supports are employed for the synthesis 
of hydrogel by this method (Talaat et al., 2008; Tong and Zhang, 2005) 
e) Polymerization by irradiation 
High energy radiations e.g., gamma rays (Karadao et al., 2001) and electron beams (Ajji 
et al., 2008) could be useful as an initiator. This method could be employed for 
unsaturated compounds. Radicals are formed on polymer chain by irradiation of aqueous 
polymer solution. Moreover, hydroxyl radicals are formed by radiolysis of water 
molecules. These hydroxyl groups attack the polymer chains to form macro-radicals. 
These macro-radicals are covalently bonded on different chains resulting in the formation 
of crosslink structure. 
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2.4.2.6. Swelling behaviour of hydrogels 
The most desirable characteristic of hydrogels is their ability to swell, when come in 
contact with a compatible solvent. In initial state, solvent molecules attack hydrogel 
surface and start penetrating in polymeric network resulting in surface rubbery phase. In 
such situation unsolvated glassy phase remains separated from rubbery state with a 
moving boundary. Rubbery phase continue expanding on regular bases thus solvent 
penetrates throughout polymeric network. Achilleos et al. (2000) has studied dynamic 
deformation of hydrogels during swelling. Against osmotic force an opposite force is 
acting referred as elasticity force, which balances network stretching and thus avoids 
deformation of polymeric network. At swelling equilibrium both elasticity and osmotic 
forces are in balance state so no further swelling occurs (Vervoort et al., 2005). 
When hydrogels are neutral in nature, Van der Waals repulsive forces between monomer 
are suppressed by applied pressure resulting in decreased gel volume. While considering 
polyelectrolyte hydrogels pressure of counter-ions will restrict applied pressure resulting 
in large solvent volume release (Vervoort et al., 2005). 
Swelling rate is also another important feature of hydrogel determined by various 
physicochemical properties of hydrogel like type of porous structure and extent of 
porosity. On the basis of porosity, hydrogels can be classified into following four classes 
which are given in table 2.3; 
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Table 2.3. Swelling behaviour of different types of hydrogels 
 
Type Swelling mechanism Morphology Swelling rate Application 
Micro-
porous 
Combination of 
diffusion and 
confection through 
water filled channels 
 
Varying 
porosity 
having 
closed cell 
structure 
(100-1000 
A˚) 
Depends upon 
sample size, 
generally 
slow 
Various 
biomedical 
applications 
and controlled 
release 
techniques 
Macro-
porous 
Diffusion through 
water filled channels 
Varying 
porosity 
having 
closed cell 
structure 
(0.1-1µm) 
Depends upon 
sample size, 
generally fast 
Used in baby 
diapers 
Non-porous Diffusion through free 
volumes 
No pores Depends upon 
sample size, 
generally  
very slow 
Various 
applications 
ranging from 
contact lenses 
to artificial 
muscles 
Super-
porous 
Capillary forces Highly 
porous 
having inter 
connected 
open cell 
structure 
Depends upon 
sample size, 
generally very 
fast 
Drug delivery 
system 
spatially for 
delivery to 
GIT  
(Fariba et al., 2010) 
In view of Lowman definition, non-porous gels have molecular sized pores. That’s why 
non porous hydrogels are densely packed resulting in limited solute transport by diffusion 
process. So degree of hydration depends upon diffusion coefficient of solute in 
membrane to diffusion coefficient of solute in pure solvent. 
Dry state hydrogel volume and hydrogel volume in equilibrium swollen state can be 
calculated by following equations i.e., equation 2.1 and 2.2 (Hickey and Peppas, 1997; 
Hamid and Oguz, 1996). 
                               
         
  
               (Equation……… 2.1) 
                               
     
  
                                      (Equation……… 2.2) 
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Where ma denotes mass of initial dry polymer in air and mh mass of dry polymer in n-
heptane while ma,s is mass of swollen hydrogel in air in swelling equilibrium state, mh,s is 
mass of swollen hydrogel in n-heptane in swelling equilibrium state. Where ―h‖ refers to 
density of n-heptane (0.688 g cm
–3
). 
2.4.2.7. Mechanism of release from hydrogels 
Depending upon type of polymer, additives, drug, pore size and shape, method of 
preparation, experimental conditions and various other physic-chemical phenomena 
affect drug release kinetics. 
Depending on the composition of hydrogel (type of polymer, type of drug and additives), 
geometry (size and shape), preparation technique and environmental conditions during 
drug release, one or more of the following physical and chemical phenomena affect the 
drug release kinetics (Siepmann and Siepmann, 2008; Siepmann and Gopferich, 2001): 
1. Wetting of the drug delivery device 
2. Degradation of drug/polymer 
3. pH changes inside the hydrogel matrix 
4. Creation of pores filled with water 
5. Diffusion of drug inside the hydrogel matrix 
6. Swelling of polymer 
7. Osmotic effects 
All above mentioned phenomena could not be considered simultaneously. Only 
prominent physical and chemical processes are taken into account by any mathematical 
model. Moreover these phenomena only consider drug transport in model system rather 
in living organism. While considering drug transport in living organism, various 
additional phenomena become important like enzymatic degradation, active and passive 
transport, protein binding, drug interactions with compounds in extra and intracellular 
space (Siepmann and Siepmann, 2008). 
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Regarding process engineering, release mechanism involves following phenomena: 
i. Exterior diffusion 
ii. Interior diffusion 
iii. Desorption 
iv. Chemical reactions 
i. Exterior diffusion 
Release mechanism collectively consists of exterior and interior diffusion processes. In 
exterior diffusion from surface of hydrogel drug molecules diffuse into bulk of solvent. In 
this process mass transfer can be described as below: 
The rate of mass transfer can be described by the following expressions: 
             
       
                                                      
          (   
       
 )                                                
Here: 
NA  Drug flux 
kL  Mass transfer coefficient 
GA  Mass transfer rate 
C
*
AL  Surface concentration of drug 
A  Area of mass transfer 
C 
δ
AL  Bulk concentration of drug 
 
ii. Interior diffusion 
Generally release rate is controlled by interior diffusion. 
In general, the rate of drug release is controlled by interior diffusion. Fick’s law based 
theories describes two distinguish types of systems which are diagrammatically 
represented in figure 2.7 i.e. 
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a) Reservoir type devices 
b) Monolithic type devices 
 
Figure 2.7. Reservoir and matrix type device 
a) Reservoir type devices 
In this type of system, pure drug, drug solution or suspension is enclosed by a polymer 
membrane (Arifin et al., 2006; Bajpai et al., 2008). In such systems diffusion of drug 
from membrane is derived by concentration gradient that is rate limiting step. Sink 
condition I achieved then drug is diffused into surrounding device. This drug diffusion 
can be elaborated by Fick’s first law of diffusion. 
where: 
J  Drug flux 
D  Diffusion coefficient 
𝜙  Concentration in dimensions of amount of substance per unit volume 
𝜘  Length in ―m‖ 
 
      
  
  
                                                (Equation………. 2.5) 
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b) Matrix type devices 
In matrix-type devices, drug release is followed by Fickian diffusion, which is related 
with concentration gradient, diffusion length and the degree of swelling (Siepmann and 
Siepmann, 2008). 
iii. Simultaneous diffusion and desorption of drug 
Drug molecules can be adsorbed either chemically or physically on the pore surface 
either physically or chemically (Berger et al., 2004). In case of chemical adsorption, 
electronic density of adsorbate molecule is altered while in case of physical adsorption, 
adsorbate molecule show weak adherence secondary interactions like van der Waals 
forces. 
iv. Chemical reactions 
Various types of chemical reactions taking place during drug release can result in drug or 
polymer degradation resulting in various degradation products. When dissolution media 
diffuses with in hydrogel it can react chemically with these degradation products. This 
reaction can be slow, fast, reversible, irreversible, simple or complex resulting over all 
diffusion or release process. 
2.4.2.8. Features of an ideal hydrogel 
The functional characteristics of an ideal hydrogel are given below (Mohammad and 
Kourosh, 2008): 
 Greatest absorption capacity in basic medium 
 Desired absorption or release profile 
 Less soluble content and monomer residues 
 Economical 
 Appealing stability upon storage and in swelling medium 
 Biodegradability, no toxic residues 
 Odorless 
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 Photo stability 
 Re-wetting capability 
2.4.2.9. Applications  
Common uses of hydrogels are; 
 In tissue engineering as scaffolds for tissue repair 
 Hydrogel coated wells for cell culture (Amir et al., 2014) 
 Smart hydrogels for targeted delivery 
 Sustain release drug delivery 
 Used as biosensor 
 Used in contact lenses 
 EEG and ECG medical electrodes using hydrogels 
 Rectal drug delivery and diagnosis 
2.4.3. Organogels 
Organogels are thermoplastic solid material which is non-crystalline and non-glassy 
consisting of liquid organic phase that is enclosed by a three dimensionally crosslink 
network. Liquid could be mineral oil, vegetable oil or organic solvent. Firmness or 
elastic properties of organogels are two important factors that control 
solubility and particle dimensions of structure. Organogels have various applications in 
different areas like pharmaceuticals (Kumar and Katare, 2005), cosmetics, art 
conservation (Carretti et al., 2005) and food (Pernetti et al., 2007). 
2.4.4. Xerogels 
A gel which is formed by drying with unhindered shrinkage is referred as xerogel. It 
possesses greater porosity (15–50%). When solvent is removed under various conditions, 
network does not shrink resulting in highly porous, low-density material referred as 
an aerogel. 
 
30 
 
2.5. Polymers and advanced drug delivery system 
Initial use of polymers as stabilizers, solubilizes and mechanical supporter has now been 
replaced by various other functionalities of polymer e.g. specific need or problem solving 
ability of polymer in various advanced drug delivery systems. Regarding advanced drug 
delivery systems polymers can be classified on various bases are given in table number 
2.4, 2.5, 2.6 and 2.7 as follows (Chandel and Rajkumari, 2013): 
Table 2.4. On the basis of source 
Natural Synthetic Semi synthetic 
Alginate, Albumin, 
Dextran, Polyethylene 
glycol (PEG), Chitosan, 
Gelatin, Collagen, 
Cyclodextrin 
Polyethylene, Polyglycolic 
acid, Polylactic acid, 
Polyhydroxy butyrate, 
Polypropylene, Poly 
acrylamide 
Hydroxy propyl cellulose 
(HPC), Hydroxy propyl 
methyl cellulose (HPMC), 
Methyl cellulose (MC), 
Hydroxy ethyl cellulose, 
Sodium carboxymethyl 
cellulose (Na-CMC) 
Table 2.5. On the basis of type of polymerization 
Addition polymer Condensation polymers 
Poly ethylene glycol, Polyvinyl chloride, 
Polypropylene 
Polyester, polyurethane 
Table 2.6. On the basis of degradability 
Biodegradable Non-biodegradable 
Polyglycolic acid, Polylactic acid, 
Polyanhydrides, Polycarpolactone 
Polyether urethane, Polydimethyl siloxane, 
Ethyl cellulose 
Table 2.7. On the basis of nature of water polymer interaction 
Hydrophobic polymer Hydrophilic polymer Hydrogel material 
Polydimethyl siloxane, 
Ethyl cellulose 
Methyl cellulose, 
Hydroxypropyl methyl 
cellulose, Sod. 
Carboxymethyl cellulose, 
Sodium alginate, Xanthan 
gums, Guar gum, Pectin 
Polyethylene oxide, 
Crosslink polyvinyl alcohol, 
Polyacrylamide 
(Chandel and Rajkumari, 2013) 
2.5.1. Hydroxy propyl methyl cellulose (HPMC) 
HPMC chemically shown as C6H7O2(OH)x(OCH3)y(OC3H7)z where x + y + z = 3 (Sunil, 
2011). Structure of HPMC is shown in figure 2.8. 
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Figure 2.8. Structure of HPMC 
Where n is number of glucose units in cellulose molecule 
It is tasteless, odorless white to off white free flowing powder regarded as semisynthetic 
and hydrophilic polymer. It is produced by modification of alkali cellulose by treating it 
with 18% sodium hydroxide solution. It has many valuable applications e.g., used as 
basic material for sustained release formulations, as enteric coating film material and as 
matrix binders. As it has non-toxic, easy compression, appealing swelling profile and 
greater drug loading capacity, so it is an ideal candidate for oral drug delivery system 
when sustain release profile is needed (Croweley et al., 2000). 
On the basis of desired properties or application, degree of substitution of HPMC can be 
varied as added groups/molecules, impart various unique or desired properties. Ideal 
properties for its wide spread acceptance includes (Kajal et al., 2011): 
1. Wide range of solubility profile in GI fluids and in various aqueous solvent 
systems 
2. Attractive stability profile in numerous conditions like light, heat or moisture etc. 
3. Capacity to accommodate color and other additives 
4. Biocompatibility, biodegradability and non-toxic profile 
5. Easy availability and handling 
6. Attribute for an ideal film coating material 
7. Ideal candidate for controlled release drug delivery system (Kajal et al., 2011) 
In virtue of high swellability and thermal gelation properties, HPMC has gained attention 
as important carrier material for advance drug delivery systems (Kajal et al., 2011). 
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2.5.2. Sodium carboxy methyl cellulose (Sod. CMC) 
As name indicates it is a cellulose derivative in which carboxymethyl groups (-CH2-
COOH) are linked with the hydroxyl groups of glucopyranose. Chemically it is 
[C6H7O2(OH)x(OCH2COONa)y]n where n is degree of polymerization, x = 1.50 to 2.80, y 
= 0.2 to 1.50, (y = degree of substitution). Structure of CMC is shown in figure 2.9. 
 
Figure 2.9. Structure of CMC 
Physically it is odorless white or slightly yellowish hygroscopic granules, powder or fine 
fibers. It is classified as semisynthetic hydrophilic anionic polymer. It is produced from 
cellulose by treating with alkali and chloroacetic acid. Its polar groups impart 
solubility and chemically reactivity resulting in its increased functionality. Its functional 
properties are attributed to (Croweley et al., 2002); 
a) Hydroxyl groups taking part in reaction 
b) Chain length of cellulose back bone 
c) Degree of clustering of carboxymethyl groups 
It has numerous reported applications like in food industry, various paper products, 
stabilizer, viscosity modifier, thickening agent, suspending agent lubricant in artificial 
tears. It also has wide spread acceptance as controlled/advanced drug delivery system. It 
is also employed to characterize enzyme activity (Croweley et al., 2002). 
 
33 
 
2.5.3. Acrylic acid (AA) 
Structure of acrylic acid is shown in figure 2.10. 
 
Figure 2.10. Structure of AA 
 
Acrylic acid (prop-2-enoic acid) is an organic compound having formula CH2=CHCO2H. 
It is one of the simplest unsaturated carboxylic acid containing vinyl group linked with 
terminal carboxylic acid group. It is a colorless liquid with characteristic tart smell. As far 
as miscibility is concerned, it is miscible with chloroform, alcohols, water and ethers. 
A byproduct of ethylene and gasoline production called propene which is used to produce 
acrylic acid. It undergoes typical carboxylic acid reactions. It formulates respective ester 
upon treating with an alcohol. Acrylic acid salts are referred as propenoates or acrylates 
which include methyl butyl ethyl acrylate and 2-ethylhexyl acrylate. Acrylic acid and 
esters have ability to combine with themselves or with other monomers to form 
homopolymers or copolymers. 
Being severely irritating and corrosive in nature it can damage skin, respiratory tract and 
eyes. However, low exposure levels had no health hazard. 
Due to presence of carboxylic acid groups, ionic repulsion is produced imparting pH 
sensitivity to material. That’s why it can cause complexes with polybases (Ray et al., 
2008). All these characteristics make it ideal for advanced delivery systems (Dimitrov et 
al., 2003). 
Its pharmaceutical applications include drug delivery systems for nasal, gastrointestinal, 
buccal, ocular and transdermal use as it is a biocompatible material and have little 
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antigenic profile (Huang et al., 2007). High tolerance profile of acrylic acid has been 
exhibited in living cells (Fournier et al., 2003). 
2.5.4. Hydroxyethylmethacrylate (HEMA) 
 
Figure 2.11. Structure of HEMA 
Structure of HEMA is given in figure 2.11. 2-Hydroxyethylmethacrylate (HEMA) 
(molecular formula C6H10O3 having molecular weight 130.14 g mol
−1
) is a hydrophilic 
monomer but upon contact with water it swell because of molecule's hydrophilic pendant 
group. This monomer is employed to formulate polymer polyhydroxyethylmethacrylate. 
In combination with various other polymers or monomers it is used to synthesize new 
formulations with desired characteristic. On the basis of physicochemical properties it 
can absorb 10 to 600% water as compared to its dry weight. This property makes it first 
materials to be positively employed in the synthesis of flexible contact lenses. 
It is a colorless liquid with pungent smell. Its acute toxicity profile is low (Oral LD50 > 
4000 mg/kg; Dermal LD50 > 3000 mg/kg). It is somewhat irritating to skin and 
moderately irritating to eyes. It is hydrolyzed to methacrylic acid and ethylene glycol 
(Podkoecielna et al., 2012). 
2.5.5. Methacrylic acid (MAA) 
Methacrylic acid (an organic compound) is a colorless viscous liquid having unpleasant 
smell. It has good solubility profile in warm water. It is miscible with lots of organic 
solvents. Structure of Methacrylic acid is shown in figure 2.12. 
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Figure 2.12. Structure of Methacrylic acid 
Source: http://en.wikipedia.org/wiki/Methacrylic_acid 
Various uses of MAA has been reported e.g. used in manufacturing of polymers such as 
Lucite and Plexiglas. Methacrylic acid was initially obtained as its ethyl ester by 
treating phosphorus pentachloride with oxyisobutyric ester. It can also be prepared by 
boiling citra- or meso-brompyrotartaric acids with alkalis. Methacrylic acid its self 
naturally obtained from oil of Roman chamomile in small amounts. MAA has distinctive 
properties as carriers for various types of drugs (Aaron and Nicholas, 2004; Ahmet et al., 
2002). 
2.6 Angina 
Transient myocardial ischemia can lead to chest pain that is termed as angina or angina 
pectoris. Various diseases like coronary artery disease, as atherosclerosis and aortic 
stenosis can lead to situation called angina. The root cause of angina involves vasospasm 
of coronary arteries. One of the reasons of coronary vasospasm includes enhanced Rho 
kinase activity. This increased level of Rho kinase activity inhibits myosin phosphatase 
activity resulting in enhanced calcium sensitivity and ultimately leading to 
hypercontraction (Kandabashi et al., 2000). Rho-kinase also causes reduction in nitric 
oxide synthase resulting in decreased nitric oxide concentrations (Takemoto et al., 2002). 
Angina can be really severe in some cases; even in start of 20th century this was 
acknowledged to be a forerunner of death. Current therapeutic regimens has somehow 
overcome problem. Morbidity rate was found 8% approximately in 62 years old age 
people with complaint of moderate to severe angina (William et al., 2014). 
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2.6.1 Classification 
Angina can be classified into different types as given below: 
a) Stable angina 
b) Unstable angina 
c) Microvascular angina 
2.6.1.1 Stable angina 
It is typical kind of angina associated with myocardial ischemia also called as effort 
angina. Its characteristic presentations include chest discomfort and activity related 
symptoms (like walk, stairs climbing or running). Its symptoms are relieved or minimized 
by rest or taking sublingual nitroglycerin (Tobin, 2010). Other factors that aggravate 
symptoms include heavy meals, cold weather and emotional stress. 
2.6.1.2 Unstable angina 
It is referred as angina pectoris which changes or worsens with time. It is also called as 
―crescendo angina‖ which is a type of acute coronary syndrome. 
One or more of following features can be depicted in unstable angina; 
 It usually stays for 3-5 minutes occurring at rest or even with less exertion 
 Within early 4-6 weeks it worsens with new onset 
 It has a an outline in which symptoms get worsen, prolonged and frequent 
Unpredictable attack of unstable angina at rest could be serious pointer of an imminent 
heart attack. Pathophysiology of atherosclerosis is a major difference between stable 
angina and unstable angina. In unstable angina coronary flow is decreased because of 
transient platelet aggregation, coronary artery spasms or coronary thrombosis which is 
basic pathophysiology of unstable angina (Hombach et al., 1998). It involves 
development of atheroma which is covered by fibrous cap referred as atherosclerotic 
plaque. Rupture of this atherosclerotic plaque in unstable angina results in blood clots 
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causing narrowing of coronary vessel's lumen. This pathophysiology depicts how 
unstable angina is independent of activity. 
2.6.1.3 Microvascular angina 
This type of angina is recognized by chest pain, in view of normal epicardial coronary 
arteries upon angiography. It is also called as Syndrome X depicting that patient shows 
ischemic changes on exercise (ST depressions with stress) instead of normal coronary 
arteries. Since microvascular angina is not characterized by major arterial blockages, it is 
harder to recognize and diagnose. Basic reason of microvascular angina is not known but 
some aggravation factors include reduced blood flow as a result of spasm and resistance 
of blood vessels of heart. As microvascular angina is not caused by arterial blockages, it 
is difficult to identify and diagnose. 
2.6.2 Signs and symptoms of angina pectoris 
Typical symptoms include: 
 Chest pain (moderate to severe) 
 Chest discomfort (tightness, heaviness, burning, squeezing, pressure or choking 
sensation) 
 Pain in inner left arm, upper central abdomen, neck, jaw, back or shoulders 
 Breathlessness 
 Rarely sweating 
 Increased pulse rate and blood pressure 
 Rarely autonomic symptoms, nausea and vomiting 
2.6.3 Major risk factors for angina 
Major risk factors include: 
 Age (≥ 55 for females, ≥ 45 years for males) 
 Cigarette smoking 
 Dyslipidemia 
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 Diabetes mellitus 
 Family history (e.g., premature heart disease) 
 High cholesterol 
 High blood pressure 
 Hypertension 
 Obesity (Body mass index ≥ 30 kg/m2) 
 Kidney disease (GFR<60 mL/min) 
 Physical stillness 
 Persistent psychosocial stress 
(Chobanian et al., 2003; Linden et al., 1996; Sun et al., 2002) 
Avoiding these risk factor and life style modification can reduce chance of occurrence 
(Moyer, 2012). 
2.6.4 Clinical Situations enhancing risk factors 
 Medications 
 Hypovolaemia 
 Hypervolaemia 
 Anemia 
 Hyperthyroidism 
 Tachyarrhythmia 
 Bradyarrhythmia 
 Valvular heart disease 
 Hypertrophic cardiomyopathy 
(Daly et al., 1985; Daly et al., 1983; Shinozaki et al., 2008) 
2.6.5 Treatment 
Basic aim of treating angina pectoris is to relief symptoms and reduce advancement of 
disease and avoid future events like heart attacks and even death. Morbidity and mortality 
can significantly be reduced by using beta blockers (e.g. carvedilol, atenolol 
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and propranolol). For symptomatic treatment of angina pectoris short 
acting nitroglycerin has been employed since 1879. Moreover, isosorbide mononitrate, 
calcium channel blockers (e.g., nifedipine and amlodipine) and nicorandil are commonly 
recommended vasodilators for chronic stable angina (Sulfi and Timmis, 2006). Minimal 
dose of aspirin lessen chances of heart attack in patients having complaint of chronic 
stable angina and it takes position as part of standard treatment. However, because of 
greater risk of  haemorrhagic stroke and gastrointestinal bleeding, are limiting factor of 
aspirin use and now it is not advised until risk of infarction is really high (Barnett et al., 
2010). Regular physical activity or exercise is good long term management for angina 
(Ades et al., 1993). 
2.7 Nicorandil 
2.7.1 Introduction 
Nicorandil (IUPA name; 2-(pyridine-3-carbonylamino)ethyl nitrate is a derivative of 
niacinamide. It is a vasodilator indicated for angina having dual properties of 
nitrate and K
+
ATP channel agonist.  Nitrate component of nicorandil dilates large 
coronary arteries in humans. When plasma concentrations of nicorandil are higher it 
causes reduction in coronary vascular resistance resulting in K
+
ATP channel opening 
(Nakae et al., 2002). 
2.7.2 Physicochemical properties 
Its molecular formula is C8H9N3O4 with molecular weight 211.174 g/mol, apparently it is 
white to off white crystalline powder. It is freely soluble in acetone, ethanol, methanol 
and acetonitrile, soluble in chloroform and ethyl acetate, sparingly soluble in water and 
slightly soluble in ether. Structure of nicorandil is illustrated in figure 2.13. 
 
40 
 
 
Figure 2.13. Structure of nicorandil 
2.7.3 Mechanism of action 
As nitrate; Nitrate component of nicorandil excites guanylate cyclase to raise formation 
of cyclic GMP (cGMP) which further stimulates protein kinase G (PKG) leading to 
phosphorylation and inhibition of GTPase RhoA and thus reduced Rho-kinase activity. 
This decreased Rho-kinase activity allows enhanced myosin phosphatase activity which 
ultimately reduces the calcium sensitivity of smooth muscles (Sauzeau et al., 2006). 
Protein kinase G (PKG) promotes sarcolemma calcium pump to eradicate activating 
calcium (Vrolix et al., 1988). PKG turns on K
+
 channels to stimulate K
+
 efflux and 
succeeding hyperpolarization hinders voltage-gated calcium channels (Nakae et al., 
2002). Ultimately easing of smooth muscle and coronary vasodilation ensues. 
As K
+
ATP channel opener: Nicorandil triggers K
+
ATP channel leading to K
+
 efflux 
which results into hyperpolarization of cells that results in inactivation of voltage gated 
calcium channels and diminishes free intracellular Ca
2+ 
(Nakae et al., 2002). 
Vasodilator effect of nicorandil is primarily accredited to its nitrate property. It is also 
found that nicorandil is operative in situations where nitrates (like nitroglycerine) are not 
effective. Nicorandil triggers K
+
ATP channels in mitochondria of myocardium that 
seems to relay cardio protective effects, though mechanism is not known till now (Liu et 
al., 1998). 
2.7.4 Clinical uses 
It possesses a variety of advantageous hemodynamic effects and has proven to be 
operative in treating angina with appreciable efficacy. Moreover, it has beneficial effects 
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in unstable and variant angina. Treatment benefits also include prevention and/or 
reduction of complaint arising from angina pectoris (Knight et al., 1995). 
2.7.5 Side effects 
Side effects according to British National Formulary include; 
 Palpitations 
 Flushing 
 Weakness 
 Perianal, illeal, peristomal and anal ulceration 
 Vomiting 
 Nasal congestion 
 Toothache 
2.7.6 Pharmacokinetics 
Absorption of nicorandil from GIT is rapid and almost complete. It lacks first-pass effect 
as its metabolism by liver is not significant. Its reported bioavailability is 75-100%. 
When administered with food, absorption is delayed with little or no effect on Cmax. 
However, plasma concentration and area under the curve (AUC) has linear relationship 
with administered dose (i.e., 5, 10, 20 or 40 mg). Steady state plasma concentration is 
achieved within 96-120 h after constant dosing of 20 mg twice daily which is attributed 
to its distribution and metabolism designs. Approximately reported average Cmax is 
300ng/mL reached within 30 min of administration. It has low plasma protein binding 
profile i.e. approximately 25%. Reported volume of administration (Vd) is 1.0 L/kg body 
weight approximately. It is metabolized extensively and majorly eliminated via kidney, 
only less than 2% is excreted via biliary route. Its elimination half-life is very short i.e. 
about 1 h and total body clearance is almost 1.15 L/min i.e., less than blood flow to liver 
(Frydman, 1992). 
2.7.7 Dosage 
Its recommended dose is 10-20 mg twice daily with maximum 30-40 mg twice daily. 
42 
 
2.7.8 Warnings and precaution  
Patients with complaint of hypovolaemia (low volume of blood), heart disease, low blood 
pressure and during pregnancy it should be administered with precaution. It may result in 
dizziness so do not drive while on this medication. 
43 
 
3.0. Materials & methods 
3.1. Instrumentation and chemicals 
3.1.1. Instrumentation and apparatus 
High Performance Liquid Chromatographic Pump
1
, UV/Visible Spectrophotometer 
Detector
2
, HPLC Modular
3
,
 
Sonicator
4
, Centrifuge Machine
5
, pH Meter
6
, Ultrasonic Bath
7
, 
Digital Weighing Balance
8
, Membrane Filter
9
, Magnetic Stirrer
10
, B.P. Apparatus
11
, Vacuum 
Pump
12
, Distillation Plant
13
, Ultra-low Freezer
14
, Micropipettes
15
, Filtration Assembly
16
, 
Measuring Cylinder
17
, Beakers
18
 50, 100, 250, 500 & 1000 mL, Measuring Flasks
19
 50, 100, 
250, 500 & 1000 mL, Centrifuge Tubes
20
, Sample Test Tubes
21
, Disposable Syringes
22
, 
Vortex Mixer
23
, Incubator
24
, Centrifuge
25
, Fourier Transform Infrared Spectroscopy 
(FTIR)
26
, Scanning Electron Microscopy (SEM)
27
, Differential Scanning Calorimeter and 
Thermo Gravimetric Analyzer (DSC & TGA)
28
, XRD
29
, , Dissolution apparatus
30
, 
Automated sample collector
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1-3. Agilent 1100 Series U.S.A. 
4. Elma, Germany 
5. Model 4000-China 
6. WTW pH 300-Germany 
7. Fisher Scientific FS 28 H-Germany 
8. Percia XB 120A 
9. Sartorius (0.45 μm filters)-Germany 
10. Gallen Kamp-England 
11. Model No 500-China 
12. Rotary Vane Pump ILMVAC-Germany 
13. WDA/4 R & M England 
14. Sanyo-Japan 
15. Softpet- Finland 
16-21.  Pyrex-France 
22. BD-Pakistan 
23. Seouline BioScirnce-Korea 
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24. Velp Scientifica-Italy 
25. Hettich-Germany 
26. Bruker, Tenser 27, Germany 
27. Hitachi, S3400N, Quanat 300-500 µm 
28. DuPont thermal analyzer with 2010 DSC194 module 
29. Philips Analytical   XRD Model: PW 3710, Holland 
30. PTCF II Pharma Test-Germany 
31. PT-DT7 Pharma Test- Germany 
 
3.1.2. Chemicals  
Acrylic Acid
1
 (Anhydrous, 180-200ppm MEHQ as inhibitor, 99%), 2-Hydroxyethyl 
Methacrylate
2
 (97%, 200-220 ppm monomethyl ether hydroquinone as inhibitor), 
Methanol
3
 HPLC grade, Distilled water
4
, Acetonitrile
5
 HPLC grade, 
(Hydroxypropyl)methyl cellulose (80-120cP)
6
, N,N Methylene-bis-acrylamide
7
 (98%),  
Potassium persulphate
8 
(99%), Potassium dihydrogen phosphate
9
 (98-100%), Ethanol 
Absolute
9
, Nicorandil
10
, (99.8%), Heparin
 16
 
1. Sigma Aldrich-Netherlands 
2. Sigma Aldrich-Germany 
3. Merck-Germany. 
4. The Islamia University of Bahawalpur. 
5. Wilson Pharmaceuticals 
6. Sigma Aldrich-USA 
7.         Fluka-Switzerland  
8.  AnalaR, BDH-England 
9.  Merck- Germany 
10.  Getz Pharma-Pakistan 
16. Medicare Pharma-Malaysia 
˚ 
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3.2. Methods 
3.2.1. Formulation development 
Synthesis of hydrogels 
a) Preparation of HEMA-co-AA hydrogel 
Method for preparing hydrogels was free radical polymerization. Acrylic acid (AA) 
solution was maintained on water bath at 70 
°
C with stirring at 300 rpm. Potassium 
persulphate (KPS) solution as an initiator was added drop wise in above solution and 
continue stirring at 300 rpm and 70 
°
C for 35 min. The mixture was cooled down to 
ambient temperature. Calculated amount of 2-hydroxyethyl methacrylate solution was 
added to mixture at room temperature and stirred at 300 rpm for 1-2 min. N,N 
Methylene-bis-acrylamide solution was also added to above mixture in drop wise manner 
at room temperature and whole mixture was stirred at room temperature for 2-3 minutes. 
Final volume was make up with water quantity sufficient up to 100 g. Final solution was 
poured into glass test tube and placed in water bath at 80 
°
C for 3 hrs. After completion of 
3 hr reaction time formulated hydrogel was cut into small discs of 4 mm thickness with 
sharp scissors. These discs were first washed with distilled water and then placed in 
ethanol:water (50:50) solution for 24 hrs to dewater formulation. Discs were oven dried 
at 46 
°
C till drying equilibrium is reached. These discs were subjected to further in vitro 
and invivo studies. HEMA-co-AA hydrogels in different weight ratios were prepared as 
given in table 3.1. 
b) Preparation of HPMC-co-AA hydrogel 
HPMC-co-AA hydrogels were prepared by free radical polymerization. Hydroxypropyl 
methyl cellulose (HPMC) solution was maintained on water bath at 75 
°
C with stirring at 
300 rpm. Potassium persulphate (KPS) solution as an initiator was added drop wise in 
above solution and continue stirring at 300 rpm and 75 
°
C for 35 min. The mixture was 
cooled down to room temperature. Calculated amount of acrylic acid was added to 
mixture at room temperature and stirred at 300 rpm for 1-2 min. N,N Methylene-bis-
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acrylamide solution was also added to above mixture in drop wise manner at same time 
and whole mixture was stirred at room temperature for 2-3 minutes. Final volume was 
make up with water quantity sufficient up to 100 g. Final solution was poured into glass 
test tube and placed in water bath at 80 
°
C for 3 hrs. After completion of 3 hours reaction 
time formulated hydrogel was cut into small discs of 4 mm thickness with sharp scissors. 
These discs were first washed with distilled water and then placed in ethanol: water 
(50:50) solution for 24 hrs to dewater formulation. Discs were oven dried at 46 
°
C till 
drying equilibrium is reached. These discs were subjected to further in-vitro and in-vivo 
studies. HPMC-co-AA hydrogels in different weight ratios were prepared as given in 
table 3.2. 
c) Preparation of HPMC-co-AA-co-HEMA hydrogel 
HPMC-co-AA-co-HEMA hydrogels were prepared by free radical solution 
polymerization. Hydroxypropyl methyl cellulose (HPMC) solution was maintained on 
water bath at 75 
°
C with stirring at 300 rpm. Potassium persulphate (KPS) solution as an 
initiator was added drop wise in above solution and continue stirring at 300 rpm and 75 
°
C for 35 min. The mixture was cooled down to room temperature. Calculated amount of 
acrylic acid and 2-hydroxyethyl methacrylate solution was added to mixture at room 
temperature and stirred at 300 rpm for 1-2 min. N, N Methylene-bis-acrylamide solution 
was also added to above mixture in drop wise manner at room temperature and whole 
mixture was stirred at room temperature for 2-3 minutes. Final volume was make up with 
water quantity sufficient up to 100 g. Final solution was poured into glass test tube and 
placed in water bath at 80 
°
C for 3 hrs. After completion of 3 hours reaction time 
formulated hydrogel was cut into small discs of 4 mm thickness with sharp scissors. 
These discs were first washed with distilled water and then placed in ethanol: water 
(50:50) solution for 24 hrs to dewater formulation. Discs were oven dried at 46 
°
C till 
drying equilibrium is reached. These discs were subjected to further in-vitro and in-vivo 
studies. HPMC-co-AA-co-HEMA hydrogels in different weight ratios were prepared as 
given in table 3.3. 
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d) Preparation of CMC-co-MAA-co-AMPS hydrogel 
CMC-co-MAA-co-AMPS hydrogels were prepared by free radical solution 
polymerization. Carboxy methyl cellulose (CMC) solution was maintained on water bath 
at 70 
°
C with stirring at 300 rpm. Potassium persulphate (KPS) solution as an initiator 
was added drop wise in above solution and continue stirring at 300 rpm and 70 
°
C for 35 
min. The mixture was cooled down to room temperature. Calculated amount of 
methacrylic acid and 2-hydroxyethyl methacrylate solution was added to mixture at room 
temperature and stirred at 300 rpm for 1-2 min. N,N Methylene-bis-acrylamide solution 
as crosslinker was also added to above mixture in drop wise manner at room temperature 
and whole mixture was stirred at room temperature for 2-3 minutes. Final volume was 
make up with water quantity sufficient up to 100 g. Final solution was poured into glass 
test tube and placed in water bath at 80 
°
C for 3 hrs. After completion of 3 hours reaction 
time formulated hydrogel was cut into small discs of 4 mm thickness with sharp scissors. 
These discs were first washed with distilled water and then placed in ethanol: water 
(50:50) solution for 24 hrs to dewater formulation. Discs were oven dried at 46 
°
C till 
drying equilibrium is reached. These discs were subjected to further in-vitro and in-vivo 
studies. CMC-co-MAA-co-AMPS hydrogels in different weight ratios were prepared as 
given in table 3.4. 
Where: 
AA      Acrylic Acid 
HEMA   2-Hydroxyethyl Methacrylate 
KPS    Potassium persulphate 
MBA    N,NMrthylene-bis-acrylamide 
HPMC  (Hydroxypropyl)methyl cellulose 
CMC   Carboxymethyl Cellulose 
MAA   Methacrylic acid 
AMPS   2-Acrylamido-2-methylpropane sulfonic acid 
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Table 3.1: Composition of HEMA-co-AA hydrogels/100g 
Formulations AA g 
(%w/w) 
HEMA g 
(%w/w) 
KPS g 
(%w/w) 
MBA g 
(%w/w) 
F1 16.5 0.84 0.015 0.015 
F2 16.5 1.68 0.015 0.015 
F3 16.5 3.36 0.015 0.015 
F4 10.5 2.52 0.015 0.015 
F5 12.5 2.52 0.015 0.015 
F6 14.5 2.52 0.015 0.015 
F7 14.5 2.52 0.015 0.020 
F8 14.5 2.52 0.015 0.025 
F9 14.5 2.52 0.015 0.030 
 
Table 3.2: Composition of HPMC-co-AA hydrogels/100g 
Formulations AA g 
(%w/w) 
HPMC g 
(%w/w) 
KPS g 
(%w/w) 
MBA g 
(%w/w) 
F10 12.5 0.6 0.15 0.15 
F11 12.5 0.9 0.15 0.15 
F12 12.5 1.2 0.15 0.15 
F13 7.5 0.3 0.15 0.15 
F14 10 0.3 0.15 0.15 
F15 12.5 0.3 0.15 0.15 
F16 7.5 0.3 0.15 0.20 
F17 7.5 0.3 0.15 0.25 
F18 7.5 0.3 0.15 0.30 
 
Table 3.3: Composition of HPMC-co-AA-co-HEMA hydrogels/100g  
Formulations AA g 
(%w/w) 
HPMC g 
(%w/w) 
HEMA g 
(%w/w) 
KPS g 
(%w/w) 
MBA g 
(%w/w) 
F19 7.5 2.5 0.5 0.15 0.15 
F20 7.5 2.5 1 0.15 0.15 
F21 7.5 2.5 1.5 0.15 0.15 
F22 10 2.5 0.5 0.15 0.15 
F23 12.5 2.5 0.5 0.15 0.15 
F24 15 2.5 0.5 0.15 0.15 
F25 7.5 5 0.5 0.15 0.15 
F26 7.5 7.5 0.5 0.15 0.15 
F27 7.5 10 0.5 0.15 0.15 
F28 7.5 2.5 0.5 0.15 0.20 
F29 7.5 2.5 0.5 0.15 0.25 
F30 7.5 2.5 0.5 0.15 0.30 
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Table 3.4: Composition of CMC-co-MAA-co-AMPS hydrogels/100g 
Formulations CMC g 
(%w/w) 
AMPS g 
(%w/w) 
MAA g 
(%w/w) 
KPS g 
(%w/w) 
MBA g 
(%w/w) 
F31 0.5 3 6 0.040 0.040 
F32 0.5 3 7 0.040 0.040 
F33 0.5 3 8 0.040 0.040 
F34 0.5 4 6 0.040 0.040 
F35 0.5 5 6 0.040 0.040 
F36 0.5 6 6 0.040 0.040 
F37 1.0 4 6 0.040 0.040 
F38 1.5 4 6 0.040 0.040 
F39 2.0 4 6 0.040 0.040 
F40 0.5 4 6 0.040 0.045 
F41 0.5 4 6 0.040 0.050 
F42 0.5 4 6 0.040 0.055 
 
3.2.2. Preparation of buffer (British Pharmacopoeia Volume V) solutions of 
different pH for swelling studies 
3.2.2.1. Buffer of pH 1.2 
250 mL solution of 0.2 M sodium chloride (NaCl) was taken and mixed with 425 mL of 0.2 
M hydrochloric acid (HCl). The final volume was made up to 1000 mL with distilled water. 
3.2.2.2. Buffer of pH 5.8 
250 mL solution of 0.2 M potassium dihydrogen phosphate (KH2PO4) was mixed with 18 
mL of sodium hydroxide (NaOH) solution 0.2 M. The final solution was diluted up to 1000 
mL with distilled water. 
3.2.2.3. Buffer of pH 7.4 
250 mL solution of 0.2 M potassium dihydrogen phosphate (KH2PO4) was mixed with 195.5 
mL of sodium hydroxide (NaOH) solution 0.2 M. The final solution was diluted up to 1000 
mL with distilled water. 
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3.2.3. Preparation of stock solutions and standard curve 
Stock solution of nicorandil was prepared by dissolving 100 mg in 100 mL of phosphate 
buffer of pH 7.4. Further serial dilutions of 2, 4, 6, 8, 10, 15, 20, 25 and 30 µg/mL were 
made from this stock solution in phosphate buffer of pH 7.4. These serial dilutions were 
analyzed in triplicates by using UV visible spectrophotometer at 225 nm. Standard curve was 
constructed by absorbance verses concentration (Andrew et al., 2004). 
3.2.4. Swelling studies 
Swelling studies of all formulations were performed at pH 1.2, 5.8 and 7.4 till swelling 
equilibrium, at prescheduled time points. For swelling study, weighed disc of formulation 
was soaked in 100 mL buffer of relevant pH. At specific time points, discs were blot dried 
and weighed at analytical weight balance. 
Dynamic swelling and equilibrium swelling ratio of all formulations were determined by 
using following equation. 
                               q = Wh/Wd      (Equation………3.1)                               
Where “q” is dynamic swelling 
Wh  shows swollen gel’s weight at time t 
Wd  shows initial weight of dried hydrogel disc (Peppas and Barr-Howell, 1987) 
3.2.4.1 Equilibrium swelling measurements (%ES) 
The swelling measurement was carried out until equilibrium weight of gel. Percent 
equilibrium swelling was carried out by following equation. 
                                     
      
   
                              (Equation ……3.2) 
Meq is mass of swollen gel at equilibrium 
Mo is mass of dried gel disc (Ranjha et al., 2011) 
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3.2.4.2. Percent gel content (%gc) 
Freshly prepared hydrogel discs (3-4 mm) were subjected to drying in a vacuum oven at 
45
o
C to a constant weight (Wo). Then this constant weight dried gel disc was processed 
through extraction with deionized water for 24hr. Non reacted polymer/monomer was 
washed away via this extraction. The disc was again dried in oven at 45
o
C till constant 
weight (W1). By using following formula % gel content was determined. 
                   (   )  
  
  
                               (Equation………..3.3) 
Where W1 is the weight of dry gel after extraction in distilled water and W0 is the initial 
weight of dry gel (Dafader et al., 2011). 
3.2.4.3. Porosity measurement 
Computing fraction of voids volume over total volume between 0 and 1 or in case of percent 
between 0 to 100 % is stated as porosity. Solvent replacement method was chosen to figure 
out porosity measurement. Dried weighed hydrogel disc (Md) was immersed in absolute 
ethanol for 24 hrs (till constant weight). After 24 hrs, hydrated hydrogel disc (Mh) was blot 
dried to remove excess surface ethanol and weighed on analytical weight balance. Percent 
porosity (%P) was computed by equation 3.4. 
                    
(     )
  
                                                     (Equation………..3.4) 
Where 𝜌 refers to density of absolute ethanol and V is hydrogel volume (Samiullah and 
Nazar, 2014). 
3.2.5. Drug loading 
Drug loading was done by absorption method. 1% solution of drug in phosphate buffer of pH 
7.4 was prepared. One disc of each formulation was allowed to swell and reach to swelling 
equilibrium in 100 mL of 1% drug solution. After swelling, equilibrium was achieved, discs 
were removed from solution and washed out with distilled water to remove surplus surface 
drug. Then allowed to air dry at room temperature first and then in oven at 40
 
°C till drying 
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equilibrium (Sudhair et al., 2013). Drug loading in discs was determined by following 
formula, given in equation number 3.5. 
                               
     
  
                                    (Equation………..3.5) 
Where WL is weight of dried drug loaded disc and Wu is weight of dried unloaded disc (Liu 
et al., 2004). 
3.2.6. Characterization 
3.2.6.1. Fourier Transform Infra Red (FTIR) Spectroscopy 
All formulated combinations along with polymers, monomers and drug were subjected to 
Fourier transform infrared analyzer (Bruker, Tensor 27, Germany) at 25ºC. 
3.2.6.2. X-Ray Diffraction (XRD) 
To check crystallinity of blank formulations, one optimum formulation from each 
combinations of hydrogels was subjected to X-ray diffractometer (Bruker D8 Discover, 
Germany) with Ni-filtered CuK alpha radiation source having tube voltage of 35 KV, 
current of 35 mA and scanning rate of 5° min
-1
, over a range of 8°-60° diffraction angle 
(2θ) range (Osiris and Manal, 2012). 
3.2.6.3. Thermal Gravimetric Analysis and Differential Scanning Calorimetry 
(TGA & DSC) 
All combination of hydrogel formulations were subjected to thermal analysis and 
differential scanning calorimetry by sealing prior to test and putting them in aluminum 
pans. Measurements were achieved at a rate of 10
 
°C per minute,
 
under nitrogen flow of 
25 mL per minute,
 
at temperature range of 20
 
°C to 900
 
°C. The standard uncertainty of 
sample mass measurement was ± 1%. Equipment calibration was accomplished with 
calcium oxalate supplied with instrument (Osiris and Manal, 2012). 
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3.2.6.4. Scanning Electron Microscopy (SEM) 
Surface morphology of all combinations of hydrogel formulations was determined by 
scanning electron microscope (Hitachi, S3400N). Samples were coated with gold by 
Hummer Sputter Coater (Richard et al., 2000). 
3.2.6. In vitro drug release evaluation 
In vitro drug release of hydrogel discs loaded with nicorandil was evaluated according to 
specifications of United States Pharmacopeia by using USP apparatus II. 900 mL of 
required dissolution medium i.e. 0.1 M HCl pH 1.2 and phosphate buffer pH 7.4 were 
used. Stirring of media was maintained at 50 rmp at 37
 
°C ± 0.5
 
°C. 5 mL of aliquot was 
drawn at intervals of 0, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 24 hour with an automated 
sample collector after filtering through sintered filters (10 µm). At each interval, fresh 5 
mL medium was added to preserve volume. Collected samples were diluted up to 50 mL 
with respective buffer and analyzed at 225 nm using a UV-spectrophotometer. The in 
vitro cumulative drug release study was conducted in triplicate (Fatemeh et al., 2004). 
Different kinetic models are pragmatic to appraise release kinetics, given as under in 
equations 3.6 to 3.10; 
Zero order kinetic model    Dt=Do+Kot  (Equation………..3.6) 
First order kinetics model    In Dt=In Do+K1t (Equation………..3.7) 
Higuchi kinetic model    Dt=Do + KHt 
½  (Equation………..3.8) 
Hixson Crowell kinetic model   Dt
3
-Do
3
=KHCt  (Equation………..3.9) 
Korsmeyer – Peppas kinetic model   Dt/Dα=Kkt
n  (Equation……..3.10) 
Dt refers to cumulative amount of drug is released by the formulation at time t and Do 
refers to initial drug amount in formulation. Ko, K1, KH, KHC and Kk are rate constants for 
zero order, first order, and Higuchi, Hixson-Crowell and Korsmeyer-Peppas models, 
respectively.   
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Dt/Dα refers to drug fraction release at any time point t and “n” denotes release exponent. 
Value of n was computed from slope of Korsmeyer-Peppas plot. 
3.2.7. In vivo studies 
3.2.7.1 Animals 
Twelve healthy male rabbits were enrolled in study weighing 2 ± 0.5 kg in agreement 
with standard protocols by “the Pharmacy Research Ethics Committee” of Faculty of 
Pharmacy and Alternative medicine (approval certificate number 105-2014/PREC), The 
Islamia University of Bahawalpur, Punjab, Pakistan. All animal handling was in good 
agreement with the animal scientific procedure Act, 1986 (Muhammad et al., 2014). 
Weights of animals are given in table 3.5. 
Table 3.5. Weight of rabbits (Kifayat and Gul, 2012) 
Sr. No. Animal Weight 
1 A 2.3 
2 B 2.1 
3 C 2.2 
4 D 2.2 
5 E 2.3 
6 F 2.1 
7 G 2.4 
8 H 2.5 
9 I 2.5 
10 J 2.4 
11 K 2.3 
12 L 2.3 
3.2.7.2. Experimental design 
Single dose study was conducted on animal model (rabbits). Each animal received single 
dose (6.5 mg/kg) orally with the help of a 3 mL syringe having smoothly cut barrel at 
needle end in view of avoiding damage to oral mucosa of rabbit. Dose was given to 
rabbits shifting them to placement restraints (wooden catcher) at time of administration. 
During intervals, rabbits were resting in their respective cages having free access to water 
and feed. After ratifying swallowing of formulation, 10 mL of tape water was given to 
rabbit by a 10 mL syringe with oral tube (Muhammad et al., 2014). 
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3.2.7.3. Sample collection 
2 mL blood sample was withdrawn from jugular vein of rabbit by 3 mL syringe. Samples 
were collected into heparinized centrifuge tubes at zero time before dosing and at 
intervals of 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours after dosing. Collected blood samples 
were centrifuged at 5000 rpm for 10 minutes. Separated plasma samples were frozen at -
70
° 
C in ultra-low freezer (Sanyo-Japan, maximum -86
° 
C) until assay (Kifayat and Gul, 
2012). Steadiness of plasma samples were appraised at -70
° 
C for two months and at 
room temperature for 24 h with potency (>95%).  
3.2.7.4. Preparation of the mobile phase 
Mobile phase of Water and acetonitrile (750: 250 v/v) was transported at flow rate of 1 
mL/min at ambient temperature. Injection volume was 20 µL. Detection was achieved at 256 
nm. 
3.2.7.5 Method for sample analysis 
a)  Preparation of stock solutions 
The stock solution was prepared by dissolving 100 mg of nicorandil in 100 mL of mobile 
phase. Stock solutions of nicorandil were prepared in triplicate. Additional dilutions were 
made from this stock solution in mobile phase. Dilutions in range of 31.25 ng/mL to 500 
ng/mL were prepared. 
b) Preparation of standard curve 
Standard curve was raised to embrace projected ranges of plasma concentrations. By spiking 
different drug concentrations in 0.5 mL plasma standard curve was constructed covering 
points equivalent to 31.25 ng/mL to 500 ng/mL. 20 µl were injected into loop and spectra 
were taken of each concentration. Peak areas were figured out for each concentration.  
c)  Preparation of the sample (Extraction) 
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0.5 mL of plasma aliquot was taken into glass centrifuge tube with teflon lined cap. 0.2 
mL of 0.1M sodium hydroxide was added to plasma sample followed by addition of 2 
mL of chloroform as organic solvent. Mixture was vortexed for 5 min followed by 
centrifugation at 50000 rpm for 10 min. Organic layer was separated into another glass 
tube with teflon lined cap. Remaining aqueous portion was again extracted with 2 mL of 
chloroform. Organic layer evaporated to dryness under nitrogen gas stream. Residues 
were reconstituted with 0.2 mL of mobile phase just before injection (Hassan et al., 
2003). 
d) High Performance Liquid Chromatographic Conditions 
An HPLC system of Agilent consisted of a pump, a column (BDS hypersil C8 4.6 mm x 250 
mm) and UV visible detector used to examine prepared plasma samples. The UV detection 
of nicorandil was set at 256 nm. Mobile phase consisting of water and acetonitrile (750: 250 
v/v) was transported at flow rate of 1 mL/min at ambient temperature. HPLC conditions are 
given in table 3.6. 
Table.3.6. HPLC conditions 
Flow rate HPLC Pump HPLC Detector HPLC Column ʎ max 
1.00 mL/min Agilent Agilent BDS Hypersil C8 256 nm 
e) Pharmacokinetic analysis 
Pharmacokinetic parameters were evaluated by non-compartmental pharmacokinetic 
approach. Maximum concentration (Cmax), time to reach peak plasma concentrations (Tmax) 
and other bioparameters (AUC0-∞, AUMC0-∞, t1/2, Ke and MRT were analyzed by using 
pharmacokinetic software, Kinetica version 4.1.1. 
3.2.8. Statistical analysis 
Software Kinetica version 4.1.1 was used for evaluation of pharmacokinetic parameters and 
Microsoft Excel 2010 was engaged for estimation of bio parameters of nicorandil. One way 
ANOVA was used to compare major pharmacokinetic parameters e.g. Cmax, Tmax and AUC. 
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4.0 Results  
4.1 Swelling ratios at pH 1.2, pH 5.8 and pH 7.4 
Dynamic swelling of formulated hydrogels was determined at different time intervals 
over a period of 72 hrs (till swelling equilibrium reached) in buffer solution of different 
pH. These swelling ratios are given in tables 4.1 to 4.14 and represented 
diagrammatically in figures 4.1 to 4.14. 
Formulations (F1 to F3) having different concentrations of HEMA exhibited excellent 
swelling ratio F1 (1 to 3.498), F2 (1 to 3.190) and F3 (1 to 3.013) at pH 1.2; F1 (1 to 
10.810), F2 (1 to 9.635) and F3 (1 to 9.163) at pH 5.8; F1 (1 to 16.358), F2 (1 to 
14.824) and F3 (1 to 13.696) at pH 7.4 as shown in table 4.1. 
Table 4.1. Comparative swelling ratios of HEMA-co-AA hydrogels using different     
concentrations of HEMA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F1 F2 F3 F1 F2 F3 F1 F2 F3 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.33±0.23 1.17±0.19 1.15±0.22 1.26±0.22 1.23±0.21 1.17±0.2 1.38±0.21 1.28±0.23 1.26±0.24 
0.33 1.50±0.21 1.25±0.22 1.23±0.24 1.42±0.23 1.33±0.24 1.24±0.22 1.61±0.32 1.47±0.33 1.41±0.28 
0.5 1.59±0.29 1.31±0.28 1.31±0.27 1.49±0.34 1.40±0.33 1.32±0.31 1.78±0.33 1.62±0.35 1.58±0.31 
1.0 1.83±0.43 1.44±0.29 1.43±0.31 1.73±0.38 1.63±0.34 1.45±0.35 2.22±0.67 1.96±0.61 1.89±0.42 
2.0 2.18±0.32 1.66±0.31 1.65±0.32 2.15±0.41 2.02±0.38 1.75±0.39 3.01±0.77 2.62±0.73 2.48±0.47 
3.0 2.46±0.22 1.85±0.3 1.85±0.27 2.47±0.43 2.35±0.42 1.96±0.41 3.59±0.79 3.10±0.77 2.96±0.54 
4.0 2.49±0.32 1.94±0.28 1.91±0.3 2.81±0.45 2.68±0.46 2.21±0.44 4.21±0.79 3.58±0.75 3.43±0.66 
5.0 2.61±0.33 2.02±0.32 2.00±0.31 3.20±0.54 3.01±0.53 2.47±0.51 4.74±0.57 4.16±0.67 3.92±0.68 
6.0 2.73±0.35 2.10±0.31 2.09±0.33 3.63±0.68 3.36±0.63 2.72±0.62 5.21±0.35 4.47±0.75 4.32±0.71 
8.0 2.85±0.35 2.20±0.32 2.18±0.34 4.03±0.77 3.76±0.74 3.08±0.73 5.70±0.87 5.03±0.77 5.00±0.75 
10.0 2.96±0.36 2.34±0.33 2.29±0.31 4.44±0.79 4.25±0.75 3.46±0.77 6.61±0.83 5.88±0.79 5.59±0.79 
12.0 3.16±0.34 2.51±0.33 2.47±0.33 4.88±0.81 4.68±0.81 3.88±0.8 7.20±0.65 6.32±0.71 6.08±0.81 
24.0 3.41±0.34 2.85±0.34 2.73±0.33 6.81±0.83 6.22±0.82 5.51±0.83 10.53±0.74 9.40±0.75 8.93±0.83 
48.0 3.50±0.35 3.14±0.33 2.95±0.34 9.14±0.86 8.15±0.84 7.39±0.85 13.88±0.79 12.65±0.78 11.77±0.84 
72.0 3.50±0.35 3.19±0.35 3.01±0.34 10.81±0.88 9.64±0.89 9.16±0.87 16.36±0.85 14.82±0.81 13.70±0.85 
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Figure 4.1. Comparative swelling ratios of HEMA-co-AA hydrogels using different 
concentrations of HEMA 
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Formulations (F4 to F6) having varying compositions of AA showed good swelling 
ratio F4 (1 to 2.932), F5 (1 to 3.115) and F6 (1 to 3.173) at pH 1.2; F4 (1 to 9.397), F5 
(1 to 10.188) and F6 (1 to 10.508) at pH 5.8; F4 (1 to 15.013), F5 (1 to 16.005) and F6 
(1 to 16.420) at pH 7.4 as shown in table 4.2. 
Table 4.2. Comparative swelling ratios of HEMA-co-AA hydrogels using different 
concentrations of AA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F4 F5 F6 F4 F5 F6 F4 F5 F6 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.19±0.23 1.18±0.19 1.17±0.22 1.20±0.22 1.19±0.21 1.18±0.2 1.24±0.21 1.25±0.23 1.28±0.24 
0.33 1.27±0.21 1.31±0.24 1.26±0.24 1.31±0.33 1.29±0.24 1.28±0.22 1.47±0.32 1.43±0.33 1.51±0.33 
0.5 1.36±0.29 1.42±0.27 1.33±0.27 1.42±0.34 1.36±0.33 1.39±0.31 1.60±0.33 1.58±0.35 1.96±0.67 
1.0 1.45±0.43 1.50±0.31 1.44±0.31 1.58±0.38 1.54±0.34 1.53±0.35 1.95±0.67 1.91±0.61 2.08±0.77 
2.0 1.70±0.32 1.66±0.31 1.68±0.32 1.98±0.42 1.89±0.38 1.94±0.39 2.55±0.67 2.50±0.73 2.86±0.79 
3.0 1.90±0.22 1.91±0.3 1.87±0.27 2.28±0.43 2.16±0.42 2.23±0.41 2.99±0.77 2.96±0.77 3.51±0.79 
4.0 1.96±0.32 1.99±0.28 1.96±0.3 2.59±0.45 2.41±0.46 2.54±0.44 3.50±0.79 3.78±0.75 4.06±0.66 
5.0 2.03±0.33 2.07±0.32 2.05±0.29 2.86±0.54 2.70±0.53 2.87±0.51 3.99±0.79 3.88±0.67 4.73±0.68 
6.0 2.15±0.35 2.21±0.31 2.15±0.31 3.19±0.51 2.99±0.54 3.20±0.74 4.40±0.35 4.55±0.75 5.23±0.71 
8.0 2.25±0.31 2.30±0.27 2.26±0.31 3.70±0.62 3.43±0.51 3.66±0.75 4.91±0.87 5.02±0.77 6.74±0.75 
10.0 2.33±0.33 2.51±0.31 2.41±0.27 4.06±0.73 3.89±0.62 4.11±0.81 5.74±0.83 5.56±0.71 7.75±0.35 
12.0 2.55±0.34 2.64±0.32 2.58±0.31 4.48±0.77 4.35±0.73 4.64±0.8 6.30±0.65 6.10±0.75 8.67±0.87 
24.0 2.80±0.31 2.93±0.34 2.90±0.34 6.31±0.83 5.84±0.82 6.54±0.83 9.24±0.74 10.78±0.79 12.95±0.83 
48.0 2.90±0.33 3.11±0.33 3.13±0.34 7.98±0.86 7.95±0.84 8.99±0.86 12.57±0.79 14.85±0.81 15.64±0.65 
72.0 2.93±0.35 3.12±0.35 3.17±0.34 9.40±0.88 10.19±0.89 10.51±0.88 15.01±0.85 16.01±0.81 16.42±0.74 
 
 
Figure 4.2. Comparative swelling ratios of HEMA-co-AA hydrogels using different 
concentrations of AA 
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Formulations (F7 to F9) with changing concentration of crosslinker MBA exhibited less 
swelling ratio F7 (1 to 2.917), F8 (1 to 2.805) and F9 (1 to 2.528) at pH 1.2; F7 (1 to 
9.904), F8 (1 to 8.986) and F9 (1 to 6.193) at pH 5.8; F7 (1 to 10.104), F8 (1 to 15.066) 
and F9 (1 to 13.775) at pH 7.4 as shown in table 4.3. 
Table 4.3. Comparative swelling ratios of HEMA-co-AA hydrogels using different 
concentrations of MBA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F7 F8 F9 F7 F8 F9 F7 F8 F9 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.14±0.19 1.09±0.23 1.01±0.22 1.18±0.21 1.22±0.22 1.19±0.21 1.28±0.23 1.43±0.24 1.06±0.21 
0.33 1.22±0.22 1.14±0.29 1.05±0.24 1.28±0.24 1.34±0.23 1.39±0.24 1.51±0.32 1.76±0.28 1.41±0.32 
0.5 1.31±0.32 1.25±0.31 1.1±0.19 1.42±0.33 1.48±0.34 1.41±0.33 1.96±0.33 2.02±0.31 1.53±0.33 
1.0 1.45±0.27 1.46±0.3 1.28±0.22 1.54±0.34 1.67±0.38 1.6±0.45 2.08±0.61 2.58±0.42 1.73±0.77 
2.0 1.61±0.3 1.56±0.28 1.42±0.32 1.98±0.38 1.7±0.41 1.75±4.21 2.86±0.73 3.63±0.47 1.91±0.77 
3.0 1.83±0.31 1.76±0.32 1.5±0.33 2.28±0.42 1.86±0.43 1.89±4.76 3.51±0.77 4.44±0.77 2.12±0.75 
4.0 1.94±0.33 1.97±0.31 1.75±0.35 0.43±0.46 1.93±0.45 1.97±6.73 4.06±0.75 5.04±0.75 2.89±0.67 
5.0 1.99±0.32 2.04±0.33 1.86±0.35 0.45±0.53 2.56±4.21 2.36±0.53 4.73±0.67 5.73±0.67 3.36±0.77 
6.0 2.09±0.31 2.13±0.35 1.94±0.36 0.54±0.63 2.78±4.76 2.43±0.63 5.23±0.75 6.56±0.87 3.77±0.35 
8.0 2.19±0.32 2.17±0.35 1.99±0.34 0.68±0.74 3.38±6.73 3.05±0.74 6.74±0.77 7.26±0.83 4.3±0.87 
10.0 2.28±0.35 2.26±0.36 2.11±0.34 4.21±0.75 3.97±0.74 3.29±0.75 7.75±0.79 8.32±0.65 5.02±0.83 
12.0 2.5±0.36 2.55±0.34 2.33±0.33 4.76±0.81 4.13±0.75 3.39±0.81 8.67±0.71 9.11±0.74 5.58±0.65 
24.0 2.73±0.34 2.76±0.34 2.39±0.33 6.73±0.82 5.45±0.81 4.45±0.82 12.95±0.75 12.58±0.79 9.15±0.74 
48.0 2.9±0.34 2.78±0.35 2.5±0.34 9.22±0.84 7.34±0.82 5.43±0.84 15.64±0.78 14.77±0.84 12.74±0.79 
72.0 2.92±0.35 2.81±0.35 2.53±0.34 9.9±0.89 8.99±0.88 6.19±0.89 10.1±0.81 15.07±0.85 13.78±0.85 
 
 
Figure 4.3. Comparative swelling ratios of HEMA-co-AA hydrogels using different 
concentrations of MBA 
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Formulations (F10 to F12) with varying compositions of HPMC were subjected to 
swelling at various pH and exhibited excellent swelling ratio F10 (1 to 5.412), F11 (1 to 
5.878) and F12 (1 to 6.245) at pH 1.2; F10 (1 to 22.974), F11 (1 to 27.902) and F12 (1 
to 31.327) at pH 5.8; F10 (1 to 51.033), F11 (1 to 55.027) and F12 (1 to 69.647) at pH 
7.4 as shown in table 4.2. 
Table 4.4. Comparative swelling ratios of HPMC-co-AA hydrogels using different 
concentrations of HPMC (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F10 F11 F12 F10 F11 F12 F10 F11 F12 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.09±0.23 1.27±0.19 1.37±0.22 1.23±0.24 1.23±0.21 1.32±0.2 1.31±0.21 1.37±0.23 1.86±1.17 
0.33 1.19±0.21 1.43±0.22 1.55±0.24 1.42±0.33 1.56±0.24 1.73±0.22 1.6±0.32 1.78±1.17 2.23±1.44 
0.5 1.27±0.29 1.54±0.32 1.66±0.33 1.62±0.34 1.74±0.33 1.88±0.31 1.81±1.17 2.08±1.44 2.71±2.13 
1.0 1.4±0.43 1.6±0.33 1.75±0.51 1.81±0.68 1.9±0.63 2.25±0.62 2.06±1.26 2.62±2.13 3.27±2.23 
2.0 1.46±0.32 2.08±0.35 2.3±0.62 1.88±0.77 2.88±0.74 3.5±0.73 2.33±1.44 4.84±2.23 5.95±2.48 
3.0 1.52±0.22 2.27±0.35 2.49±0.73 2.18±0.79 3.2±0.75 3.63±0.77 3.68±2.13 5.68±2.29 6.95±2.5 
4.0 1.99±0.32 2.45±0.36 2.63±0.77 2.75±0.81 3.65±0.81 4.61±0.8 5.21±2.19 6.7±2.37 8.11±2.31 
5.0 2.14±0.33 2.62±0.54 2.89±0.65 3.44±0.83 3.92±0.82 5.22±0.83 5.83±2.23 8.16±2.48 9.79±2.41 
6.0 2.27±0.35 2.88±0.68 3.13±0.74 3.73±0.86 4.4±0.84 6.65±0.85 7.03±2.31 9.57±2.5 11.29±2.38 
8.0 2.46±0.35 3.1±0.77 3.33±0.79 3.94±0.88 5.41±0.89 8.11±0.87 8.17±2.5 9.8±2.38 12.56±2.56 
10.0 2.63±0.36 3.25±0.79 3.46±0.85 4.96±0.79 7.13±0.75 9.2±0.77 9.83±2.41 10.89±2.56 14.54±3.33 
12.0 2.82±0.34 3.59±0.68 3.59±0.77 7.35±0.85 8.79±0.81 10.45±0.8 10.92±2.56 14.24±3.33 18.19±3.34 
24.0 3.77±0.34 4.45±0.81 4.9±0.8 9.89±0.92 11.66±0.8 12.55±1.1 18.14±2.33 23.64±3.34 27.63±3.46 
48.0 4.61±0.35 5.27±0.82 5.34±0.83 13.42±1.0 18.15±1.2 20.91±1.3 30.46±2.54 36.79±3.46 43.2±3.57 
72.0 5.41±0.35 5.88±0.84 6.25±0.85 22.97±1.4 27.9±1.3 31.33±1.5 51.03±2.85 55.03±3.57 69.65±3.62 
 
 
Figure 4.4. Comparative swelling ratios of HPMC-co-AA hydrogels using different 
concentrations of HPMC 
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Formulations (F13 to F15) with changing concentration of monomer AA exhibited 
swelling ratio F13 (1 to 6.395), F14 (1 to 6.457) and F15 (1 to 6.719) at pH 1.2; F13 (1 
to 17.640), F14 (1 to 19.927) and F15 (1 to 25.963) at pH 5.8; F13 (1 to 37.716), F14 (1 
to 40.668) and F15 (1 to 47.380) at pH 7.4 as shown in table 4.5. 
Table 4.5. Comparative swelling ratios of HPMC-co-AA hydrogels using different 
concentrations of AA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F13 F14 F15 F13 F14 F15 F13 F14 F15 
0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.4±0.23 1.31±0.19 1.5±0.22 1.07±0.24 1.02±0.21 1.48±0.2 1.08±0.21 1.08±0.23 1.75±1.17 
0.33 1.57±0.22 1.56±0.22 1.61±0.24 1.13±0.33 1.04±0.31 1.66±0.22 1.13±0.32 1.09±1.17 2.18±1.44 
0.5 1.68±0.32 1.65±0.32 1.71±0.32 1.2±0.34 1.17±0.62 1.82±0.31 1.23±1.17 1.31±1.44 2.46±1.17 
1 1.74±0.43 1.72±0.33 1.93±0.33 1.32±0.68 1.3±0.73 2.18±0.62 1.44±1.26 1.61±2.13 3.21±1.44 
2 2.28±0.32 2.24±0.35 2.24±0.35 1.57±0.77 2.07±0.77 2.89±0.73 2.51±1.44 2.83±2.23 4.58±2.13 
3 2.42±0.22 2.42±0.35 2.5±0.35 2.18±0.79 2.8±0.75 3.53±0.77 3.19±2.13 3.41±2.29 5.56±2.5 
4 2.66±0.32 2.64±0.36 2.68±0.68 2.52±0.81 3.09±0.81 4.12±0.75 3.69±2.19 4.07±2.37 6.41±2.31 
5 2.82±0.33 2.82±0.54 2.78±0.77 2.9±0.83 3.84±0.82 4.6±0.81 4.1±2.23 4.92±2.13 7.13±2.41 
6 2.92±0.35 2.98±0.85 2.88±0.74 3.5±0.86 4.68±0.84 5.38±0.82 5.2±2.31 5.85±2.23 7.84±2.38 
8 3.16±0.35 3.06±0.77 3.09±0.79 4.2±0.88 5.55±0.89 6.33±0.84 5.8±2.5 6.85±2.48 9.13±2.46 
10 3.31±0.36 3.14±0.8 3.38±0.85 4.74±0.79 6.51±0.75 7.36±0.77 6.55±2.41 7.84±2.5 10.48±2.33 
12 3.36±0.34 3.25±0.83 3.5±0.77 6.03±0.85 7.47±0.8 8.39±0.83 9.19±0.81 9.61±2.33 12.71±2.34 
24 4.87±0.34 4.91±0.81 4.74±0.8 9.54±0.92 11.01±1.1 13.47±1.1 13.69±0.8 14.76±2.34 21.79±2.46 
48 5.97±0.35 4.99±0.82 6.07±0.83 14.25±1.01 18.24±1.3 21.23±1.4 19.32±1.1 23.8±2.46 36.9±2.57 
72 6.4±0.35 6.46±0.84 6.72±0.85 17.64±1.44 19.93±1.5 25.96±1.4 37.72±1.4 40.67±2.57 47.38±2.62 
 
 
Figure 4.5. Comparative swelling ratios of HPMC-co-AA hydrogels using different 
concentrations of AA 
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Formulations (F16 to F18) with varying compositions of crosslinker showed less 
swelling ratio F16 (1 to 5.434), F17 (1 to 5.303) and F18 (1 to 5.091) at pH 1.2; F16 (1 
to 19.606), F17 (1 to 16.741) and F18 (1 to 14.631) at pH 5.8; F16 (1 to 35.379), F17 (1 
to 31.230) and F18 (1 to 28.633) at pH 7.4 as shown in table 4.6. 
Table 4.6. Comparative swelling ratios of HPMC-co-AA hydrogels using different 
concentrations of MBA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F16 F17 F18 F16 F17 F18 F16 F17 F18 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.45±0.23 1.43±0.19 1.37±0.22 1.36±0.24 1.31±0.21 1.3±0.2 1.66±0.21 1.84±0.23 1.45±1.17 
0.33 1.55±0.22 1.53±0.22 1.47±0.24 1.52±0.33 1.43±0.31 1.41±0.22 2.02±0.32 2.07±1.17 1.65±1.44 
0.5 1.63±0.32 1.62±0.32 1.55±0.32 1.6±0.34 1.52±0.62 1.48±0.31 2.3±1.44 2.25±1.44 1.8±1.17 
1.0 1.8±0.43 1.82±0.22 1.73±0.33 1.88±0.68 1.74±0.73 1.62±0.62 2.93±2.13 2.73±2.13 2.19±1.44 
2.0 2.1±0.32 2.16±0.32 2.05±0.35 2.6±0.77 2.32±0.31 2.16±0.73 4.07±2.5 3.57±2.23 3.02±2.13 
3.0 2.3±0.22 2.38±0.33 2.24±0.35 2.81±0.79 2.65±0.62 2.45±0.77 4.93±2.31 4.34±2.29 3.72±2.5 
4.0 2.46±0.32 2.58±0.36 2.45±0.68 3.16±0.81 2.96±0.73 2.71±0.75 5.7±2.41 4.99±2.31 4.39±2.31 
5.0 2.55±0.33 2.65±0.54 2.57±0.77 3.49±0.83 3.23±0.77 3.11±0.81 6.42±2.38 5.55±2.5 5.03±2.41 
6.0 2.68±0.35 2.72±0.85 2.75±0.74 4.13±0.86 3.92±0.84 3.64±0.81 7.46±2.31 6.2±2.41 6.22±2.38 
8.0 2.77±0.35 2.77±0.77 2.87±0.79 4.49±0.88 4.28±0.89 3.73±0.83 8.84±2.5 7.17±2.48 6.87±2.33 
10.0 2.81±0.77 2.84±0.8 2.99±0.85 5.19±0.89 4.96±0.75 4.82±0.86 9.65±2.41 8.5±2.5 8.1±2.34 
12.0 2.92±0.8 2.85±0.83 3.02±0.77 5.97±0.75 5.52±0.8 5.13±0.83 10.82±2.34 9.25±2.33 9.03±2.46 
24.0 4.18±0.83 4.29±0.81 4.26±0.8 9.33±0.8 9.11±1.1 8.16±1.19 17.6±2.46 16.68±2.34 14.28±2.59 
48.0 5.07±0.81 5.02±0.82 4.84±0.83 15.37±1.2 14.52±1.3 13.11±1.3 28.24±1.26 26.03±2.36 23.64±2.55 
72.0 5.43±0.81 5.3±0.84 5.09±0.85 19.61±1.3 16.74±1.4 14.63±1.3 35.38±1.39 31.23±2.47 28.63±2.65 
 
 
Figure 4.6. Comparative swelling ratios of HPMC-co-AA hydrogels using different 
concentrations of MBA 
0
10
20
30
40
50
60
70
80
0 20 40 60 80
S
w
el
li
n
g
 R
a
ti
o
 (
q
) 
Time (hrs) 
F16 pH 1.2
F17 pH 1.2
F18 pH 1.2
F16 pH 5.8
F17 pH 5.8
F18 pH 5.8
F16 pH 7.4
F17 pH 7.4
F18 pH 7.4
64 
 
Formulations (F19 to F21) having varying compositions of HEMA showed swelling 
ratio ranging F19 (1 to 5.416), F20 (1 to 4.374) and F21 (1 to 3.368) at pH 1.2; F19 (1 
to 25.284), F20 (1 to 23.104) and F21 (1 to 21.970) at pH 5.8; F19 (1 to 50.796), F20 (1 
to 46.482) and F21 (1 to 39.365) at pH 7.4 as shown in table 4.7. 
Table 4.7. Comparative swelling ratios of HPMC-co-AA-co-HEMA hydrogels using 
different concentrations of HEMA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F19 F20 F21 F19 F20 F21 F19 F20 F21 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.1±0.23 1.08±0.19 1.13±0.22 1.4±0.24 1.34±0.21 1.23±0.2 1.21±0.21 1.04±0.23 1.02±0.34 
0.33 1.53±0.22 1.18±0.22 1.21±0.24 1.79±0.33 1.58±0.31 1.46±0.22 1.77±0.32 1.25±0.22 1.2±0.68 
0.5 1.68±0.32 1.45±0.32 1.33±0.32 2.06±0.34 1.77±0.62 1.66±0.31 2.01±1.17 1.51±0.31 1.5±0.77 
1.0 1.96±0.43 1.67±0.33 1.48±0.33 2.24±0.68 2.07±0.73 1.81±0.62 2.54±1.26 1.8±0.62 1.79±0.79 
2.0 2.21±0.32 1.86±0.35 1.65±0.35 2.72±0.77 2.48±0.77 1.98±0.73 3.99±1.44 2.71±0.73 2.34±0.81 
3.0 2.55±0.22 2.15±0.35 1.76±0.35 3.39±0.79 3.07±0.75 2.29±0.77 5.47±2.13 3.34±0.77 3.01±0.83 
4.0 2.83±0.32 2.29±0.36 1.87±0.68 3.64±0.81 3.37±0.73 2.63±0.75 6.78±2.19 4.38±0.75 3.9±0.8 
5.0 3.05±0.33 2.49±0.54 2.01±0.77 4.04±0.83 3.49±0.77 3.05±0.81 7.5±2.23 4.76±0.75 4.98±0.83 
6.0 3.3±0.35 2.81±0.85 2.09±0.77 4.33±0.86 3.8±0.75 3.44±0.82 11.23±2.3 5.98±0.89 5.35±0.85 
8.0 3.52±0.35 3.01±0.77 2.23±0.68 5.29±0.88 4.07±0.89 3.64±0.84 14.43±2.5 8.75±0.75 6.6±0.75 
10.0 3.8±0.36 3.28±0.68 2.4±0.65 6.02±0.79 4.99±0.75 4±0.77 17.39±2.4 11.22±0.8 10.64±0.8 
12.0 4.05±0.34 3.42±0.77 2.61±0.77 7.47±0.85 5.54±0.8 4.31±0.89 19.93±0.8 14.36±1.1 11.63±1.1 
24.0 4.34±0.34 3.67±0.74 2.84±0.8 11.59±0.9 9.14±1.17 7.35±0.75 27.85±0.8 22.79±1.3 18.88±1.3 
48.0 4.6±0.35 3.91±0.79 2.96±0.73 17.12±1.0 14.68±1.3 13.16±0.8 39.8±1.17 36.59±1.4 30.62±1.5 
72.0 5.42±0.35 4.37±0.75 3.37±0.75 25.28±1.4 23.1±1.32 21.97±1.1 50.8±1.44 46.48±1.5 39.37±1.6 
 
 
Figure 4.7. Comparative swelling ratios of HPMC-co-AA-co-HEMA hydrogels using 
different concentrations of HEMA 
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Formulations (F22 to F23) with increasing concentration of AA showed increasing 
trend in swelling ratio as F22 (1 to 5.00), F23 (1 to 5.280) and F24 (1 to 5.784) at pH 
1.2; F22 (1 to 26.849), F23 (1 to 31.258) and F24 (1 to 36.369) at pH 5.8; F22 (1 to 
47.436), F23 (1 to 56.431) and F24 (1 to 62.270) at pH 7.4 has shown in table 4.8. 
Table 4.8. Comparative swelling ratios of HPMC-co-AA-co-HEMA hydrogels using 
different concentrations of AA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F22 F23 F24 F22 F23 F24 F22 F23 F24 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.04±0.23 1.28±0.19 1.24±0.22 1.23±0.24 2.04±0.21 2.43±0.2 1.56±0.21 1.93±0.23 1.64±0.86 
0.33 1.1±0.22 1.49±0.22 1.39±0.32 1.26±0.33 2.3±0.31 2.94±0.22 1.85±0.32 2.3±0.83 2.87±0.83 
0.5 1.16±0.32 1.61±0.32 1.5±0.43 1.46±0.34 2.57±0.62 4.01±0.34 2.18±0.86 2.67±0.86 3.32±0.88 
1.0 1.27±0.43 1.53±0.22 1.62±0.32 1.57±0.68 2.9±0.73 4.64±0.68 2.33±0.83 4.11±0.88 3.85±1.38 
2.0 1.48±0.32 1.9±0.32 1.98±0.35 2.02±0.77 3.42±0.31 5.89±0.77 4.28±0.86 5.51±1.38 7.61±1.17 
3.0 1.54±0.22 2.01±0.33 2.09±0.35 3.07±0.79 4.17±0.62 6.71±0.77 4.89±0.88 7.2±1.44 10.13±1.24 
4.0 1.59±0.32 2.16±0.36 2.26±0.68 3.56±0.81 5.18±0.73 7.05±0.75 5.73±1.38 8.54±1.17 11.27±1.31 
5.0 1.66±0.33 2.26±0.35 2.37±0.77 4.24±0.83 5.83±0.77 7.76±0.81 7.25±1.17 10.71±1.44 12.3±1.41 
6.0 1.87±0.35 2.33±0.68 2.6±0.74 5.6±0.86 6.13±0.84 8.28±0.81 8.01±1.24 11.47±1.41 13.83±1.38 
8.0 2.01±0.35 2.42±0.77 2.53±0.79 5.8±0.88 7.09±0.89 9.43±0.83 10.48±1.42 14.08±1.48 17.56±1.33 
10.0 2.28±0.35 2.58±0.74 2.63±0.85 6.98±0.8 8.15±0.7 11.27±0.86 12.89±1.41 16.57±0.8 19.54±1.34 
12.0 2.48±0.68 2.69±0.79 2.88±0.77 7.98±0.7 9.71±0.8 12.49±0.83 14.25±1.34 18.37±1.17 21.61±1.46 
24.0 3.23±0.77 3.52±0.81 3.76±0.8 12.52±0.8 14.68±1.1 18.43±0.86 22.37±1.46 26.15±1.24 30.52±1.59 
48.0 3.99±0.74 4.21±0.82 4.48±0.83 20.58±1.1 24.03±1.2 27.94±0.88 34.25±1.26 38.81±1.42 44.28±2.15 
72.0 5±0.79 5.28±0.84 5.78±0.85 26.85±1.3 31.26±1.4 36.37±1.38 47.44±1.39 56.43±2.17 62.27±2.25 
 
 
Figure 4.8. Comparative swelling ratios of HPMC-co-AA-co-HEMA hydrogels using 
different concentrations of AA 
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Formulations (F25 to F27) with different concentrations of HPMC showed swelling 
ratio ranging F25 (1 to 4.127), F26 (1 to 4.294) and F27 (1 to 4.500) at pH 1.2; F25 (1 
to 23.500), F26 (1 to 25.826) and F27 (1 to 29.075) at pH 5.8; F25 (1 to 42.618), F26 (1 
to 45.604) and F27 (1 to 49.011) at pH 7.4 as shown in table 4.9. 
Table 4.9. Comparative swelling ratios of HPMC-co-AA-co-HEMA hydrogels using 
different concentrations of HPMC (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F25 F26 F27 F25 F26 F27 F25 F26 F27 
0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 1.29±0.23 1.33±0.22 1.43±0.22 1.66±0.24 1.53±0.21 1.78±0.2 1.45±0.23 1.58±0.23 1.98±0.34 
0.33 1.43±0.22 1.46±0.32 1.63±0.24 1.74±0.33 1.88±0.31 2.25±0.22 1.75±0.22 1.92±0.22 2.21±0.68 
0.5 1.51±0.32 1.56±0.43 1.74±0.32 1.88±0.34 2.16±0.62 2.62±0.31 2.09±0.31 2.2±0.31 2.51±0.77 
1 1.56±0.43 1.65±0.32 1.87±0.33 2.06±0.68 2.47±0.73 3.03±0.62 2.52±0.62 2.72±0.62 3.09±0.79 
2 2.01±0.32 2.09±0.35 2.2±0.35 2.63±0.77 3.03±0.31 3.67±0.73 4.33±0.73 4.8±0.73 5.18±0.81 
3 2.12±0.22 2.25±0.35 2.36±0.35 2.87±0.79 3.9±0.62 4.52±0.62 5.05±0.77 5.6±0.77 7.1±0.83 
4 2.31±0.32 2.35±0.68 2.45±0.68 3.51±0.81 4.68±0.73 5.9±0.73 5.92±0.75 6.5±0.75 8.03±0.8 
5 2.43±0.33 2.54±0.77 2.59±0.77 4.76±0.83 5.88±0.77 7.25±0.75 7.7±0.75 8.57±0.75 9.73±0.83 
6 2.57±0.35 2.59±0.74 2.77±0.74 5.92±0.86 7.17±0.84 8.7±0.75 8.38±0.89 9.28±0.83 11.07±0.85 
8 2.75±0.35 2.69±0.83 2.98±0.79 6.48±0.88 8.55±0.89 10.26±0.8 9.28±0.75 10.95±0.8 13.55±0.75 
10 2.91±0.77 2.86±0.86 3.12±0.85 7.41±0.89 9.26±0.75 11.06±1.17 10.59±0.8 13.11±0.8 15.53±0.8 
12 3.05±0.8 3.15±0.88 3.26±0.77 8.62±0.75 10.29±0.8 12.21±0.83 11.92±1.1 14.9±0.8 16.93±1.17 
24 3.56±0.83 3.75±0.8 3.93±0.8 13.02±0.8 15.26±1.1 17.81±1.19 18.56±1.3 21.45±1.3 24.67±1.34 
48 4.02±0.81 4.12±0.83 4.26±0.83 19.22±1.1 21.93±1.2 24.69±1.33 29.88±1.4 33.5±1.46 36.67±1.57 
72 4.13±0.81 4.29±0.85 4.5±0.85 23.5±1.34 25.83±1.4 29.08±1.38 42.62±1.5 45.6±1.57 49.01±1.62 
 
 
Figure 4.9. Comparative swelling ratios of HPMC-co-AA-co-HEMA hydrogels using 
different concentrations of HPMC 
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Formulations (F28 to F30) having varying composition of MBA showed swelling ratio 
ranging F28 (1 to 2.896), F29 (1 to 2.663) and F30 (1 to 2.322) at pH 1.2; F28 (1 to 
16.690), F29 (1 to 14.972) and F30 (1 to 12.582) at pH 5.8; F28 (1 to 30.398), F29 (1 to 
26.659) and F30 (1 to 21.592) at pH 7.4 as shown in table 4.10. 
Table 4.10. Comparative swelling ratios of HPMC-co-AA-co-HEMA hydrogels using 
different concentrations of MBA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F28 F29 F30 F28 F29 F30 F28 F29 F30 
0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 0.91±0.19 0.85±0.23 0.72±0.22 0.99±0.21 1.06±0.22 0.77±0.21 1.04±0.23 0.92±0.24 0.87±0.21 
0.33 1±0.22 0.96±0.29 0.79±0.24 1.22±0.24 1.11±0.23 0.97±0.24 1.25±0.32 1.12±0.28 0.97±0.32 
0.5 1.06±0.32 1.03±0.31 0.84±0.19 1.39±0.33 1.2±0.34 1.13±0.33 1.49±0.33 1.29±0.31 1.11±0.33 
1 1.1±0.27 1.11±0.3 0.89±0.22 1.6±0.34 1.32±0.42 1.31±0.45 1.8±0.61 1.59±0.42 1.36±0.61 
2 1.41±0.3 1.3±0.28 1.13±0.32 1.96±0.38 1.67±0.46 1.58±0.21 3.09±0.73 2.81±0.47 2.28±0.73 
3 1.49±0.31 1.4±0.32 1.22±0.33 2.52±0.42 1.83±0.53 1.95±0.76 3.6±0.77 3.28±0.77 3.13±0.77 
4 1.62±0.33 1.45±0.31 1.27±0.35 3.03±0.46 2.23±0.45 2.54±0.73 4.22±0.75 3.8±0.75 3.54±0.67 
5 1.71±0.32 1.53±0.32 1.37±0.35 3.8±0.53 3.03±0.21 3.13±0.53 5.5±0.67 5.01±0.67 4.28±0.77 
6 1.8±0.31 1.64±0.35 1.4±0.36 4.64±0.63 3.77±0.76 3.75±0.63 5.98±0.75 5.43±0.87 4.88±0.35 
8 1.93±0.32 1.77±0.36 1.45±0.34 5.53±0.74 4.13±0.73 4.42±0.74 6.62±0.67 6.4±0.83 5.97±0.87 
10 2.05±0.35 1.85±0.36 1.54±0.34 5.99±0.75 4.72±0.74 4.76±0.75 7.56±0.77 7.66±0.65 6.84±0.83 
12 2.14±0.36 1.93±0.34 1.7±0.33 6.65±0.81 5.49±0.75 5.26±0.81 8.5±0.71 8.71±0.74 7.46±0.65 
24 2.5±0.34 2.32±0.34 2.03±0.33 9.86±0.82 8.29±0.81 7.67±0.82 13.24±0.7 12.54±0.79 10.87±0.74 
48 2.82±0.34 2.52±0.35 2.23±0.34 14.17±0.8 12.24±0.8 10.64±0.8 21.31±0.7 19.61±0.84 16.16±0.79 
72 2.9±0.35 2.66±0.35 2.32±0.34 16.69±0.8 14.97±0.8 12.53±0.8 30.4±0.81 26.66±0.85 21.59±0.85 
 
 
Figure 4.10. Comparative swelling ratios of HPMC-co-AA-co-HEMA hydrogels 
using different concentrations of MBA 
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Formulations (F31 to F33) having different concentrations of MAA showed swelling 
ratio ranging F31 (1 to 58.692), F32 (1 to 57.404) and F33 (1 to 56.754) at pH 1.2; F31 
(1 to 59.545), F32 (1 to 59.791) and F33 (1 to 59.003) at pH 5.8; F31 (1 to 69.052), F32 
(1 to 65.532) and F33 (1 to 62.716) at pH 7.4 as shown in table 4.11. 
Table 4.11. Comparative swelling ratios of CMC-co-MAA-co-AMPS hydrogels using 
different concentrations of MAA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F31 F32 F33 F31 F32 F33 F31 F32 F33 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 6.29±0.21 5.86±0.23 5.71±1.17 62.21±0.2 6.08±0.23 6.46±1.17 7.45±0.2 6.66±0.2 6.87±1.1 
0.33 9.31±0.32 8.5±1.17 8.24±1.44 6.65±0.32 8.92±1.17 9.86±1.44 11.2±0.3 9.77±1.1 10.5±1.4 
0.5 16.53±1.17 16.09±1.44 15.42±1.17 10.02±1.4 16.42±1.4 16.34±1.1 19.1±1.1 17.9±1.4 17.4±2.1 
1.0 21.59±1.26 21.08±2.13 20.03±1.44 17.05±2.1 21.45±2.1 21.35±1.4 24.7±1.3 23.5±2.1 22.7±2.2 
2.0 31.52±1.44 30.67±2.23 29.35±2.13 22.07±2.5 31.31±2.2 31.15±2.1 35.9±1.4 34.3±2.2 33.1±2.4 
3.0 34.34±2.13 33.29±2.29 31.29±2.5 32.1±2.31 34.11±2.2 32.79±2.5 39.3±2.1 37.3±2.2 34.9±2.5 
4.0 43.15±2.19 41.95±2.37 40.5±2.31 35.06±2.4 42.86±2.3 42.65±2.3 49.1±2.1 46.9±2.3 45.3±2.3 
5.0 48.72±2.23 47.84±2.13 45.68±2.41 43.8±2.38 49.47±2.5 47.58±2.4 55.9±2.2 54.2±2.4 50.6±2.4 
6.0 54.21±2.31 53.21±2.23 50.99±2.38 49.96±2.3 54.4±2.41 52.48±2.3 61.5±2.3 59.6±2.5 55.8±2.4 
8.0 56.45±2.5 55.36±2.48 53.11±2.46 54.98±2.5 56.07±2.4 54.27±2.3 63.5±2.5 61.5±2.3 57.7±2.6 
10.0 56.75±2.41 55.66±2.5 55.03±2.33 56.73±2.4 58.03±2.5 57.41±2.3 66.7±2.4 63.6±2.5 61.1±3.3 
12.0 58.69±0.81 57.4±2.33 56.75±2.34 59.55±2.3 59.79±2.3 59±2.46 69.1±2.5 65.5±3.3 62.7±3.3 
 
 
Figure 4.11. Comparative swelling ratios of CMC-co-MAA-co-AMPS hydrogels using 
different concentrations of MAA 
 
0
10
20
30
40
50
60
70
80
0 2 4 6 8 10 12 14
S
w
el
li
n
g
 R
a
ti
o
 (
q
) 
 
Time (hrs) 
F31 pH 1.2
F32 pH 1.2
F33 pH 1.2
F31 pH 5.8
F32 pH 5.8
F33 pH 5.8
F31 pH 7.4
F32 pH 7.4
F33 pH 7.4
69 
 
Formulations from F34 to F36 with increasing concentration of AMPS showed 
increasing trend in swelling ratio as F34 (1 to 65.963), F35 (1 to 69.005) and F36 (1 to 
75.030) at pH 1.2; F34 (1 to 66.184), F35 (1 to 70.075) and F36 (1 to 76.050) at pH 5.8; 
F34 (1 to 66.638), F35 (1 to 70.562) and F36 (1 to 76.476) at pH 7.4 has shown in table 
4.12. 
Table 4.12. Comparative swelling ratios of CMC-co-MAA-co-AMPS hydrogels using 
different concentrations of AMPS (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F34 F35 F36 F34 F35 F36 F34 F35 F36 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 14.61±0.21 16.6±0.23 18.31±0.3 14.59±0.2 16.86±0.2 18.55±1.1 14.1±0.2 16.9±0.2 18.6±1.1 
0.33 20.96±0.32 23.08±1.1 25.49±1.4 21.17±0.3 23.44±0.2 25.96±1.4 21.3±0.3 23.6±0.2 26.1±1.4 
0.5 33.16±0.32 35.54±1.4 40.24±1.1 33.81±1.4 36.09±0.3 40.8±1.17 34.1±1.1 36.3±0.3 41.1±2.1 
1.0 44.89±1.44 47.5±1.44 53.17±1.4 45.48±2.1 48.24±0.3 53.8±1.44 45.7±1.2 48.5±1.1 54.1±2.3 
2.0 61.47±1.17 64.42±1.1 71.45±2.1 62.22±2.5 65.42±1.4 72.34±2.1 62.6±1.4 65.8±1.2 72.7±2.4 
3.0 65.96±1.44 69±1.44 74.93±2.5 66.16±2.3 70.07±1.1 75.95±2.5 66.6±2.1 70.5±1.4 76.3±2.5 
4.0 65.96±1.13 69±2.13 74.94±2.3 66.17±2.4 70.07±1.4 75.96±2.3 66.6±2.1 70.5±2.1 76.4±2.5 
5.0 65.96±1.23 69±2.13 74.96±2.4 66.12±2.3 70.07±2.5 75.98±2.4 66.5±2.2 70.5±2.4 76.4±2.4 
6.0 65.96±1.31 69±2.23 74.98±2.3 66.15±2.3 70.07±2.4 76±2.38 66.6±2.3 70.5±2.5 76.4±2.3 
8.0 65.96±1.5 69±2.48 75.02±2.4 66.17±2.3 70.07±2.4 76.04±2.3 66.6±2.4 70.5±2.3 76.4±2.5 
10.0 65.96±1.41 69±2.5 75.01±2.3 66.18±2.4 70.07±2.5 76.04±2.3 66.6±2.5 70.5±2.4 76.4±3.1 
12.0 65.96±1.81 69.01±2.3 75.03±2.3 66.18±2.3 70.08±2.3 76.05±2.4 66.6±2.5 70.5±2.5 76.5±3.2 
 
 
Figure 4.12. Comparative swelling ratios of CMC-co-MAA-co-AMPS hydrogels using 
different concentrations of AMPS 
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Formulations from F37 to F39 with increasing concentration of CMC exhibited drift in 
swelling ratio as F37 (1 to 66.626), F38 (1 to 67.627) and F39 (1 to 68.856) at pH 1.2; 
F37 (1 to 68.241), F38 (1 to 69.694) and F39 (1 to 70.425) at pH 5.8; F37 (1 to 71.111), 
F38 (1 to 73.524) and F39 (1 to 75.309) at pH 7.4 has shown in table 4.13. 
Table 4.13. Comparative swelling ratios of CMC-co-MAA-co-AMPS hydrogels using 
different concentrations of CMC (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 5.8 Swelling ratio (q) at pH 7.4 
F37 F38 F39 F37 F38 F39 F37 F38 F39 
0.0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 
0.16 14.69±0.2 14.6±0.2 15.5±1.1 17.39±0.2 16.98±0.2 17.07±1.1 15.7±0.2 16.8±0.2 17.81±1.1 
0.33 21.3±0.32 21.3±1.1 22.23±1.4 24.04±0.3 23.6±1.17 24.13±1.4 22.3±0.3 23.7±0.2 24.85±1.4 
0.5 34.03±1.1 34.4±1.4 34.86±1.1 36.94±1.1 36.34±1.4 37.28±2.1 35.4±1.4 36.95±0.3 39.13±1.1 
1.0 45.77±1.1 45.8±2.1 47.42±1.4 48.77±1.2 48.57±2.1 50.13±2.2 47.1±2.1 49.12±0.3 51.98±1.4 
2.0 62.63±1.4 62.3±2.2 63.23±2.1 65.95±1.4 65.87±2.2 66.79±2.4 63.5±2.5 65.5±1.44 68.65±2.1 
3.0 66.59±2.1 67.6±2.3 67.81±2.5 66.68±2.1 69.69±2.2 70.5±2.5 68.7±2.3 71.79±1.1 72.35±2.5 
4.0 66.6±2.23 67.6±2.3 68.15±2.3 68.15±2.1 69.69±2.3 70.38±2.3 71.1±2.4 73.52±1.4 74.29±2.3 
5.0 66.54±2.2 67.6±2.1 68.15±2.4 68.17±2.2 69.69±2.4 70.42±2.4 71.1±2.3 73.52±2.5 74.87±2.4 
6.0 66.59±2.3 67.6±2.2 68.17±2.4 68.19±2.3 69.69±2.5 70.42±2.3 71.1±2.3 73.52±2.4 75.26±2.3 
8.0 66.61±2.5 67.6±2.4 68.85±2.5 68.23±2.5 69.69±2.3 70.47±2.5 71.1±2.3 73.52±2.4 75.3±2.33 
10.0 66.63±2.4 67.6±2.5 68.85±2.3 68.23±2.4 69.69±2.5 70.47±3.3 71.1±2.4 73.52±2.5 75.29±2.3 
12.0 66.63±0.8 67.6±2.3 68.86±2.3 68.24±2.5 69.69±3.3 70.43±3.3 71.1±2.4 73.52±2.3 75.31±2.4 
 
 
Figure 4.13. Comparative swelling ratios of CMC-co-MAA-co-AMPS hydrogels using 
different concentrations of CMC 
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Formulations (F40 to F42) having varying concentrations of MBA showed swelling 
ratio ranging F40 (1 to 51.427), F41 (1 to 49.171) and F42 (1 to 52.899) at pH 1.2; F40 
(1 to 56.680), F41 (1 to 54.617) and F42 (1 to 52.901) at pH 5.8; F40 (1 to 66.829), F41 
(1 to 64.300) and F42 (1 to 57.864) at pH 7.4 as shown in table 4.14. 
Table 4.14. Comparative swelling ratios of CMC-co-MAA-co-AMPS hydrogels using 
different concentrations of MBA (n=3) 
Time 
(hrs) 
Swelling ratio (q) at pH 
1.2 
Swelling ratio (q) at pH 
5.8 
Swelling ratio (q) at pH 
7.4 
F40 F41 F42 F40 F41 F42 F40 F41 F42 
0.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
10 min 12.91 11.27 11.44 13.77 11.49 11.44 14.27 13.77 11.82 
20 min 18.87 18.57 17.44 20.12 18.01 17.44 20.96 20.12 19.47 
0.5 29.69 29.00 28.35 31.67 27.65 28.35 32.83 31.67 30.41 
1.0 40.53 37.74 37.70 43.23 37.46 37.70 44.72 43.23 40.55 
2.0 56.07 45.88 45.51 55.07 48.77 50.38 60.97 59.80 55.26 
3.0 51.43 47.43 46.60 56.68 54.61 51.32 64.79 64.29 57.86 
4.0 51.43 48.98 47.27 56.68 54.61 52.89 65.13 64.29 57.86 
5.0 51.43 49.17 47.27 56.68 54.61 52.90 66.79 64.30 57.86 
6.0 51.43 49.17 47.27 56.68 54.61 52.90 66.83 64.30 57.86 
8.0 51.43 49.17 47.27 56.68 54.61 52.90 66.83 64.30 57.86 
10.0 51.43 49.17 47.27 56.68 54.62 52.90 66.83 64.30 57.86 
12.0 51.43 49.17 47.27 56.68 54.62 52.90 66.83 64.30 57.86 
 
 
Figure 4.14. Comparative swelling ratios of CMC-co-MAA-co-AMPS hydrogels using 
different concentrations of MBA 
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4.2. Percent equilibrium swelling (%ES) 
The swelling measurement was carried out until equilibrium weight of gel was obtained 
(i.e. 72 hrs) and then percent equilibrium swelling was carried out. Percent equilibrium 
swelling (%ES) covering different concentrations of all components at pH 1.2, 5.8 and 
7.4 is given in tables 4.15 to 4.21 and represented graphically in figures 4.15 to 4.21. 
With increasing concentration of HEMA from 0.8 g to 2.5 g (%w/w) percent 
equilibrium swelling was noted to be decreased 93.886 % to 92.699 % at pH 7.4, 
90.749 % to 89.087 % at pH 5.8 and 71.416 % to 66.818 % at pH 1.2 as given in table 
4.15. 
 
Table 4.15. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of HEMA from HEMA-co-AA hydrogels 
% w/w of HEMA % Equilibrium Swelling (%ES) 
pH 1.2 pH 5.8 pH 7.4 
0.8 71.416 90.749 93.886 
1.6 68.661 89.621 93.254 
2.5 66.818 89.087 92.699 
 
 
 
Figure 4.15. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of HEMA from HEMA-co-AA hydrogels 
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Percent equilibrium swelling has direct relation with increasing concentration of AA 
from 10.5 g to 14.5 g (%w/w) as percent equilibrium swelling was noted to be 
increased from 93.339 % to 93.909 % at pH 7.4, 89.359 % to 90.483 % at pH 5.8 and 
65.897 % to 68.491 % at pH 1.2 as given in table 4.16. 
 
Table 4.16. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of AA from HEMA-co-AA hydrogels 
% w/w of AA % Equilibrium Swelling (%ES) 
pH 1.2 pH 5.8 pH 7.4 
10.5 65.897 89.359 93.339 
12.5 67.904 90.184 93.752 
14.5 68.491 90.483 93.909 
 
 
 
Figure 4.16. Percent equilibrium swelling (%ES) of HEMA-co-AA hydrogels at 
different pH containing different %w/w ratio of AA 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20
%
 E
q
u
il
ib
ri
u
m
 S
w
el
li
n
g
 
Ratio (% w/w) 
Effect of Differnt Ratio (%w/w) of AA on %ES 
pH 1.2
pH5.8
pH 7.4
74 
 
Influence of increasing concentration of MBA on percent equilibrium swelling was 
noted. As %w/w ratio of MBA was increased from 0.020 g to 0.030 g, percent 
equilibrium swelling was noted to be decreased from 94.084 % to 92.740 % at pH 7.4, 
89.903 % to 83.853 % at pH 5.8 and 65.728 % to 60.451 % at pH 1.2 as given in table 
4.17. 
 
Table 4.17. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of MBA from HEMA-co-AA hydrogels 
% w/w of MBA % Equilibrium Swelling (%ES) 
pH 1.2 pH 5.8 pH 7.4 
0.020 65.728 89.903 94.084 
0.025 64.349 88.872 93.362 
0.030 60.451 83.853 92.740 
 
 
 
 
Figure 4.17. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of MBA from HEMA-co-AA hydrogels 
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With increasing concentration of HPMC from 0.6 g to 1.2 g (%w/w) percent 
equilibrium swelling was noted to be increased from 97.173 % to 97.793 % at pH 7.4, 
94.899 % to 96.797 % at pH 5.8 and 81.598 % to 80.359 % at pH 1.2 as given in table 
4.18. 
 
Table 4.18. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of HPMC from HPMC-co-AA hydrogels 
% w/w of HPMC % Equilibrium Swelling (%ES) 
pH 1.2 pH 5.8 pH 7.4 
0.6 81.598 94.899 97.173 
0.9 81.142 96.507 97.566 
1.2 80.359 96.797 97.793 
 
 
 
 
Figure 4.18. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of HPMC from HPMC-co-AA hydrogels 
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Percent equilibrium swelling has relation with increasing concentration of MAA from 6 
g to 8 g (%w/w) as percent equilibrium swelling was noted to be decreased from 98.564 
% to 98.454 % at pH 7.4, 98.392 % to 98.356 % at pH 5.8 and 98.330 % to 98.259 % at 
pH 1.2 as given in table 4.19. 
 
Table 4.19. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of MAA from CMC-co-MAA-co-AMPS hydrogels 
% w/w of MAA % Equilibrium Swelling (%ES) 
pH 1.2 pH 5.8 pH 7.4 
6 98.330 98.392 98.564 
7 98.278 98.364 98.508 
8 98.259 98.356 98.454 
 
 
 
 
Figure 4.19. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of MAA from CMC-co-MAA-co-AMPS hydrogels 
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Influence of increasing concentration of AMPS on percent equilibrium swelling was 
noted. As %w/w ratio of AMPS was increased from 4 g to 6 g, percent equilibrium 
swelling was noted to be increased from 98.499 % to 98.692 % at pH 7.4, 98.489 % to 
98.685 % at pH 5.8 and 98.484 % to 98.667 % at pH 1.2 as given in table 4.20. 
 
Table 4.20. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of AMPS from CMC-co-MAA-co-AMPS hydrogels 
% w/w of AMPS % Equilibrium Swelling (%ES) 
pH 1.2 pH 5.8 pH 7.4 
4 98.484 98.489 98.499 
5 98.550 98.573 98.582 
6 98.667 98.685 98.692 
 
 
 
 
Figure 4.20. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of AMPS from CMC-co-MAA-co-AMPS hydrogels 
 
 
 
98.45
98.5
98.55
98.6
98.65
98.7
98.75
0 2 4 6 8
%
 E
q
u
il
ib
ri
u
m
 S
w
el
li
n
g
 
Ratio (% w/w) 
Effect of Differnt Ratio (%w/w) of AMPS on %ES 
pH 1.2
pH5.8
pH 7.4
78 
 
Effect of increasing concentration of CMC on percent equilibrium swelling was 
observed. It was noted that as %w/w ratio of CMC was increase from 1 g to 2 g percent 
equilibrium swelling was increased from 98.594 % to 98.672 % at pH 7.4, 98.534 % to 
98.580 % at pH 5.8 and 98.499 % to 98.547 % at pH 1.2 as given in table 4.21. 
 
Table 4.21. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of CMC from CMC-co-MAA-co-AMPS hydrogels 
% w/w of CMC % Equilibrium Swelling (%ES) 
pH 1.2 pH 5.8 pH 7.4 
1 98.499 98.534 98.594 
1.5 98.521 98.565 98.639 
2 98.547 98.580 98.672 
 
 
 
 
Figure 4.21. Percent equilibrium swelling (%ES) at different pH containing different 
%w/w ratio of CMC from CMC-co-MAA-co-AMPS hydrogels 
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4.3. Determination of percent gel content (%gc), %porosity (%P) 
measurement and drug loading 
Percent gel content (%gc), percent porosity (%P) and drug loading measurements of all 
formulations casing different concentrations of components computed thereby 
evaluating effects of varying concentrations of all components on these parameters 
were noted and results are given in tables 4.22 to 4.25 and in figures 4.22 to 4.29. 
Effect of varying concentrations of HEMA, AA and MBA on percent gel content 
(%gc), percent porosity (%P) and drug loading was determined as in formulations F1 to 
F9. Formulations (F1 to F3) having variable quantities of HEMA exhibited % gel 
fraction ranging from 83.758 % to 93.269 %, % porosity from 14.425 % to 11.744 % 
and drug loading from 58.501 mg to 45.037 mg indicating that with increasing 
concentration of HEMA percent gel content (%gc) was increased while percent porosity 
(%P) and drug loading was noted to be decreased. Moreover increasing concentration 
of AA (10.5 g to 14.5 g) also has direct influence on percent gel content (%gc), percent 
porosity (%P) and drug loading as these were noted to be increased from 80.577 % to 
85.536 %, 8.974 to 11.151 % and 29.465 mg to 35.055 mg respectively as in 
formulation F4 to F6. Increasing concentration of MBA (F7 to F9) resulted in increased 
percent gel content (81.382 % to 87.988), decreased percent porosity (8.926 % to 5.377 
%) and decrease drug loading (25.465 mg to 20.130 mg). 
Table 4.22. Percent gel content (%gC), percent porosity (%P) measurement and drug 
loading of HEMA-co-AA hydrogels containing different %w/w of 
components 
Formulation 
Code 
Varying 
Component 
%w/w Ratio 
(g) 
% gc % P Drug loading 
(mg/0.45g disc) 
F1 HEMA 0.84 83.758 14.425 58.501 
F2 1.68 86.885 12.845 53.811 
F3 3.36 93.269 11.744 45.037 
F4 AA 10.5 80.577 8.974 29.465 
F5 12.5 82.741 9.321 32.608 
F6 14.5 85.536 11.151 35.055 
F7 MBA 0.02 81.382 8.926 25.465 
F8 0.025 84.764 6.078 22.265 
F9 0.03 87.988 5.377 20.130 
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Figure 4.22. Percent gel content (%gC) of HEMA-co-AA hydrogels containing 
different %w/w of components 
 
 
Figure 4.23. Percent porosity (% P) of HEMA-co-AA hydrogels containing different 
%w/w of components 
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Effect of changing concentrations of HPMC, AA and MBA on percent gel content 
(%gc), percent porosity (%P) and drug loading was noted as in formulations F10 to F18. 
Formulations (F10 to F12) with changing concentration of HPMC showed % gel 
fraction ranging from 85.614 % to 93.990 %, % porosity from 27.037 % to 33.157 % 
and drug loading from 84.101 mg to 93.077 mg indicating that with increasing 
concentration of HPMC percent gel content (%gc), percent porosity (%P) and drug 
loading was increased. Similarly increasing concentration of AA (12.5 g to 7.5 g) also 
has direct influence on percent gel content (%gc), percent porosity (%P) and drug 
loading as these were noted to be increased from 86.352 % to 80.468 %, 32.771 to 
29.670 % and 81.632 mg to 73.166 mg respectively as in case of formulation F13 to 
F15. Increasing concentration of MBA (F16 to F18) resulted in increased percent gel 
content (82.180 % to 88.268), decreased percent porosity (61.325 % to 39.831 %) and 
decrease drug loading (61.325 mg to 39.831 mg). 
Table 4.23. Percent gel content (%gC), percent porosity (%P) measurement and drug 
loading of HPMC-co-AA hydrogels containing different %w/w of 
components 
Formulation 
Code 
Varying 
Component 
%w/w Ratio 
(g) 
% gc % P Drug loading 
(mg/0.46g disc) 
F10 HPMC 0.6 85.614 27.037 84.101 
F11 0.9 90.866 30.698 88.211 
F12 1.2 93.990 33.157 93.077 
F13 AA 12.5 86.352 32.771 81.632 
F14 10 83.291 32.607 78.228 
F15 7.5 80.468 29.670 73.166 
F16 MBA 0.2 82.180 28.708 61.325 
F17 0.25 84.764 24.506 52.445 
F18 0.3 88.268 21.860 39.831 
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Figure 4.24. Percent gel content (%gC) of HPMC-co-AA hydrogels containing different 
%w/w of components 
 
 
Figure 4.25. Percent porosity (% P) of HPMC-co-AA hydrogels containing different 
%w/w of components 
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Effect of changing concentrations of HEMA, AA, HPMC and MBA on percent gel 
content (%gc), percent porosity (%P) and drug loading was noted as in formulations 
F19 to F30. Formulations (F19 to F21) with increasing concentration of HEMA 
exhibited % gel fraction ranging from 82.844 % to 90.569 %, % porosity from 19.567 
% to 16.473 % and drug loading from 47.862 mg to 38.623 mg indicating that with 
increasing concentration of HEMA percent gel content (%gc) was increased while 
percent porosity (%P) and drug loading was decreased. Similarly increasing 
concentration of AA (10 g to 15 g) also has direct influence on percent gel content 
(%gc), percent porosity (%P) and drug loading as these were noted to be increased from 
86.352 % to 93.489 %, 25.394 to 38.934 % and 69.832 mg to 79.271 mg respectively as 
in case of formulation F22 to F24. Increasing concentration of HPMC (F25 to F27) also 
resulted in increase in percent gel content (%gc), percent porosity (%P) and drug 
loading (84.840 to 93.854, 20.205 to 25.383 and 58.521 mg to 67.261 mg respectively). 
Increasing concentration of MBA (F28 to F30) resulted in increased percent gel content 
(85.372% to 94.413), decreased percent porosity (16.961% to 12.911%) and decrease 
drug loading (35.831 mg to 24.862 mg). 
Table 4.24. Percent gel content (%gC), percent porosity (%P) measurement and drug 
loading of HPMC-co-AA-co-HEMA hydrogels containing different %w/w 
of components 
Formulation 
Code 
Varying 
Component 
%w/w Ratio 
(g) 
% gc % P Drug loading 
(mg/0.46g disc) 
F19 HEMA 0.5 82.844 19.567 47.862 
F20 1 86.529 17.278 42.331 
F21 1.5 90.596 16.473 38.623 
F22 AA 10 86.352 25.394 69.832 
F23 12.5 88.354 31.164 74.115 
F24 15 93.489 38.934 79.271 
F25 HPMC 5 84.840 20.205 58.521 
F26 7.5 88.642 23.793 63.142 
F27 10 93.854 25.383 67.261 
F28 MBA 0.2 85.372 16.961 35.831 
F29 0.25 89.196 14.174 30.613 
F30 0.3 94.413 12.911 24.862 
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Figure 4.26. Percent gel content (%gC) of HPMC-co-AA-co-HEMA hydrogels 
containing different %w/w of components 
 
 
Figure 4.27. Percent porosity (% P) of HPMC-co-AA-co-HEMA hydrogels containing 
different %w/w of components 
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Effect of changing concentrations of MAA, AMPS, CMC and MBA on percent gel 
content (%gc), percent porosity (%P) and drug loading was observed as in formulations 
F31 to F42. Formulations (F31 to F33) with increasing concentration of MAA exhibited 
% gel fraction ranging from 82.016% to 89.179%, % porosity from 42.278% to 
36.278% and drug loading from 117.417mg to 106.371 mg indicating that with 
increasing concentration of HEMA percent gel content (%gc) was increased while 
percent porosity (%P) and drug loading was decreased. Similarly increasing 
concentration of AMPS (4 g to 6 g) also has direct influence on percent gel content 
(%gc), percent porosity (%P) and drug loading as these were noted to be increased from 
92.804 % to 96.515%, 45.104 to 59.489% and 123.714 mg to 145.732 mg respectively 
as in case of formulation F34 to F36. Increasing concentration of CMC (F37 to F39) 
also resulted in increase in percent gel content (%gc), percent porosity (%P) and drug 
loading (94.755 to 96.985, 46.291 to 53.243 and 126.634 mg to 133.153 mg 
respectively). Increasing concentration of MBA (F40 to F42) resulted in increased 
percent gel content (91.528 % to 96.703 %), decreased percent porosity (44.693 % to 
35.749 %) and decrease drug loading (115.631 mg to 102.613 mg). 
Table 4.25. Percent gel content (%gC), percent porosity (%P) measurement and drug 
loading of CMC-co-MAA-co-AMPS hydrogels containing different %w/w 
of components 
Formulation 
Code 
Varying 
Component 
%w/w Ratio 
(g) 
% gc % P Drug loading 
(mg/0.45g disc) 
F31 MAA 6 82.016 42.278 117.417 
F32 7 86.493 39.237 111.631 
F33 8 89.179 36.278 106.371 
F34 AMPS 4 92.804 45.104 123.714 
F35 5 94.690 51.302 132.621 
F36 6 96.515 59.489 145.732 
F37 CMC 1 94.755 46.291 126.634 
F38 1.5 96.539 49.321 130.631 
F39 2 96.985 53.243 133.153 
F40 MBA 0.045 91.528 44.693 115.631 
F41 0.050 94.652 40.182 109.741 
F42 0.055 96.703 35.749 102.613 
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Figure 4.28. Percent gel content (%gC) of CMC-co-MAA-co-AMPS hydrogels 
containing different %w/w of components 
 
 
 
Figure 4.29. Percent porosity (% P) of CMC-co-MAA-co-AMPS hydrogels containing 
different %w/w of components 
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4.4. Characterization: 
4.4.1 FTIR Analysis: 
In this study, attenuated total reflectance (ATR) technology along with OPUS data 
collection software was employed to compute fourier transform infrared (FTIR) spectra 
of all samples using Bruker FTIR (Tensor 27 series, Germany) in the range of 500 cm
-1
 
4000 cm
-1
. Characteristics band were observed 3247 cm−1 for (NH); 1675 cm−1 for 
(C=O, CONH) and 1362 cm−1 for (CH2). FTIR spectrum of pure components and 
loaded and unloaded formulations are shown in figures 4.30 to 4.33. 
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Figure 4.30. FTIR spectrum of HEMA-co-AA hydrogel 
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Figure 4.31. FTIR spectrum of HPMC-co-AA hydrogels 
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Figure 4.32. FTIR spectrum of HPMC-co-AA-co-HEMA hydrogels 
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Figure 4.33. FTIR spectrum of CMC-co-MAA-co-AMPS hydrogels 
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4.4.2 Scanning Electron Microscopy (SEM) 
For morphological studies scanning electron microscopy was carried out. Results of 
scanning electron microscopy (SEM) of all combinations are illustrated in figures 4.34 
to 4.37. 
Heterogeneous distribution of pores was observed as seen in SEM micrograph of 
HEMA-co-AA as shown in figure 4.34. 
  
Figure 4.34. Scanning electron micrographs (SEM) of surface of HEMA-co-AA 
hydrogels at magnification of 100X and 200X (left to right) and 500µm 
scale bar and 300µm scale bar respectively 
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SEM micrograph of HPMC-co-AA hydrogel at magnification of 100X and 200X 
exhibited uneven pores in size and shape distribution as shown in figure 4.35. 
  
Figure 4.35. Scanning electron micrographs (SEM) of surface of HPMC-co-AA 
hydrogels at magnification of 100X and 200X (left to right) and 500µm 
scale bar and 300µm scale bar respectively 
 
SEM images of HPMC-co-AA-co-HEMA hydrogels have given loose network 
structure of lamellar shape as shown in figure 4.36.  
  
Figure 4.36. Scanning electron micrographs (SEM) of surface of HPMC-co-AA-co-
HEMA hydrogels at magnification of 100X and 200X (left to right) and 
500µm scale bar and 300µm scale bar respectively 
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Scanning electron microgram of CMC-co-MAA-co-AMPS hydrogels showed coarse 
porous structure with heavy mesh networking as shown in figure 4.37. 
  
Figure 4.37. Scanning electron micrographs (SEM) of surface of CMC-co-MAA-co-
AMPS hydrogels at magnification of 100X and 200X (left to right) and 
500µm scale bar and 300µm scale bar respectively 
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4.4.3 Thermal Gravimetric Analysis and Differential Scanning Calorimetery 
(TGA & DSC) 
Thermal transition behavior of prepared formulation was analyzed by thermal 
gravimetric analysis and differential scanning calorimeter (DuPont thermal analyzer 
with 2010 DSC194 module) in temperature range of 20 
°
C to 900
 °
C at heating rate of 
10
 °
C/min under nitrogen atmosphere and flow rate of 20 mL/min at temperature range 
of 0 
°
C to 1000 
°
C . Results TGA and DSC of all combinations are illustrated in figures 
4.38 to 4.45 of all combinations are illustrated in figures 4.38 to 4.45. 
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Figure 4.38. TGA thermogram for HEMA-co-AA hydrogels 
 
Figure 4.39. DSC thermogram for HEMA-co-AA hydrogels 
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Figure 4.40. TGA thermogram for HPMC-co-AA hydrogels 
 
 
Figure 4.41. DSC thermogram for HPMC-co-AA hydrogels 
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Figure 4.42. TGA thermogram for HPMC-co-AA-co-HEMA hydrogels 
 
 
Figure 4.43. DSC thermogram for HPMC-co-AA-co-HEMA hydrogels 
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Figure 4.44. TGA thermogram for CMC-co-MAA-co-AMPS hydrogels 
 
 
Figure 4.45. DSC thermogram for CMC-co-MAA-co-AMPS hydrogels 
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4.4.5 X-ray diffraction 
To check crystallinity of pure drug (nicorandil), blank formulations, formulations 
containing drug and all formulated combinations of hydrogels were subjected to X-ray 
diffractometer (Bruker D8 Discover, Germany) with Ni-filtered CuK alpha radiation 
source having tube voltage of 35KV, current of 35 mA and scanning rate of 5° min
-1
, 
over a range of 8°-60° diffraction angle (2θ) range (Osiris and Manal, 2012). Results 
showed amorphous nature of formulated hydrogels as given in figure 4.46. 
 
Figure 4.46: X-ray diffraction patterns of drug and formulation 
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4.5 In-vitro drug release study 
4.5.1 In vitro drug release studies 
Over all in vitro drug release studies were followed in ascending order with increasing 
pH from acidic to basic with respect to time. 
Drug release was prominently affected by change in monomers concentration and as 
well as crosslinker concentration as elaborated in tables 4.26 to 4.40 and figures 4.47 to 
4.58. 
Formulations F1 to F3 having different concentrations of HEMA yielded drug release 
F1 (9.731 % to 17.236 %), F2 (9.716 % to 16.628 %) and F3 (9.091 % to 15.408 %) at 
pH 1.2. Similarly at pH 7.4 higher cumulative percent drug release was observed i.e. F1 
(20.77 % to 96.09 %), F2 (14.663 b% to 92.962 %) and F3 (18.383 % to 93.702 %) as 
shown in table 4.26. 
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Table 4.26. Cumulative percent drug release of formulation F1 to F3 (n=6) 
Time 
Hrs 
F1 F2 F3 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 9.73±0.11 20.77±1.22 9.71±0.21 14.66±1.1 9.09±0.24 18.38±1.2 
1 11.01±0.32 24.72±1.78 10.37±0.23 26.81±1.4 9.73±0.21 22.09±1.3 
1.5 12.22±0.33 27.45±2.08 11.59±0.34 29.82±2.1 10.95±0.2 25.12±1.7 
2 12.80±0.67 31.02±1.23 12.80±0.45 31.57±2.2 12.16±0.4 27.54±2.1 
3 13.36±0.77 35.42±3.33 13.36±0.54 37.06±2.4 12.73±0.7 30.50±3.2 
4 13.92±0.79 41.5±3.34 13.92±0.78 40.87±2.5 13.30±0.7 34.27±3.3 
6 13.86±0.79 45.38±3.46 13.86±0.87 46.72±2.3 13.85±0.7 43.56±3.4 
8 14.40±0.57 49.85±2.56 14.40±0.9 51.36±2.5 14.40±0.4 48.92±2.7 
10 14.95±0.45 54.69±3.23 14.33±0.65 57.79±3.3 14.33±0.4 55.57±3 
12 16.10±0.45 62.44±3.24 15.48±0.33 60.27±3.3 14.87±0.4 63.79±2.2 
24 17.23±0.56 96.09±3.36 16.62±0.35 92.96±3.4 15.40±0.5 93.70±2.4 
 
 
 
 
Figure 4.47. Dynamic release profile of formulations with changing concentration of 
HEMA 
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In formulations F4 to F6 cumulative percent drug release with varying concentrations 
of AA was observed. It was noted that cumulative percent drug release was 9.093 % to 
12.962 %, 9.092 % to 13.577 % and 9.091 % to 14.794 % for F4, F5 and F6 
respectively at pH 1.2. Moreover cumulative percent drug release at pH 7.4 was found 
to be higher than that of pH 1.2 i.e. F4 (19.777 % to 85.993 %), F5 (20.292 % to 87.726 
%) and F6 (23.795 % to 89.387 %) as shown in table 4.27. 
Table 4.27. Cumulative percent drug release of formulation F4 to F6 (n=6) 
Time 
Hrs 
F4 F5 F6 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 9.09±0.21 19.78±1.21 9.09±0.22 20.29±1.1 9.09±0.23 23.8±1.23 
1 9.1±0.32 24.99±1.48 9.1±0.23 27.97±1.7 9.09±0.21 28.91±1.4 
1.5 9.69±0.33 29.66±2.13 9.69±0.34 29.7±2.08 10.32±0.2 33.49±1.5 
2 10.89±0.67 33.42±2.11 10.89±0.45 35.36±2.2 11.54±0.4 37.62±1.7 
3 11.48±0.77 38.83±2.46 11.48±0.54 41.69±2.4 12.1±0.32 45.97±1.9 
4 11.42±0.79 43.79±2.46 12.04±0.78 43.65±2.5 12.68±0.2 54.26±2.1 
6 11.99±0.79 48.25±2.18 12.61±0.87 49.16±2.3 13.24±0.3 57.1±2.33 
8 12.55±0.57 53.51±2.56 13.16±0.9 53.53±2.5 13.79±0.4 59.48±2.7 
10 12.48±0.35 55.37±3.23 13.71±0.56 58.58±3.3 14.34±0.4 60.72±3 
12 13.04±0.87 60.53±3.24 13.64±0.33 66.03±3.3 14.26±0.4 62.66±2.9 
24 12.96±0.65 85.99±3.43 13.58±0.65 87.73±3.5 14.79±0.3 89.39±4.1 
 
 
 
Figure 4.48. Dynamic release profile of formulations with changing concentration of 
AA 
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Cumulative percent drug release was found to be varied with changing concentration of 
MBA as in formulations F7 to F9. It was observed that cumulative percent drug release 
at pH 7.4 was higher than that of pH 1.2 as cumulative percent drug release was 8.456 
% to 11.139 %, 8.459 % to 9.908 % and 8.459 % to 9.298 % at pH 1.2 for F7, F8 and 
F9 respectively and 17.319 % to 77.348 %, 18.066 % to 73.573 % and 15.492 % to 
70.992 % at pH 7.4 for F7, F8 and F9 respectively as shown in table 4.28. 
Table 4.28. Cumulative percent drug release of formulation F7 to F9 (n=6) 
Time 
Hrs 
F7 F8 F9 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 8.45±0.11 17.31±1.2 8.45±0.2 18.06±1.1 8.45±0.27 15.49±1.2 
1 9.09±0.21 23.85±2.11 8.45±0.23 23.24±1.4 8.45±0.24 21.86±1.2 
1.5 9.04±0.23 28.28±2.23 9.04±0.34 29.45±2.1 8.41±0.29 30.02±1.7 
2 10.26±0.34 34.14±2.48 9.01±0.79 34.47±2.2 8.37±0.43 33.07±3.3 
3 10.84±0.29 38.46±3.33 9.58±0.57 39.99±2.4 8.32±0.77 37.93±3.3 
4 11.41±0.43 45.69±3.34 10.16±0.45 48.85±2.5 8.91±0.79 42.76±3.4 
6 11.36±0.79 51.38±3.46 10.11±0.45 53.14±2.3 8.86±0.79 47.54±2.5 
8 11.31±0.57 57.01±2.56 10.06±0.9 56.24±2.5 8.82±0.43 52.26±3.2 
10 11.24±0.45 58.69±3.23 10.01±0.56 60.41±3.3 9.39±0.45 56.32±3.3 
12 11.19±0.56 61.29±3.24 9.96±0.33 63.44±3.3 9.34±0.21 60.94±3.4 
24 11.13±0.45 77.34±3.42 9.91±0.64 73.57±3.5 9.29±0.34 70.99±3.9 
 
 
 
Figure 4.49. Dynamic release profile of formulations with changing concentration of 
MBA 
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Kinetics of drug release of formulation F1 to F9 was found to be varied with changing 
concentration of components i.e. polymer, monomer and crosslinker. Release exponent 
(n) was found vary in range of 0.625 to 0.214. Higuchi model was found to best fit as 
value of R2 lies between 0.901 to 0.996 i.e. close to 1. 
Table 4.29. Kinetics of drug release of formulation F1 to F9 
C
o
d
e 
Zero order 
release model 
First order 
release model 
Higuchi model 
Korsmayer-
Peppas model 
Release 
exponent  
R2 K0 R2 K1 R2 K2 R2 K3 (n) 
F1 0.983 2.804 0.324 0.016 0.975 19.614 0.960 13.314 0.622 
F2 0.953 2.724 0.303 0.016 0.981 18.975 0.972 12.748 0.625 
F3 0.984 2.493 0.359 0.014 0.984 19.126 0.996 16.074 0.555 
F4 0.933 1.808 0.277 0.010 0.992 17.906 0.974 23.835 0.410 
F5 0.872 2.227 0.248 0.013 0.958 18.245 0.901 17.539 0.512 
F6 0.935 2.123 0.283 0.013 0.990 17.553 0.972 17.180 0.507 
F7 0.830 1.338 0.267 0.008 0.963 15.787 0.981 26.623 0.336 
F8 0.767 0.844 0.252 0.005 0.929 15.017 0.960 37.301 0.214 
F9 0.804 0.838 0.259 0.006 0.950 14.491 0.991 35.256 0.220 
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Cumulative percent drug release was found to be varied with changing concentration of 
HPMC as in formulations F10 to F12. It was observed that cumulative percent drug 
release at pH 7.4 was higher than that of pH 1.2 as cumulative percent drug release was 
7.812 % to 15.408 %, 8.451 % to 16.017 % and 8.459 % to 17.239 % at pH 1.2 for F10, 
F11 and F12 respectively and 12.932 % to 89.817 %, 13.573 % to 91.038 % and 15.493 
% to 92.878 % at pH 7.4 for F7, F8 and F9 respectively as shown in table 4.30. 
Table 4.30. Cumulative percent drug release of formulation F10 to F12 (n=6) 
Time 
Hrs 
F10 F11 F12 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 7.81±0.11 12.93±1.22 8.45±0.2 13.57±1.1 8.46±0.23 15.49±1.2 
1 8.46±0.32 22.49±1.78 8.46±0.23 23.76±1.4 9.1±0.21 26.33±1.4 
1.5 9.69±0.33 28.76±2.08 10.94±0.34 30.04±2.1 12.22±0.2 31.95±1.5 
2 10.89±0.67 32.44±1.23 12.16±0.79 33.71±2.2 12.18±0.4 36.24±1.7 
3 12.11±0.77 36.68±3.33 12.11±0.57 37.94±2.4 12.74±0.3 40.47±1.9 
4 12.67±0.79 40.27±3.34 13.3±0.45 39.65±2.5 13.3±0.22 42.77±2.1 
6 13.24±0.79 44.43±3.46 13.23±0.45 42.55±2.3 13.86±0.3 46.3±2.33 
8 13.79±0.57 48.54±2.56 14.4±0.9 47.91±2.5 14.4±0.43 49.16±2.7 
10 13.71±0.45 52.62±3.23 14.34±0.56 53.23±3.3 14.95±0.4 53.23±3 
12 14.26±0.45 56.03±3.24 14.87±0.33 55.43±3.3 15.49±0.4 59.7±2.99 
24 15.41±0.56 89.82±3.36 16.02±0.64 91.04±3.5 17.24±0.3 92.88±4.1 
 
 
 
 
Figure 4.50. Dynamic release profile of formulations with changing concentration of 
HPMC 
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Formulations F13 to F15 having different concentrations of AA yielded drug release 
F13 (7.17 % to 13.57 %), F14 (7.81 % to 14.18 %) and F15 (7.81 % to 14.79 %) at pH 
1.2. Similarly at pH 7.4 higher cumulative percent drug release was observed i.e. F13 
(12.96 % to 75.78 %), F14 (12.93 % to 78.83 %) and F15 (12.29 % to 84.93 %) as 
shown in table 4.31. 
Table 4.31. Cumulative percent drug release of formulation F13 to F15 (n=6) 
Time 
Hrs 
F13 F14 F15 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 7.17±0.11 12.96±1.24 7.81±0.2 12.93±1.17 7.81±0.27 12.29±1.23 
1 7.81±0.32 16.75±2.11 7.81±0.23 17.39±1.44 8.45±0.24 19.3±1.28 
1.5 7.77±0.33 19.86±2.23 8.4±0.34 21.76±2.13 9.68±0.29 24.31±1.75 
2 8.36±0.67 24.19±2.48 9±0.79 24.83±2.23 9.63±0.43 27.99±3.33 
3 8.95±0.77 26.6±3.33 9.58±0.57 27.86±2.48 10.84±0.77 36.03±3.34 
4 9.53±0.79 30.84±3.34 10.16±0.45 33.35±2.5 10.79±0.79 38.38±3.46 
6 10.11±0.79 35.68±3.46 10.73±0.45 36.93±2.38 11.98±0.79 41.92±2.56 
8 10.68±0.57 37.99±2.56 11.3±0.9 41.09±2.56 11.92±0.43 44.2±3.24 
10 11.24±0.45 43.34±3.23 11.86±0.56 45.2±3.33 13.09±0.45 50.74±3.36 
12 12.41±0.45 48.03±3.24 13.02±0.33 48.65±3.34 13.64±0.21 52.96±3.43 
24 13.57±0.56 75.78±3.42 14.18±0.64 78.83±3.57 14.79±0.34 84.93±3.9 
 
 
 
 
Figure 4.51. Dynamic release profile of formulations with changing concentration of 
AA 
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In formulations F16 to F18 cumulative percent drug release with varying concentrations 
of MBA was observed. It was noted that cumulative percent drug release was 7.15 % to 
12.98 %, 7.15 % to 12.31 % and 6.53 % to 11.72 % for F16, F17 and F18 respectively 
at pH 1.2. Moreover cumulative percent drug release at pH 7.4 was found to be higher 
than that of pH 1.2 i.e. F16 (13.57 % to 66.63 %), F17 (12.29 % to 60.53 %) and F18 
(12.29 % to 56.26 %) as shown in table 4.32. 
Table 4.32. Cumulative percent drug release of formulation F16 to F18 (n=6) 
Time 
Hrs 
F16 F17 F18 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 7.15±0.21 13.57±1.22 7.15±0.21 12.29±1.18 6.53±0.24 12.29±1.26 
1 7.79±0.23 17.39±1.78 7.17±0.23 16.11±1.48 7.16±0.21 15.48±1.3 
1.5 7.73±0.34 19.23±2.08 7.68±0.24 17.32±2.13 7.72±0.29 16.68±1.78 
2 7.76±0.45 21.66±1.23 7.72±0.21 20.39±2.23 7.78±0.21 18.5±2.08 
3 8.24±0.54 25.33±2.33 8.29±0.29 24.07±2.48 7.88±0.23 22.8±3.24 
4 8.29±0.23 29.59±2.34 8.18±0.23 27.71±2.5 8.26±0.24 25.83±3.36 
6 8.75±0.34 31.94±2.46 8.74±0.34 30.69±2.38 8.81±0.21 30.06±3.43 
8 8.79±0.45 34.88±2.56 9.38±0.45 32.4±2.56 8.85±0.29 31.17±2.77 
10 10.11±0.65 37.79±2.23 10.08±0.45 35.32±2.33 9.33±0.23 34.08±3 
12 11.25±0.33 41.28±2.24 11.19±0.65 38.21±2.34 10.51±0.34 36.37±2.23 
24 12.98±0.35 66.63±2.36 12.31±0.33 60.53±2.46 11.72±0.45 56.26±2.48 
 
 
 
  
Figure 4.52. Dynamic release profile of formulations with changing concentration of 
MBA 
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Kinetics of drug release of formulation F10 to F18 was found to be varied with 
changing concentration of components i.e. polymer, monomer and crosslinker. Release 
exponent (n) was found vary in range of 0.7159 to 0.6375. Higuchi model was found to 
best fit as value of R2 lies between 0.952 to 0.982 i.e. close to 1. 
Table 4.33. Kinetics of drug release of formulation F10 to F18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
o
d
e
 
Zero order 
release model 
First order 
release model 
Higuchi model 
Korsmayer-Peppas 
model 
Release 
exponent  
R2 K0 R2 K1 R2 K2 R2 K3 (n) 
F10 0.940 2.815 0.305 0.017 0.966 18.332 0.937 10.324 0.680 
F11 0.944 2.967 0.299 0.018 0.953 18.581 0.913 9.355 0.715 
F12 0.939 2.764 0.282 0.016 0.952 18.957 0.901 12.246 0.637 
F13 0.938 2.664 0.326 0.017 0.970 17.336 0.914 9.741 0.681 
F14 0.969 2.515 0.354 0.017 0.979 16.091 0.964 8.622 0.696 
F15 0.975 2.312 0.364 0.016 0.979 15.468 0.969 9.365 0.657 
F16 0.975 2.112 0.344 0.017 0.970 13.600 0.939 7.418 0.690 
F17 0.965 1.860 0.344 0.016 0.975 12.355 0.940 7.343 0.663 
F18 0.962 1.657 0.346 0.015 0.982 11.484 0.957 7.612 0.629 
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Cumulative percent drug release was found to be varied with changing concentration of 
HEMA as in formulations F19 to F21. It was observed that cumulative percent drug 
release at pH 7.4 was higher than that of pH 1.2 as cumulative percent drug release was 
7.04 % to 13.02 %, 6.98 % to 12.95 % and 6.79 % to 11.79 % at pH 1.2 for F19, F20 
and F21 respectively and 12.36 % to 67.46 %, 12.16 % to 63.62 % and 11.65 % to 
59.64 % at pH 7.4 for F19, F20 and F21 respectively as shown in table 4.34. 
Table 4.34. Cumulative percent drug release of formulation F19 to F21 (n=6) 
Time 
Hrs 
F19 F20 F21 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 7.04±0.11 12.36±1.24 6.98±0.2 12.16±1.17 6.79±0.27 11.65±1.23 
1 7.62±0.21 18.72±1.17 7.42±0.23 17.96±1.44 7.17±0.24 16.68±1.28 
1.5 7.64±0.23 24.34±1.44 7.52±0.34 21.8±2.13 7.2±0.29 19.25±1.17 
2 8.17±0.2 26.14±2.23 7.92±0.27 24.87±2.23 7.48±0.43 21.7±1.44 
3 8.64±0.23 31.37±2.48 8.32±0.24 29.49±2.48 7.69±0.34 26.33±2.48 
4 9.22±0.34 35.07±2.5 8.66±0.29 32.56±2.5 8.28±0.57 30.67±2.5 
6 9.8±0.57 38.65±2.38 8.92±0.2 37.39±2.38 8.61±0.45 36.14±2.38 
8 10.37±0.45 42.11±2.56 9.93±0.23 39.63±2.56 9.43±0.45 37.77±2.56 
10 10.93±0.45 44.43±2.23 10.62±0.34 42.58±2.23 10.07±0.45 41.34±2.16 
12 11.79±0.56 50.47±2.24 10.57±0.33 48.69±2.24 10.38±0.21 47.46±2.33 
24 13.02±0.45 67.46±2.42 12.95±0.45 63.62±2.47 11.79±0.34 59.64±2.49 
 
 
 
Figure 4.53. Dynamic release profile of formulations with changing concentration of 
HEMA 
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Formulations F22 to F24 having different concentrations of AA yielded drug release 
F22 (7.81 % to 18.44 %), F 23 (7.90 % to 19.05 %) and F24 (8.03 % to 21.49 %) at pH 
1.2. Similarly at pH 7.4 higher cumulative percent drug release was observed i.e. F22 
(12.93 % to 75.80 %), F23 (12.29 % to 78.25 %) and F24 (13.57 % to 82.82 %) as 
shown in table 4.35. 
Table 4.35. Cumulative percent drug release of formulation F22 to F24 (n=6) 
Time 
Hrs 
F22 F23 F24 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 7.81±0.11 12.93±1.24 7.9±0.2 12.29±1.17 8.03±0.27 13.57±1.23 
1 8.45±0.32 19.3±2.11 8.72±0.23 20.57±1.44 8.85±0.24 23.02±1.28 
1.5 9.04±0.33 24.94±2.23 9.17±0.34 25.58±2.13 9.42±0.29 27.94±1.75 
2 9.13±0.67 28±2.48 9.39±0.79 29.89±2.23 9.58±0.43 31.71±3.33 
3 9.46±0.77 33.52±3.33 9.69±0.57 35.41±2.48 9.95±0.77 37.75±3.34 
4 9.91±0.79 37.74±3.34 10.03±0.45 40.25±2.5 10.5±0.79 42.16±3.46 
6 10.57±0.79 41.3±3.46 10.63±0.45 43.18±2.38 10.94±0.79 46.16±2.56 
8 11.17±0.57 43.58±2.56 11.26±0.9 45.44±2.56 11.51±0.43 49.08±3.24 
10 11.61±0.45 47.67±3.23 11.72±0.56 50.14±3.33 13.53±0.45 51.89±3.36 
12 14.43±0.45 51.72±3.24 14.56±0.33 54.18±3.34 16.41±0.21 55.93±3.43 
24 18.44±0.56 75.8±3.42 19.05±0.64 78.25±3.57 21.49±0.34 82.82±3.9 
 
 
 
 
Figure 4.54. Dynamic release profile of formulations with changing concentration of 
AA 
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In formulations F25 to F27 cumulative percent drug release with varying concentrations 
of HPMC was observed. It was noted that cumulative percent drug release was 7.11 % 
to 14.24 %, 7.43 % to 16.07 % and 7.68 % to 17.77 % for F25, F26 and F27 
respectively at pH 1.2. Moreover cumulative percent drug release at pH 7.4 was found 
to be higher than that of pH 1.2 i.e. F25 (12.61 % to 69.29 %), F26 (12.87 % to 71.73 
%) and F27 (13.06 % to 73.38 %) as shown in table 4.36. 
Table 4.36. Cumulative percent drug release of formulation F25 to F27 (n=6) 
Time 
Hrs 
F25 F26 F27 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 7.11±0.21 12.61±1.22 7.43±0.21 12.87±1.18 7.68±0.24 13.06±1.26 
1 7.81±0.23 19.24±1.78 8.25±0.23 20±1.48 8.59±0.21 21.28±1.3 
1.5 7.96±0.34 25.67±2.08 8.53±0.24 26.08±2.13 8.98±0.29 27.35±1.78 
2 8.3±0.45 27.53±1.23 8.74±0.21 28.03±2.23 9.27±0.21 29.3±2.08 
3 8.83±0.54 33.89±2.33 9.08±0.29 34.08±2.48 9.57±0.23 35.34±3.24 
4 9.41±0.23 35.71±2.34 9.53±0.23 36.01±2.5 9.91±0.24 36.64±3.36 
6 9.98±0.34 39.89±2.46 10.11±0.34 40.52±2.38 10.51±0.21 41.14±3.43 
8 10.55±0.45 43.35±2.56 10.68±0.45 44.59±2.56 11.14±0.29 45.21±2.77 
10 11.12±0.65 45.06±2.23 11.24±0.45 46.29±2.33 11.59±0.23 46.91±3 
12 13.02±0.33 51.09±2.24 13.63±0.65 52.32±2.34 14.44±0.34 53.54±2.23 
24 14.24±0.35 69.29±2.36 16.07±0.33 71.73±2.46 17.77±0.45 73.38±2.48 
 
 
 
 
 
Figure 4.55. Dynamic release profile of formulations with changing concentration of 
HPMC 
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Cumulative percent drug release was found to be varied with changing concentration of 
MBA as in formulations F28 to F30. It was observed that cumulative percent drug 
release at pH 7.4 was higher than that of pH 1.2 as cumulative percent drug release was 
7.23 % to 15.88 %, 7.04 % to 11.71 % and 6.85 % to 10.49 % at pH 1.2 for F28, F29 
and F30 respectively and 11.01 % to 60.58 %, 10.37 % to 54.48 % and 9.73 % to 48.37 
% at pH 7.4 for F28, F29 and F30 respectively as shown in table 4.37. 
Table 4.37. Cumulative percent drug release of formulation F28 to F30 (n=6) 
Time 
Hrs 
F28 F29 F30 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 7.23±0.21 11.01±1.22 7.04±0.21 10.37±1.18 6.85±0.24 9.73±1.26 
1 8.19±0.23 17.38±1.18 7.81±0.23 16.1±1.48 7.3±0.21 14.19±1.3 
1.5 8.28±0.21 21.79±1.26 7.9±0.24 19.89±1.13 7.51±0.29 18.61±1.18 
2 8.43±0.23 23.6±1.3 8.11±0.21 21.07±1.23 7.6±0.21 19.81±1.08 
3 8.57±0.24 29.48±1.78 8.32±0.29 27.59±1.48 7.82±0.23 25.7±1.24 
4 8.91±0.23 31.94±1.32 8.47±0.23 30.06±1.5 8.15±0.24 26.93±1.36 
6 9.36±0.29 36.15±1.46 8.74±0.24 32.41±1.35 8.3±0.21 29.91±1.43 
8 9.75±0.23 39.01±1.56 9±0.21 35.9±1.56 8.44±0.29 32.18±1.77 
10 10.5±0.34 42.58±1.23 9.33±0.29 39.49±1.37 8.77±0.23 37.01±1.73 
12 13.63±0.33 48.02±1.28 10.56±0.23 44.33±1.34 9.95±0.34 40.04±1.83 
24 15.88±0.35 60.58±1.36 11.71±0.34 54.48±1.46 10.49±0.35 48.37±1.98 
 
 
 
 
Figure 4.56. Dynamic release profile of formulations with changing concentration of 
MBA 
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Kinetics of drug release of formulation F19 to F30 was found to be varied with 
changing concentration of components i.e. polymer, monomer and crosslinker. Release 
exponent (n) was found vary in range of 0.272 to 0.566. Higuchi model was found to 
best fit as value of R2 lies between 0.9673 to 0.988 i.e. close to 1. 
Table 4.38. Kinetics of drug release of formulation F19 to F30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code Zero order 
release model 
First order 
release model 
Higuchi model Korsmayer-
Peppas model 
Release 
exponent 
(n) R2 K0 R2 K1 R2 K2 R2 K3 
F19 0.901 1.415 0.298 0.010 0.983 13.770 0.977 17.835 0.418 
F20 0.902 1.244 0.305 0.009 0.987 12.986 0.984 18.665 0.385 
F21 0.892 1.015 0.323 0.008 0.988 12.174 0.987 20.924 0.329 
F22 0.921 2.006 0.306 0.013 0.979 15.472 0.952 13.137 0.551 
F23 0.905 2.005 0.298 0.013 0.974 15.972 0.949 14.505 0.530 
F24 0.909 2.240 0.287 0.014 0.971 16.905 0.942 13.691 0.566 
F25 0.895 1.516 0.289 0.011 0.976 14.143 0.962 17.136 0.439 
F26 0.905 1.617 0.292 0.011 0.980 14.641 0.967 16.881 0.455 
F27 0.906 1.653 0.284 0.011 0.976 14.978 0.957 17.294 0.454 
F28 0.878 1.046 0.302 0.008 0.980 12.365 0.988 20.877 0.335 
F29 0.864 0.845 0.304 0.007 0.975 11.120 0.981 21.169 0.297 
F30 0.845 0.694 0.303 0.006 0.967 9.873 0.977 20.334 0.272 
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Cumulative percent drug release was found to be varied with changing concentration of 
MAA as in formulations F31 to F33. It was observed that cumulative percent drug 
release at pH 7.4 was higher than that of pH 1.2 as cumulative percent drug release was 
25.73 % to 81.74 %, 23.81 % to 79.59 % and 23.49 % to 78.99 % at pH 1.2 for F31, 
F32 and F33 respectively and 26.37 % to 82.84 %, 24.45 % to 80.21 % and 23.75 % to 
79.32 % at pH 7.4 for F31, F32 and F33 respectively as shown in table 4.39. 
Table 4.39. Cumulative percent drug release of formulation F31 to F33 (n=6) 
Time 
Hrs 
F31 F32 F33 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 25.73±1.24 26.37±1.17 23.81±1.112 24.45±1.17 23.49±1.23 23.75±1.23 
1 37.07±2.11 37.71±1.44 35.15±1.78 35.86±1.24 33.88±1.45 34.26±1.28 
1.5 49.94±2.23 51.21±2.13 47.39±2.08 47.78±2.33 46.12±1.54 46.5±1.75 
2 56.12±2.48 57.39±2.23 53.58±2.23 54.22±2.43 52.32±1.78 52.76±3.33 
3 67.63±3.33 68.27±2.48 65.74±2.48 66.37±2.68 64.48±1.99 64.7±3.34 
4 81.61±3.34 82.24±2.5 79.1±2.5 79.73±2.85 78.54±2.11 79.04±3.46 
6 81.33±3.46 82.57±2.38 79.39±2.38 80.01±2.88 78.58±2.33 79.14±2.56 
8 81.47±2.56 82.65±2.56 78.99±2.56 80.1±2.96 78.74±2.77 79.23±3.24 
10 81.6±3.23 82.72±3.33 79.07±3.33 81.04±3.73 78.82±3 79.26±3.36 
12 81.73±3.24 82.78±3.34 79.09±3.34 80.2±3.84 78.91±2.99 79.28±3.43 
24 81.74±3.42 82.84±3.57 79.59±3.54 80.21±3.77 78.99±4.11 79.32±3.9 
 
 
 
Figure 4.57. Dynamic release profile of formulations with changing concentration of 
MAA 
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Formulations F1 to F3 having different concentrations of AMPS yielded drug release 
F34 (26.37 % to 87.06 %), F35 (27.02 % to 88.89 %) and F36 (28.30 % to 90.66 %) at 
pH 1.2. Similarly at pH 7.4 higher cumulative percent drug release was observed i.e. 
F34 (27.02 % to 88.83 %), F35 (27.66 % to 90.48 %) and F36 (30.22 % to 94.88 %) as 
shown in table 4.26. 
Table 4.40. Cumulative percent drug release of formulation F34 to F36 (n=6) 
Time 
Hrs 
F34 F35 F36 
pH 1.2 pH 7.4 pH 1.2 pH 7.4 pH 1.2 pH 7.4 
0.5 26.37±1.24 27.02±1.17 27.02±1.112 27.66±1.17 28.3±1.23 30.22±1.23 
1 38.35±1.23 39.12±1.44 39.63±1.78 42.18±1.24 41.54±1.45 42.83±1.78 
1.5 51.21±1.24 51.53±2.13 52.48±2.08 53.76±2.33 53.76±1.54 55.04±2.08 
2 58.02±2.33 60.54±2.23 59.29±2.23 60.55±2.43 60.55±1.78 61.82±2.96 
3 69.74±2.43 70.38±2.48 71.63±2.48 74.77±2.68 74.15±1.99 76.04±3.73 
4 86.61±2.68 87.87±2.5 88.5±2.5 88.82±2.85 90.38±2.23 93.51±3.84 
6 86.88±3.46 88.13±2.38 88.57±2.38 88.82±2.88 90.44±2.48 94.37±3.77 
8 86.93±2.56 88.36±3.46 88.68±2.56 88.85±2.96 90.47±3.33 94.51±3.24 
10 86.98±3.23 88.52±2.56 88.77±3.33 89.75±3.73 90.5±3.34 94.64±3.36 
12 86.99±3.24 88.68±3.24 88.8±3.34 89.97±3.84 90.58±3.46 94.76±3.43 
24 87.06±3.32 88.83±3.66 88.89±3.55 90.48±3.67 90.66±3.98 94.88±3.89 
 
 
 
 
Figure 4.58. Dynamic release profile of formulations with changing concentration of 
AMPS 
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4.6 In vivo evaluation 
4.6.1 Standard curve 
The standard curve of nicorandil was constructed using known plasma concentrations 
within ranges of 31.25 ng/mL to 500 ng/mL and linear regression was applied to fit 
straight line. Mean r
2
 value was also determined 0.9974. Standard curve is given in 
figure 4.59. Chromatograms of spiked plasma is given in figures 4.60 to 4.63. 
 
Figure 4.59. Standard curve of nicorandil 
Rabbits are divided into groups G1, G2, G3 and G4 having 6 rabbits in each group. F1 
(HEMA-co-AA), F12 (HPMC-co-AA), F24 (HPMC-co-AA-co-HEMA) and drug 
solution (1mg/mL) were administered to G1, G2, G3 and G4 respectively as a single 
dose equivalent to 15mg. Results are given in tables 4.37 to 4.95 and figures 4.72 to 
4.100. 
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Retention time of drug peak (500 ng of drug spiked in plasma) was found at 4.5 min as 
shown in chromatogram given in figure 4.60.  
 
Figure 4.60. Spiked plasma with 500 ng drug 
Plasma spiked with 250 ng of drug gave desired peak at 4.5 min as shown in 
chromatogram given in figure 4.61.  
 
Figure 4.61. Spiked plasma with 250 ng drug 
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Retention time of drug peak (125 ng of drug spiked in plasma) was found at 4.5 min as 
shown in chromatogram given in figure 4.62.  
 
Figure 4.62. Spiked plasma with 125 ng drug 
Plasma spiked with 62.5 ng of drug gave desired peak at 4.5 min as shown in 
chromatogram given in figure 4.63.  
 
Figure 4.63. Spiked plasma with 62.5 ng drug 
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4.6.2. Precision and accuracy 
Percent coefficient of variation (%CV) was determined to calculate intra-day and 
inter-day precision and accuracy of present method for nicorandil in rabbit 
plasma. The results are given in table 4.41. The validation run was consisted of 
calibration curve and three replicates of each low and high quantification 
concentrations. For inter-day analysis three batches of drug nicorandil was run on 
three different days and for intra-day analysis three batches of drug nicorandil 
was run on three different time points of same day. 
Table 4.41. Intra-day and Inter-day precision and accuracy of nicorandil in rabbit 
plasma 
Nicorandil 
Intra day 
Parameter 
LQC 
(ng/mL) 
HQC 
(ng/mL) 
Nominal Conc. 18 500 
Mean 16.14 497.27 
S.D. 0.19 1.19 
Precision CV (%) 0.6 0.2 
Accuracy (%) 97.4 99.5 
Inter day 
Parameter LQC 
(ng/mL) 
HQC 
(ng/mL) 
Nominal Conc. 18 500 
Mean 16.07 496.27 
S.D. 0.25 1.02 
Precision CV (%) 0.8 0.2 
Accuracy (%) 95.1 99.3 
 
4.6.3. Quantification and detection limits 
Limit of detection (LOD) and limit of quantitation (LOQ) of nicorandil as mean 
± SD were 10.0 ± 0.227 ng/mL and 16.0 ± 0.528 ng/mL. Lower quantitation 
limits give greater sensitivity of present method. 
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Table: 4.42. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 1 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 20.23296 
3 1 52.09269 
4 2 54.59021 
5 3 51.42908 
6 4 46.22155 
7 6 45.0774 
8 8 41.48149 
9 12 36.30666 
 
 
Figure 4.64. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 1 
 
Table 4.43.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 1 
Prameters Nicorandil 
Cmax (ng/mL) 54.5902 
Tmax  (Hrs) 2 
AUCtot (ng.h/mL) 973.22 
AUMCtot (ng.h
2
/mL) 13622 
MRT (Hrs) 13.9968 
Ke (Hr
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) 0.0773602 
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Table 4.44. Plasma concentration (ng/mL) of nicorandil administered as an oral dose of 
HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 2 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 22.84816 
3 1 55.68859 
4 2 61.45512 
5 3 63.5244 
6 4 56.35547 
7 6 51.28851 
8 8 49.65401 
9 12 47.09438 
 
 
Figure 4.65. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 2 
 
Table: 4.45.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 2 
Prameters Nicorandil 
Cmax (ng/mL) 63.5244 
Tmax  (Hrs) 3 
AUCtot (ng.h/mL) 1103.9 
AUMCtot (ng.h
2
/mL) 13634.7 
MRT (Hrs) 12.3514 
Ke (Hr
-1
) 0.0927887 
t1/2 el (Hrs) 7.47017 
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Table: 4.46. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 3 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 26.77097 
3 1 60.2652 
4 2 66.03173 
5 3 63.1975 
6 4 58.64377 
7 6 55.86512 
8 8 53.24991 
9 12 48.07508 
 
 
Figure 4.66. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 3 
 
Table: 4.47.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 3 
Prameters Nicorandil 
Cmax (ng/mL) 66.0317 
Tmax  (Hrs) 2 
AUCtot (ng.h/mL) 1130.97 
AUMCtot (ng.h
2
/mL) 13360.1 
MRT (Hrs) 11.813 
Ke (Hr
-1
) 0.0983562 
t1/2 el (Hrs) 7.04732 
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Table: 4.48. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 4 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 18.27155 
3 1 45.55467 
4 2 48.706 
5 3 49.79458 
6 4 50.47126 
7 6 47.0388 
8 8 44.7505 
9 12 41.53707 
 
 
Figure 4.67. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 4 
 
Table: 4.49.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 4 
Prameters Nicorandil 
Cmax (ng/mL) 50.4713 
Tmax  (Hrs) 4 
AUCtot (ng.h/mL) 993.097 
AUMCtot (ng.h
2
/mL) 13013.5 
MRT (Hrs) 13.1039 
Ke (Hr
-1
) 0.0872032 
t1/2 el (Hrs) 7.94865 
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Table: 4.50. Plasma concentration (ng/mL) of nicorandil administered za an oral dose 
of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 5 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 27.09787 
3 1 60.2652 
4 2 66.35863 
5 3 68.42791 
6 4 63.54728 
7 6 57.17272 
8 8 52.92301 
9 12 51.34408 
 
 
Figure 4.68. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 5 
 
Table: 4.51.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 5 
Prameters Nicorandil 
Cmax (ng/mL) 68.4279 
Tmax  (Hrs) 3 
AUCtot (ng.h/mL) 1226.27 
AUMCtot (ng.h
2
/mL) 16000.1 
MRT (Hrs) 13.0477 
Ke (Hr
-1
) 0.0794126 
t1/2 el (Hrs) 8.72843 
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Table: 4.52. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 6 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 30.36687 
3 1 48.82368 
4 2 56.55161 
5 3 59.60159 
6 4 60.60518 
7 6 52.26921 
8 8 49.65401 
9 12 45.13297 
 
 
Figure 4.69. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 6 
 
Table: 4.53.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HEMA-co-AA hydrogels equivalent to 15 mg in rabbit no. 6 
Prameters Nicorandil 
Cmax (ng/mL) 60.6052 
Tmax  (Hrs) 4 
AUCtot (ng.h/mL) 1087.8 
AUMCtot (ng.h
2
/mL) 13524.8 
MRT (Hrs) 12.4331 
Ke (Hr
-1
) 0.091721 
t1/2 el (Hrs) 7.55712 
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Table: 4.54. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HEMA-co-AA hydrogels equivalent to 15 mg in G 1 
 
 
Table: 4.55. Mean plasma concentration (ng/mL) of nicorandil administered as an oral 
dose of HEMA-co-AA hydrogels equivalent to 15 mg in G1 
Sr. No. Time (Hrs) Mean concentration (ng/mL) ± SEM 
1 0 0 ± 000 
2 0.5 24.26473 ± 1.877 
3 1 53.78167 ± 2.469 
4 2 58.94888 ± 2.834 
5 3 59.32918 ± 2.993 
6 4 55.97409 ± 2.655 
7 6 51.45196 ± 1.941 
8 8 48.61882 ± 1.898 
9 12 44.91504 ± 2.173 
 
G1 
Time 
(hrs) R1 R2 R3 R4 R5 R6 Mean 
Std 
Dev SEM 
0 0 0 0 0 0 0 0 0 0 
0.5 20.232 22.848 26.770 18.271 27.097 30.366 24.264 4.598 1.877 
1 52.092 55.688 60.265 45.554 60.265 48.823 53.781 6.046 2.469 
2 54.590 61.455 66.031 48.706 66.358 56.551 58.948 6.942 2.834 
3 51.429 63.524 63.197 49.794 68.427 59.601 59.329 7.331 2.993 
4 46.221 56.355 58.643 50.471 63.547 60.605 55.974 6.503 2.655 
6 45.077 51.288 55.865 47.038 57.172 52.269 51.451 4.754 1.941 
8 41.481 49.654 53.249 44.750 52.923 49.654 48.618 4.648 1.898 
12 36.306 47.094 48.075 41.537 51.344 45.132 44.915 5.322 2.173 
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Figure 4.70. Mean plasma concentration vs. time profile of nicorandil administered as 
an oral dose of HEMA-co-AA hydrogels equivalent to 15 mg in G1 
 
Table: 4.56.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HEMA-co-AA hydrogels equivalent to 15 mg in G1 
Prameters Mean ± SEM 
Cmax (ng/mL) 60.60 ± 2.81 
Tmax  (Hrs) 3 ± 0.36 
AUCtot (ng.h/mL) 1085.87 ± 38.02 
AUMCtot (ng.h
2
/mL) 13859.2 ± 438.41 
MRT (Hrs) 12.79 ± 0.311 
Ke (Hr
-1
) 0.087807 ± 0.01 
t1/2 el (Hrs) 7.95 ± 0.31 
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Table: 4.57. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 7 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 28.9903 
3 1 62.06315 
4 2 106.2405 
5 3 116.2469 
6 4 110.3627 
7 6 107.45 
8 8 104.8348 
9 12 102.7067 
 
 
Figure 4.71. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 7 
 
Table: 4.58.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 7 
Prameters Nicorandil 
Cmax (ng/mL) 116.247 
Tmax  (Hrs) 3 
AUCtot (ng.h/mL) 2229.96 
AUMCtot (ng.h
2
/mL) 28174.9 
MRT (Hrs) 12.6347 
Ke (Hr
-1
) 0.0954547 
t1/2 el (Hrs) 7.26153 
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Table: 4.59. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 8 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 27.45746 
3 1 57.15965 
4 2 101.0101 
5 3 108.0744 
6 4 107.0937 
7 6 104.181 
8 8 101.5658 
9 12 100.7453 
 
 
Figure 4.72. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 8 
 
Table: 4.60.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 8 
Prameters Nicorandil 
Cmax (ng/mL) 108.074 
Tmax  (Hrs) 3 
AUCtot (ng.h/mL) 2103.33 
AUMCtot (ng.h
2
/mL) 25367.4 
MRT (Hrs) 12.0606 
Ke (Hr
-1
) 12.0606 
t1/2 el (Hrs) 6.73627 
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Table: 4.61. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 9 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 26.19889 
3 1 52.619 
4 2 98.20528 
5 3 104.9198 
6 4 104.0503 
7 6 103.2003 
8 8 101.1245 
9 12 97.22458 
 
 
Figure 4.73. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 9 
 
Table: 4.62.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 9 
Prameters Nicorandil 
Cmax (ng/mL) 104.92 
Tmax  (Hrs) 3 
AUCtot (ng.h/mL) 2047.09 
AUMCtot (ng.h
2
/mL) 24640.9 
MRT (Hrs) 12.037 
Ke (Hr
-1
) 0.103524 
t1/2 el (Hrs) 6.69554 
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Table: 4.63. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 10 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 29.51039 
3 1 63.10924 
4 2 105.8548 
5 3 111.0165 
6 4 113.501 
7 6 101.2389 
8 8 94.83167 
9 12 83.92627 
 
 
Figure 4.74. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 10 
 
Table: 4.64.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 10 
Prameters Nicorandil 
Cmax (ng/mL) 113.501 
Tmax  (Hrs) 4 
AUCtot (ng.h/mL) 2161.43 
AUMCtot (ng.h
2
/mL) 31016.2 
MRT (Hrs) 14.3499 
Ke (Hr
-1
) 0.0777844 
t1/2 el (Hrs) 8.91113 
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Table: 4.65. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 11 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 32.34462 
3 1 64.48549 
4 2 100.4936 
5 3 99.16637 
6 4 93.91635 
7 6 90.7781 
8 8 82.16427 
9 12 74.99534 
 
 
Figure 4.75. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 11 
 
Table: 4.66.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 11 
Prameters Nicorandil 
Cmax (ng/mL) 100.494 
Tmax  (Hrs) 2 
AUCtot (ng.h/mL) 1944.85 
AUMCtot (ng.h
2
/mL) 28605.7 
MRT (Hrs) 14.7084 
Ke (Hr
-1
) 0.0730844 
t1/2 el (Hrs) 9.48421 
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Table: 4.67. Plasma concentration (ng/mL) of nicorandil administered as an oral dose 
of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 12 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 26.77097 
3 1 56.01549 
4 2 104.9329 
5 3 107.0937 
6 4 105.0637 
7 6 104.2464 
8 8 97.38149 
9 12 91.83726 
 
 
Figure 4.76. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 12 
 
Table: 4.68.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA hydrogels equivalent to 15 mg in rabbit no. 12 
Prameters Nicorandil 
Cmax (ng/mL) 107.094 
Tmax  (Hrs) 3 
AUCtot (ng.h/mL) 2122.4 
AUMCtot (ng.h
2
/mL) 28187.5 
MRT (Hrs) 13.281 
Ke (Hr
-1
) 0.0880364 
t1/2 el (Hrs) 7.87342 
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Table: 4.69. Plasma concentrations (ng/mL) of nicorandil administered as an oral dose 
of HPMC-co-AA hydrogels equivalent to 15 mg in G2 
G2 
Time 
(hrs) R7 R8 R9 R10 R11 R12 Mean 
Std 
Dev SEM 
0 0 0 0 0 0 0 0 0 0 
0.5 28.990 27.457 26.198 29.510 32.344 26.770 28.545 2.253 0.920 
1 62.063 57.159 52.619 63.109 64.485 56.015 59.242 4.669 1.906 
2 106.240 101.010 98.205 105.854 100.493 104.932 102.789 3.327 1.358 
3 116.246 108.074 104.919 111.016 99.166 107.093 107.752 5.746 2.346 
4 110.362 107.093 104.050 113.501 93.916 105.063 105.664 6.730 2.748 
6 107.451 104.181 103.200 101.23 90.778 104.246 101.849 5.784 2.362 
8 104.834 101.565 101.124 94.831 82.164 97.381 96.983 8.052 3.287 
12 102.706 100.745 97.224 83.926 74.995 91.837 91.905 10.702 4.369 
 
 
 
 
Table: 4.70. Mean plasma concentration (ng/mL) of nicorandil administered as an oral 
dose of HPMC-co-AA hydrogels equivalent to 15 mg in G2 
Sr. No. Time (Hrs) Concentration (ng/mL) ± SEM 
1 0 0 
2 0.5 28.54544 ± 0.920 
3 1 59.242 ± 1.906 
4 2 102.7895 ± 1.358 
5 3 107.7529 ± 2.346 
6 4 105.6646 ± 2.748 
7 6 101.8491 ± 2.362 
8 8 96.98376 ± 3.287 
9 12 91.90591 ± 4.369 
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Figure 4.77. Mean plasma concentration vs. time profile of nicorandil administered as 
an oral dose of HPMC-co-AA hydrogels equivalent to 15 mg in G2 
 
Table: 4.71.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA hydrogels equivalent to 15 mg in G2 
Prameters Mean ± SEM 
Cmax (ng/mL) 108.38 ± 2.33 
Tmax  (Hrs) 3 ± 0.25 
AUCtot (ng.h/mL) 2101.51 ± 40.01 
AUMCtot (ng.h
2
/mL) 27665.43 ± 949.95 
MRT (Hrs) 13.17 ± 0.46 
Ke (Hr
-1
) 2.08 ± 1.99 
t1/2 el (Hrs) 7.82 ± 0.47 
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Table: 4.72. Plasma concentration (ng/mL) of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 13 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 29.40252 
3 1 52.06327 
4 2 66.49593 
5 3 84.78275 
6 4 95.22395 
7 6 90.7781 
8 8 88.37538 
9 12 77.61055 
 
 
Figure 4.78. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in 
rabbit no. 13 
Table: 4.73.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 13 
Prameters Nicorandil 
Cmax (ng/mL) 95.224 
Tmax  (Hrs) 4 
AUCtot (ng.h/mL) 1794.72 
AUMCtot (ng.h
2
/mL) 23481.1 
MRT (Hrs) 13.0834 
Ke (Hr
-1
) 0.091393 
t1/2 el (Hrs) 7.58425 
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Table: 4.74. Plasma concentration (ng/mL) of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 14 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 27.27766 
3 1 56.31297 
4 2 74.99534 
5 3 98.51257 
6 4 91.95494 
7 6 88.8167 
8 8 86.41398 
9 12 82.84096 
 
 
Figure 4.79. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in 
rabbit no. 14 
Table: 4.75.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 14 
Prameters Nicorandil 
Cmax (ng/mL) 98.5126 
Tmax  (Hrs) 3 
AUCtot (ng.h/mL) 1882.88 
AUMCtot (ng.h
2
/mL) 25278.1 
MRT (Hrs) 13.4253 
Ke (Hr
-1
) 0.0876654 
t1/2 el (Hrs) 7.90674 
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Table: 4.76. Plasma concentration (ng/mL) of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 15 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 25.12012 
3 1 66.77379 
4 2 83.06652 
5 3 79.87924 
6 4 78.22512 
7 6 75.74068 
8 8 74.31866 
9 12 69.76493 
 
 
Figure 4.80. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in 
rabbit no. 15 
Table: 4.77.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 15 
Prameters Nicorandil 
Cmax (ng/mL) 83.0665 
Tmax  (Hrs) 2 
AUCtot (ng.h/mL) 1706.73 
AUMCtot (ng.h
2
/mL) 24415.4 
MRT (Hrs) 14.3054 
Ke (Hr
-1
) 0.0790355 
t1/2 el (Hrs) 8.77008 
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Table: 4.78. Plasma concentration (ng/mL) of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 16 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 31.65813 
3 1 69.0621 
4 2 79.79751 
5 3 77.59093 
6 4 76.59062 
7 6 75.83875 
8 8 74.64556 
9 12 71.07253 
 
 
Figure 4.81. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit 
no. 16 
Table: 4.79.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 16 
Prameters Nicorandil 
Cmax (ng/mL) 79.7975 
Tmax  (Hrs) 2 
AUCtot (ng.h/mL) 1713.92 
AUMCtot (ng.h
2
/mL) 24451.5 
MRT (Hrs) 14.2664 
Ke (Hr
-1
) 0.0796036 
t1/2 el (Hrs) 8.70749 
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Table: 4.80. Plasma concentration (ng/mL) of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 17 
 
 
 
Figure 4.82. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in 
rabbit no. 17 
Table: 4.81.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 17 
Prameters Nicorandil 
Cmax (ng/mL) 102.762 
Tmax  (Hrs) 3 
AUCtot (ng.h/mL) 1860.58 
AUMCtot (ng.h
2
/mL) 23911.6 
MRT (Hrs) 12.8517 
Ke (Hr
-1
) 0.0910878 
t1/2 el (Hrs) 7.60966 
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Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 32.50807 
3 1 62.85099 
4 2 81.53335 
5 3 102.7623 
6 4 98.81986 
7 6 92.41261 
8 8 89.35608 
9 12 78.26435 
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Table: 4.82. Plasma concentration (ng/mL) of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 18 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 32.31193 
3 1 63.83169 
4 2 75.5478 
5 3 92.95526 
6 4 94.57015 
7 6 89.1436 
8 8 80.85667 
9 12 73.03394 
 
 
Figure 4.83. Plasma concentration vs. time profile of nicorandil administered as an oral 
dose of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit 
no. 18 
Table: 4.83.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in rabbit no. 18 
Prameters Nicorandil 
Cmax (ng/mL) 94.5701 
Tmax  (Hrs) 4 
AUCtot (ng.h/mL) 1792.91 
AUMCtot (ng.h
2
/mL) 24507.4 
MRT (Hrs) 13.6691 
Ke (Hr
-1
) 0.0808116 
t1/2 el (Hrs) 8.57733 
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Table: 4.84. Plasma concentrations (ng/mL) of nicorandil administered as an oral dose 
of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in G3 
G3 
Time 
(hrs) R13 R14 R15 R16 R17 R18 Mean 
Std 
Dev SEM 
0 0 0 0 0 0 0 0 0 0 
0.5 29.403 27.278 25.120 31.658 32.508 32.312 29.713 3.016 1.231 
1 52.063 56.313 66.774 69.062 62.851 63.832 61.816 6.444 2.631 
2 66.496 74.995 83.067 79.798 81.533 75.548 76.906 6.026 2.460 
3 84.783 98.513 79.879 77.591 102.762 92.955 89.414 10.253 4.186 
4 95.224 91.955 78.225 76.591 98.820 94.570 89.231 9.431 3.850 
6 90.778 88.817 75.741 75.839 92.413 89.144 85.455 7.596 3.101 
8 88.375 86.414 74.319 74.646 89.356 80.857 82.328 6.753 2.757 
12 77.611 82.841 69.765 71.073 78.264 73.034 75.431 4.991 2.037 
 
 
Table: 4.85. Mean plasma concentration (ng/mL) of nicorandil administered as an oral 
dose of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in G3 
Sr. No. Time (Hrs) Concentration (ng/mL) ± SEM 
1 0 0 
2 0.5 29.71307 ± 1.231 
3 1 61.8158 ± 2.631 
4 2 76.90608 ± 2.460 
5 3 89.41384 ± 4.186 
6 4 89.23077 ± 3.850 
7 6 85.45507 ± 3.101 
8 8 82.32772 ± 2.757 
9 12 75.43121 ± 2.037 
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Figure 4.84. Mean plasma concentration vs. time profile of nicorandil administered as 
an oral dose of HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg 
in G3 
 
 
Table: 4.86.  Pharmacokinetic parameters of nicorandil administered as an oral dose of 
HPMC-co-AA-co-HEMA hydrogels equivalent to 15 mg in G3 
Prameters Mean ± SEM 
Cmax (ng/mL) 92.32 ± 3.66 
Tmax  (Hrs) 3 ± 0.36 
AUCtot (ng.h/mL) 1791.95 ± 29.63 
AUMCtot (ng.h
2
/mL) 24340.85 ± 248.15 
MRT (Hrs) 13.60 ± 0.24 
Ke (Hr
-1
) 0.08 ± 0.01 
t1/2 el (Hrs) 8.19± 0.22 
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Table: 4.87. Plasma concentration (ng/mL) of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 19 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 87.88503 
3 1 112.8668 
4 2 52.66476 
5 3 30.84415 
6 4 12.1912 
7 6 11.66489 
 
 
Figure 4.85. Plasma concentration vs. time profile of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 19 
 
Table: 4.88.  Pharmacokinetic parameters of nicorandil administered as an oral solution 
equivalent to 15 mg in rabbit no. 19 
Prameters Nicorandil 
Cmax (ng/mL) 112.867 
Tmax  (Hrs) 1 
AUCtot (ng.h/mL) 259.386 
AUMCtot (ng.h
2
/mL) 588.464 
MRT (Hrs) 2.26869 
Ke (Hr
-1
) 0.47035 
t1/2 el (Hrs) 1.47368 
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Table: 4.89. Plasma concentration (ng/mL) of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 20 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 81.34702 
3 1 109.5978 
4 2 49.39576 
5 3 27.90204 
6 4 12.06044 
7 6 11.66489 
 
 
Figure 4.86. Plasma concentration vs. time profile of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 20 
 
Table: 4.90.  Pharmacokinetic parameters of nicorandil administered as an oral solution 
equivalent to 15 mg in rabbit no. 20 
Prameters Nicorandil 
Cmax (ng/mL) 109.598 
Tmax  (Hrs) 1 
AUCtot (ng.h/mL) 247.436 
AUMCtot (ng.h
2
/mL) 570.519 
MRT (Hrs) 2.30572 
Ke (Hr
-1
) 0.460013 
t1/2 el (Hrs) 1.5068 
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Table: 4.91. Plasma concentration (ng/mL) of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 21 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 91.15404 
3 1 118.4241 
4 2 63.12558 
5 3 32.80555 
6 4 12.06044 
7 6 11.70085 
 
 
Figure 4.87. Plasma concentration vs. time profile of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 21 
 
Table: 4.92.  Pharmacokinetic parameters of nicorandil administered as an oral solution 
equivalent to 15 mg in rabbit no. 21 
Prameters Nicorandil 
Cmax (ng/mL) 118.424 
Tmax  (Hrs) 1 
AUCtot (ng.h/mL) 276.541 
AUMCtot (ng.h
2
/mL) 610.69 
MRT (Hrs) 2.20832 
Ke (Hr
-1
) 0.493018 
t1/2 el (Hrs) 1.40593 
0
20
40
60
80
100
120
140
0 1 2 3 4 5 6 7
P
la
sm
a
 c
o
n
ce
n
tr
a
ti
o
n
 (
n
g
/m
L
) 
Time (hrs) 
148 
 
Table: 4.93. Plasma concentration (ng/mL) of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 22 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 92.46164 
3 1 124.9621 
4 2 66.06769 
5 3 36.9889 
6 4 12.11601 
7 6 11.71066 
 
 
Figure 4.88. Plasma concentration vs. time profile of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 22 
 
Table: 4.94.  Pharmacokinetic parameters of nicorandil administered as an oral solution 
equivalent to 15 mg in rabbit no. 22 
Prameters Nicorandil 
Cmax (ng/mL) 124.962 
Tmax  (Hrs) 1 
AUCtot (ng.h/mL) 289.04 
AUMCtot (ng.h
2
/mL) 631.692 
MRT (Hrs) 2.18548 
Ke (Hr
-1
) 0.505915 
t1/2 el (Hrs) 1.37009 
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Table: 4.95. Plasma concentration (ng/mL) of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 23 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 85.92363 
3 1 128.2311 
4 2 69.99049 
5 3 40.58481 
6 4 12.1487 
7 6 11.70085 
 
 
Figure 4.89. Plasma concentration vs. time profile of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 23 
 
Table: 4.96.  Pharmacokinetic parameters of nicorandil administered as an oral solution 
equivalent to 15 mg in rabbit no. 23 
Prameters Nicorandil 
Cmax (ng/mL) 128.231 
Tmax  (Hrs) 1 
AUCtot (ng.h/mL) 295.605 
AUMCtot (ng.h
2
/mL) 649.283 
MRT (Hrs) 2.19645 
Ke (Hr
-1
) 0.515697 
t1/2 el (Hrs) 1.3441 
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Table: 4.97. Plasma concentration (ng/mL) of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 24 
Sr. No. Time (Hrs) Concentration (ng/mL) 
1 0 0 
2 0.5 76.11661 
3 1 111.8861 
4 2 60.18348 
5 3 34.04679 
6 4 12.08332 
7 6 11.69758 
 
 
Figure 4.90. Plasma concentration vs. time profile of nicorandil administered as an oral 
solution equivalent to 15 mg in rabbit no. 24 
 
Table: 4.98.  Pharmacokinetic parameters of nicorandil administered as an oral solution 
equivalent to 15 mg in rabbit no. 24 
Prameters Nicorandil 
Cmax (ng/mL) 111.886 
Tmax  (Hrs) 1 
AUCtot (ng.h/mL) 263.194 
AUMCtot (ng.h
2
/mL) 606.829 
MRT (Hrs) 2.30563 
Ke (Hr
-1
) 0.481159 
t1/2 el (Hrs) 1.44058 
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Table: 4.99. Mean plasma concentration (ng/mL) of nicorandil administered as an oral 
solution equivalent to 15 mg in G4 
G4 
Time 
(hrs) R19 R20 R21 R22 R23 R24 Mean 
Std 
Dev SEM 
0 0 0 0 0 0 0 0 0 0 
0.5 87.885 81.347 91.154 92.462 85.924 76.117 85.815 6.181 2.523 
1 112.86 109.598 118.424 124.962 128.231 111.886 117.661 7.576 3.093 
2 52.665 49.396 63.126 66.068 69.990 60.183 60.238 7.904 3.227 
3 30.844 27.902 32.806 36.989 40.585 34.047 33.862 4.489 1.833 
4 12.191 12.060 12.060 12.116 12.149 12.083 12.110 0.052 0.021 
6 11.665 11.665 11.701 11.711 11.701 11.698 11.690 0.020 0.008 
 
Table: 4.100. Mean plasma concentration (ng/mL) of nicorandil administered as an 
oral solution equivalent to 15 mg in G4 
Sr. No. Time (Hrs) Concentration (ng/mL) ± SEM 
1 0 0 
2 0.5 85.81466 ± 2.523 
3 1 117.6613 ± 3.093 
4 2 60.23796 ± 3.227 
5 3 33.86204 ± 1.833 
6 4 12.11002 ± 0.021 
7 6 11.68995 ± 0.008 
 
 
Figure 4.91. Mean plasma concentration vs. time profile of nicorandil administered as 
an oral solution equivalent to 15 mg in G4 
0
20
40
60
80
100
120
140
0 1 2 3 4 5 6 7
M
ea
n
 P
la
sm
a
 C
o
n
c.
 (
n
g
/m
L
) 
Time (hrs) 
152 
 
Table: 4.101. Pharmacokinetic parameters of nicorandil administered as an oral 
solution equivalent to 15 mg in G4 
Prameters Mean ± SEM 
Cmax (ng/mL) 117.66 ± 3.09 
Tmax  (Hrs) 1 ± 0.01 
AUCtot (ng.h/mL) 271.86 ± 7.54 
AUMCtot (ng.h
2
/mL) 609.57 ± 11.61 
MRT (Hrs) 2.24 ± 0.02 
Ke (Hr
-1
) 0.48 ± 0.01 
t1/2 el (Hrs) 1.42 ± 0.02 
 
 
 
Figure 4.92. Mean plasma concentration vs. time profile of nicorandil administered as 
an oral dose equivalent to15 mg 
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4.7 Statistical analysis 
One way ANOVA was applied to determined level of significance between 
pharmacokinetic parameters of different formulation groups. Results are given table no 
4.96. 
Table 4.102. Statistical analysis 
Pharmacokinetic 
parameter 
df SS MS F P-value 
Statistical 
result 
Cmax 3 11294.881 3764.960 68.9344 
0.0004 
(< 0.05) 
Highly 
significant 
Tmax 3 17.701 5.900 11.7910 
0.0001 
(< 0.05) 
Highly 
significant 
AUC 
3 11920143.071 3973381.024 665.2715 
1.0000 
(> 0.05) 
Highly 
insignificant 
df = Degree of freedom 
SS = Sum of squares 
MS =  Mean of squares 
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5.0 Discussion 
5.1 Swelling behavior 
5.1.1 HEMA-co-AA hydrogel 
Various factors control swelling behavior of hydrogel in different media or at 
different pH like equilibrium water content, pKa value, chemical architecture of 
molecular chains. As far as ionization concerned, it depends on external pH of 
media. At lower pH carboxylic groups were protonated leading to a few ionized 
groups in existing network resulting in contracted state of polymer network. 
Ultimately less swelling ratio were observed at lower pH. At higher pH swelling 
capacities were enhanced justified by opening out of originally coiled molecules due 
to electrostatic repulsion forces (Nazar et al., 2014). 
In present study swelling ratios of formulations F4 to F6 were increased from 15.013 
to 16.420 by increasing monomer concentration (AA) ranging from 10.5 to 14.5 w/w 
at pH 7.4 because of higher hydrophilic content in polymer chain as shown in table 
4.2 and figure 4.2. Whereas swelling ratio of formulations F7 to F9 were decreased 
from 10.104 to 8.775 by increasing cross linker concentration ranging from 0.020 to 
0.030 (%w/w) at pH 7.4 due to the establishment of close-fitted network structure 
shown in table 4.3 and figure 4.3. Swelling ratio of formulations F1 to F3 were 
decreased from 16.358 to 13.696 by increasing HEMA concentration ranging from 
0.84 to 3.36 (%w/w) at pH 7.4 due to formation of compact network structure shown 
in table 4.1 and figure 4.1. This swelling behaviour can be attributed to acidic 
content from acrylic acid. As acidic component increases electrostatic repulsive force 
also increases resulting in overall increases in hydration. As a result swelling 
increases with increase in acrylic acid content. While upon increasing acrylate 
component electrostatic repulsive forces decrease resulting in decreased swelling 
capacity (Patankar and Bhitre, 2013). 
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Same pattern studies were conducted by Das in 2014 where swelling ratio was 
increased by increasing monomer concentration due to increased hydration content 
and decreased by increasing cross linker concentration because of more compact 
network formation and as result less hydration or water penetration (Das et al., 
2014). 
5.1.2 Swelling kinetics HPMC-co-AA hydrogel 
Dynamic swelling of formulations F10 to F18 was determined till swelling 
equilibrium reached in buffer solution of different pH i.e. 1.2, 5.8 and 7.4 keeping in 
view different pH environment through gastrointestinal track. Percent gel content 
and percent porosity was also found. Over all swelling ratio is higher in basic 
medium as compared to acidic medium because of higher pKa value of basic 
medium. Depending upon varying components swelling ratio was also affected in 
different pH. Results showed that swelling ratios of formulations F10 to F12 were 
increased by increasing HPMC concentration from as shown in table 4.4 and figure 
4.4. It was also noted that swelling ratio was increased by increasing AA content and 
vice versa. Dynamic swelling ratio of formulations F13 to F15 was increased by 
increasing acrylic acid content as shown in table 4.5 and figure 4.5. While increase in 
cross linker (MBA) concentration resulted in overall decreased swelling ratio. 
By addition of pendant acidic or basic functional groups to a polymer chain, pH 
sensitivity can be imparted to polymer backbone. This addition of acidic or basic 
functional groups enable network to either release or accept protons in different pH 
medium. As a result electrostatic repulsion is produced which ultimately controls 
porosity of network. Ionic hydrogels having carboxylic or acid groups exhibit 
changes in swelling behaviour in different pH medium. Polymer networks having 
more pendant acidic groups show more electrostatic repulsions resulting in greater 
porosity and swelling at high pH (pH 7.4) while networks with basic pendant groups 
exhibit electrostatic repulsion at low pH values (pH 1.2). In present study HPMC-co-
AA hydrogel has more acidic pendant groups from acrylic acid, that‟s why these 
hydrogels showed greater swelling at pH 7.4 (basic pH) as compared to acidic pH 
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1.2 e.g F13 showed swelling ratio 6.719 and 47.380 at pH1.2 and 7.4 (Robert and 
Nicholas, 2003; Zhang et al., 2005). 
Same pattern of study was conducted by Patankar and Bhitre in 2003 where they 
prepared poly (acrylamide-co-acrylic acid) hydrogel and studied their swelling 
behavior at different pH. Their results showed that greater swelling was there at 
basic pH as compared to acidic pH. More over swelling ratio was increased with 
increase in acidic content that was acrylic acid. This factor was in good support with 
results of present study (Patankar and Bhitre, 2013). 
5.1.3 Swelling kinetics of HPMC-co-AA-co-HEMA hydrogel 
Dynamic swelling as function of concentration for HPMC-co-AA-co-HEMA 
hydrogels was determined at various pH buffer solution i.e. pH 1.2, pH 5.8 and pH 
7.4. Percent porosity and percent gel content was also determined for various weight 
ratios of components. Swelling ratio, percent porosity and percent gel content of 
hydrogel formulation was found to be greatly affected by varying weight ratios of 
component. 
Dynamic equilibrium swelling of HPMC-co-AA-co-HEMA hydrogels was increased 
with increased monomer concentration i.e. acrylic acid as acrylic acid hydrogel are 
anionic in nature (Esmaiel and Samyra, 2000). It can be justified as percent swelling 
of an ionic network greatly depends on concentration of ionizable groups in network 
(Tasdelen et al., 2004). Dynamic equilibrium swelling ratio for formulations F22 to 
F23 was increased from 5.000 to 5.784 in pH 1.2 and 47.436 to 62.270 in pH 7.4 by 
increasing AA concentration from 10 to 15 (%w/w) shown in table and figure 4.8. 
HPMC-co-AA-co-HEMA hydrogel contains anionic acrylic acid and non-ionic 
acrylate unit which give adequate polarity, charge and hydrogen bonding responsible 
for better hydration. Swelling ratio was also increased from 4.127 to 4.500 and 
42.618 to 49.011in buffer solution of pH 1.2 and 7.4 respectively by increasing 
concentration of HPMC from 5 to 10 (%w/w) as depicted by formulations F25 to 
F28 shown in table and figure 4.9. The basic reason for this type of swelling of 
hydrogels was free carboxylic acid groups. These carboxylic acid groups have ability 
157 
 
to release proton and have a tendency to dissociate at basic pH resulting in greater 
hydration and swelling. While at acidic pH great quantities of hydrogen bonds were 
present due to acrylic acid and acrylate chain. As pH was raised break down of 
hydrogen bonds occured, moreover carboxylic acid groups started to ionize resulting 
in greater inside osmotic pressure and electrostatic repulsion. Overall result was 
greater expansion of hydrogel at basic pH i.e. 7.4. Present data had depicted that 
formulated hydrogels have greater sensitivity towards pH so it can be used for 
sustained drug delivery through gestro intestinal tract on behalf of different pH 
environments throughout tract (Nihar and Patel, 2014). 
Similar type of study was conducted by Nihar and Patel in 2014. They formulated 
pH sensitive poly acrylamide-co-acrylic acid hydrogel for controlled and sustained 
drug delivery. They studied swelling behaviour of the hydrogels in solutions having 
different pH values and found that swelling of formulated hydrogels were increased 
with increased monomer concentration as also depicted by present study (Nihar and 
Patel, 2014). Carboxylic acid groups present in hydrogel structure were thought to be 
responsible for pH sensitive swelling behaviour. At lower or acidic pH values large 
quantities of hydrogen bonds formed were found and carboxylic acid remains in 
form of COOH. While at basic pH (7.4) carboxylic acid groups were present in free 
state able to lose proton and dissociate. As a result inner osmotic pressure of 
hydrogels was increased and electrostatic repulsion promoted network expansion 
(Patankar and Bhitre, 2013). 
5.1.4 Dynamic swelling studies of CMC-co-MAA-co-AMPS hydrogel 
Swelling behaviour of CMC-co-MAA-co-AMPS hydrogels was investigated at 
different pH i.e. pH 1.2, pH 5.8  and pH 7.4. Swelling ratio was noted to be increased 
from 66.638 to 76.489 at pH 7.4 and 65.965 to 75.043 at pH 1.2 with increasing 
AMPS content from 4 to 6 (%w/w) in formulations from F34 to F36 as given in table 
and figure 4.11. Repulsion among sulfonate groups were thought to be responsible 
for increased swelling with increasing AMPS concentration as it improved 
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hydrophilicity formulation resulting ultimately increase in swelling ratio (Yizhe et 
al., 2013). 
Present study was in good justification with study conducted by Yizhe et al., in 2013. 
Yizhe prepared CMC-g -poly(AA-co-AMPS) hydrogel. They have reported that 
swelling ratio was increased with increasing content of AMPS (Yizhe et al., 2013). 
Another study conducted by Amr in 2011 declares that increasing AMPS content 
would result in increased hydrophilicity which ultimately leads to enhanced swelling 
ability. Moreover increasing AMPS content leads to more perfect crosslinking 
structure which has capability to absorb and retain water (Amr, 2012). CMC-co-
MAA-co-AMPS hydrogel exhibited abrupt change in swelling at lower pH even at 
pH 2. AMPS possess pKa value 2. At pH less than the pKa value sulfonic groups 
collapsed and show comparatively less swelling. 
Swelling ratio was noted to be decreased from 69.662 to 64.683 at pH 7.4 and 59.898 
to 57.441 at pH 1.2 with increasing MAA content from 6 to 8 (%w/w) in 
formulations from F31 to F33 as given in table and figure 4.10. As MAA 
concentration increased more compact network was formed with less porosity and 
less hydration. As a result over swelling ratio was decreased. This fact could be 
justified by presence of reactive vinyl groups present in polymeric network. 
5.1.5 Percent gel content (%gc) and %porosity (%P) measurement 
Percent porosity depends on the volume of the pores present scaffolds of hydrogels 
and percent gel content depends upon cross linking density. 
Porosity decreased with increasing concentration of monomer i.e. HEMA and cross 
linker i.e. MBA while percent gel contentment increased due to enhanced cross 
linking density and greater physical entanglement resulting in compact structure with 
less pore density. Ultimately swelling ratio or water retention capacity was decreased 
leading to decreased drug release. While higher concentration of monomer AA led to 
lesser cross linking density and lesser physical entanglement, as a result more pore 
volume or greater pore density was observed. Same pattern study was conducted by 
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Shivani in 2013 where he confirmed that percent gel content increased with increase 
cross linking density and percent porosity was decreased and vice versa (Shivani et 
al., 2013). 
Percent gel content was noted to increase with increasing content of HEMA, HPMC 
and AMPS from 83.758% to 93.269% (F1 to F3), 85.614% to 93.990% (F10 to F12) 
and 92.804% to 96.515% (F34 to F36) respectively at pH 7.4. In hydrogel 
preparation free radicals are generated on polymer/monomer leading to formation of 
cross linked macromolecules. As concentration of polymer/monomer increased 
macromolecules come closer to each other resulting in more facilitated cross linking 
which ultimately leads to increase in gel content (Dafader et al., 2011). Similar kind 
of results was reported by Dafader et al., in 2011. Percent gel content was found 
increasing with increasing feed of monomer HEMA. Percent gel content was found 
to increase with increasing ratio of AA from 80.577% to 85.536% (F4 to F6). This 
can be attributed to increase in cross liking ratio with increase in monomer 
concentration. Results of present study were in good agreement with the studies 
conducted by Dafader et al., in 2012. He reported that gel content was increased with 
increase in AA content (Dafader et al., 2012). Similar type of results were reported 
by Kamal et al., in 2014 where he reported that % gel content was found to increase 
with increasing concentration of AA. He reported that cross liking density increases 
with increasing monomer concentration resulting in enhanced gel content (Kamal et 
al., 2014). In present study percent gel content was increased with increase in cross 
linker concentration from 81.382% to 87.988% (F7 to F9), 82.180% to 88.268% 
(F16 to F18) and 85.372% to 94.413% (F28 to F30) at pH 7.4. Results are in good 
agreement with studies conducted by Samiullah and Nazar in 2014 where they have 
reported that percent gel content increases with increase in cross linker concentration 
because of increase in cross linking density (Samiullah and Nazar, 2014). Nazar and 
Umbreen also reported same kind of results (Nazar and Umbreen, 2014). 
Percent porosity was noted to decrease with increase in monomer concentration i.e. 
HEMA and MAA while it was noted to increase with increasing concentration of 
AA, HPMC and AMPS. Percent porosity was noted to decrease with increasing cross 
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linker concentration. Increase in percent porosity can be justified by fact that 
viscosity of solution increases in such cases which prevent bubbles from escape and 
form more interconnected channels. These interconnected channels result in more 
porous network. While on other hands in cases where porosity is decreased more 
cross linking occurred resulting in formation of more entanglement structures as in 
case of increasing cross linking concentration. 
Same kind of results was reported by Samiullah and Nazar in 2014. They reported 
that percent porosity decreased with increasing concentration of cross linker while it 
increased with increasing polymer/monomer concentration (Samiullah and Nazar, 
2014). Same pattern of results were reported by Nazar and Umbreen (Nazar and 
Umbreen, 2014). 
5.2 Characterization 
5.2.1 FTIR Analysis 
5.2.1.1 HEMA-co-AA hydrogel 
FTIR results revealed drug excipients compatibility. In FTIR spectra of pure drug 
and excipients many prominent peaks are observed depicting presence of functional 
groups. Characteristics band were observed 3247 cm
-1
 for (NH); 1675 cm
-1
 for 
(C=O, CONH) and 1362 cm
-1
 for (CH2) (Sunitha et al., 2014). 
FTIR spectra of excipients and formulation were shown in figure 4.30 depicting 
characteristic bands of functional groups like 3243.17 cm
−1
 for (NH);  1627.97 cm
−1
 
for (C=O, CONH) and 1361.55 cm
−1
 for (CH2). A scientist named Abdul worked 
with FTIR spectra of nicorandil with different excipients in 2014. His work found to 
be in good support with present study (Abdul and Lila, 2014). Sindhu also conducted 
same pattern of study and results of his study supports well the results of present 
study (Sindhu et al., 2015). 
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5.2.1.2 HPMC-co-AA hydrogel 
FTIR spectra of HPMC-co-AA hydrogel were shown in figure 4.31. Absorption 
bands that appears near 3419 cm
−1
 refer to OH group stretching while absorption 
bands at 1617 cm
−1
 correspond to CH=CH stretching. In FTIR spectra of pure 
HPMC peak at 2922.90 cm
−1
 is representative of methyl and hydroxypropyl group 
responsible for –CH stretching of these groups. More over peak at 1641.92 cm−1 is 
representative of C-O stretching (Patitapabana and Subash, 2012).  In FTIR spectra 
of HPMC-co-AA hydrogel peak at 1697.92 cm
−1
 could be representative of C=O 
stretching of carboxylic group. Peak at 1450.52 cm
−1
 in formulated hydrogel refers to 
C-H deformation of alkane. Peak at 1163.16 cm
−1
 in hydrogel could be 
representative of C-O stretching in C-O-C group. These functional groups clarify 
presence of representative functional groups of HPMC and acrylic acid after 
synthesis of HPMC-co-AA hydrogels. 
Patitapabana and Subash also worked with HPMC and AA hydrogels. They describe 
FTIR spectra of HPMC-g-AA hydrogels. They also found peak around 1637cm
−1
 
representing C=O stretching of COOH and at 1116 cm
−1
 representing C-O stretching 
in C-O-C group. Their results are in very good agreement with present study 
(Patitapabana and Subash, 2012). 
5.2.1.3 HPMC-co-AA-co-HEMA hydrogel 
FTIR is an important identification tool for new formulations. FTIR spectra of 
HPMC-co-AA-co-HEMA hydrogel and of individual components were obtained as 
shown in figure 4.32. In pure HPMC spectra a broad peak at 3425.26 cm
−1
 was due 
to –OH stretching vibrations of the hydroxyl groups and peak at 1641.92 cm−1 could 
be representative of N-H group (Patitapabana and Subash, 2012). In prepared 
hydrogel a peak obtained at 2920.73 cm
−1
 was representing –CH stretching of methyl 
and hydroxypropyl groups and peak at 1698.36 cm
−1
 showed N-H deformation 
bending of hydroxypropyl methy cellulose. Prepared hydrogel consist of 
hydroxypropyl methyl cellulose back bone having carboxylate and ester functional 
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groups as side chains which are identified by sharp peak at 1698.36 cm
−1
. Peak at 
1414.85 cm
−1
 could be representative of C=O stretching. 
Muhammad in 2010 also conducted same pattern of study with chitosan, acrylic acid 
and HEMA hydrogel. He has reported peaks of monomer AA and HEMA as found 
in FTIR spectra of present study like peak at 1414.85 cm
−1
 representative of C=O 
stretching and peak around 1637cm
−1
 representing C=O stretching of COOH and at 
1116 cm
−1
. So it can be concluded that results of his study were in good agreement 
with present study. (Muhammad, 2010). 
5.2.1.4 CMC-co-MAA-co-AMPS hydrogel 
FTIR spectra of CMC-co-MAA-co-AMPS hydrogels confirmed grafting of MAA 
and AMPS with CMC as shown in figure 4.33. Characteristic sharp absorption peak 
of pure CMC at 1022.19 cm
−1
 (-OH groups) was shifted after reaction depicting that 
CMC has taken part in graft copolymerization via -OH groups. Appearance of peak 
at 1637.97 cm
−1
 was characteristic of COO asymmetrical stretching vibration of -
COO – groups while peak at 1444.00 cm−1 was characteristic representative of COO 
symmetrical stretching vibration of -COO – groups. Appearance of peak at 1143.79 
cm
−1
 in CMC-co-MAA-co-AMPS hydrogels showed stretching vibration of -SO3-H 
groups which is characteristic peak of AMPS existence in grafted system. On behalf 
of these results it can be clearly stated that that AMS and MAA were positively 
grafted onto CMC backbones. 
Yizhe also studied FTIR spectra of similar type of grafted system where he grafted 
AMPS and AA on CMC backbones. Characteristic bands of CMC and AMPS he 
mentioned were also found in FTIR spectra of present study. So we can sate that his 
results are in good support with present study (Yizhe et al., 2013). 
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5.2.2. Scanning Electron Microscopy (SEM) 
5.2.2.1 HEMA-co-AA hydrogels 
Surface SEM microgram of HEMA-co-AA hydrogels showed porous structure 
responsible for swelling of hydrogels and ultimately drug release (shown in figure 
4.34), as these pores act as water channels and serve as transporter for guest 
molecules. Shevani et al., in 2013 also reported SEM image of hydrogel having 
porous structure (Shivani et al., 2013). 
Heterogeneous distribution of pores was observed as seen in SEM micrograph that 
led to formation of medical devices with a desired morphology for successful 
sustained drug delivery. Simonida et al., in 2010 also worked with HEMA hydrogels 
and he also found porous morphology of gel responsible for its functionality 
(Simonida et al., 2010). 
5.2.2.2 HPMC-co-AA hydrogels 
SEM micrograph of HPMC-co-AA hydrogel at magnification of 100X and 200X 
exhibited uneven pores in size and shape distribution as shown in figure 4.35. This 
porous network was thought to be responsible for entrapment of aqueous media. This 
porous network is formed by grafting of monomer acrylic acid on polymer HPMC. 
Patitapabana also worked on hydroxyl propyl methyl cellulose and acrylic acid 
hydrogels. He reported that SEM image of hydrogel have porous structure with 
smooth surface. His results were in good agreement with present study (Patitapabana 
and Subash, 2012). 
Another scientist name Pitta worked with acrylic acid and HPMC hydrogels in 
various formulations. He also reported that these formulations have porous 
morphology which is responsible for their water retention capacities. These results 
are also in good agreement with results of present study (Pitta et al., 2014). 
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5.2.2.3 HPMC-co-AA-co-HEMA hydrogels 
Via SEM images of freeze dried HPMC-co-AA-co-HEMA hydrogels morphology of 
the hydrogels was shown in figure 4.36. Loose network structure of lamellar shape 
was thought to be responsible for water holding or absorbing capacity. This network 
structure was considered to be formed as a result of cross linking of 
polymer/monomer. 
Guo at al., also in 2014 worked on various HPMC and AA formulations. He also 
reported network structure of lamellar shape which is considered to be responsible 
for functionality of hydrogels (Guo et al., 2014). A scientist named Mohammad 
Sadegh said that microstructure morphology must be considered among the most 
important properties of hydrogel. His work was based on same pattern as that of 
present study. He also reported micro-porous morphology of hydrogels. He declared 
that these pores act as regions of water permeation and provides interaction sites of 
external stimuli (Mohammad, 2010). A scientist also studied scanning electron 
micrograph of HPMC and AA hydrogel in various formulation and they reported that 
these hydrogels possess porous structure and have good water absorbing and 
retention capacities (Mohammad and Mojgan, 2011). 
5.2.2.4 CMC-co-MAA-co-AMPS hydrogels 
Scanning electron microgram of CMC-co-MAA-co-AMPS hydrogels showed coarse 
porous structure with heavy mesh networking which clearly justifies its greater water 
absorbing and retention capacities as shown in figure 4.37. Mechanism behind can 
be better told by fact that sulfonate groups exert greater electrostatic repulsive forces 
as compared to carboxylate groups, so as AMPS ratio increased porosity was 
increased resulting in more water absorption and retention capacities. More over 
alkyl group of AMPS form hydrophobic regions which have capability to decrease 
hydrogen bonding among hydrophilic groups of polymer chain which will lead to 
increased pore size and expansion of polymeric network (Aiqin et al., 2010). 
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Yizhe also performed same pattern of study in 2013 where he confirmed highly 
porous network of CMC-AMPS hydrogels, which is in good agreement with results 
of present study (Yizhe et al., 2013). 
5.2.3. Thermal Gravimetric Analysis and Differential Scanning 
Calorimetery (TGA & DSC) 
5.2.3.1. HEMA-co-AA hydrogels 
TGA had depicted thermal stability of HEMA-co-AA hydrogel (F4) as shown in 
figures 4.38. Decomposition of formulation was observed in four steps. The first step 
of degradation attributed by dehydration was observed up to 275 
°
C with 21.17 % 
weight loss. Next step of degradation was observed from 275 to 400 
°
C with 35.28 % 
weight loss and third step from 400 
°
C to 475 
°
C with 30.72 % weight loss attributed 
by decomposition of functional groups of hydrogel. Final degradation of hydrogel 
was noticed at 550 
°
C with 20.71 % weight loss. 
Same pattern of study was conducted by Das in 2014 where he observed thermal 
behavior of hydrogels in TGA and found that hydrogels were thermo stable and 
showed thermal decomposition in four distinct steps (Das et al., 2014). 
Simonida have also observed thermal stability of HEMA hydrogels by TGA. He 
reported that copolymer samples exhibited much improved thermal stability than 
monomer. This can be justified probably by higher effective cross-link density 
(Simonida et al., 2010). Generally speaking we can say that formulated copolymeric 
hydrogel network has batter thermal stability as compared to reactants i.e. HEMA 
and AA. As these formulations were prepared to work at 37 °C, these showed the 
best thermal stability at this range. 
DSC thermogram of HEMA-co-AA hydrogels also declared that formulation was 
more stable as compare to individual components. Melting point range of acrylic 
acid was found in range of 60°C to 175 °C with an endothermic peak at 125 °C while 
melting range of hydroxy ethylmethacrylate was found in temperature range of 75 °C 
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to almost 200 °C with an endothermic peak at 178.4 °C. Formulation showed greater 
stability even at high temperature range up to 600 °C. Sindhu et al., (2015) 
conducted same kind of study. Results of his study were same as that of present 
study (Sindhu et al., 2015).  Mary and Nikolaos also worked on HEMA and acrylic 
acid hydrogels. He mentioned that DSC thermogram cleared that thermal stability of 
hydrogel was increased after cross linking so hid results supported results of present 
study (Mary and Nikolaos, 1969). 
5.2.3.2. HPMC-co-AA hydrogels 
For determination of effect of chemical cross linking on the thermal stability of final 
formulation TGA and DSC was performed as given in figures 4.40 and 4.41 
respectively. Thermograms were drawn by scheming percentage residual weight 
against temperature. End of first straight line portion of curve was used to find out 
initial decomposition temperature. HPMC and AA showed less thermal stability as 
compared to grafted copolymer as depicted in figure 4.36. HPMC showed for phase 
of decomposition. First decomposition was noted at 301°C with 10.2% weight loss. 
Second phase was of great decomposition phase as almost 70% weigh loss was 
observed at narrow temperature range of 301 
°
C to 350
 °
C. For acrylic acid almost 
90% weight loss was observed at temperature range of 90
 °
C to 100
 °
C. While 
thermogram of HPMC-co-AA hydrogel showed greater stability as compared to 
basic components. Only 10% weight loss was observed in first phase at 204
 °
C. 
Further 20% weight loss was observed in temperature range of 205
 °
C to 280
 °
C. 25% 
weigh was found to be remaining even at 500
 °
C in case of HPMC-co-AA hydrogel. 
On behalf of these results we can state formulate hydrogel was more thermostable as 
compared to basic ingredients. 
DSC thermogram of HPMC-co AA hydrogel depicted that formulation showed a 
broad exothermic peak transition at temperature range of 225 °C to 550 °C. Acrylic 
acid was thermo degradable as it showed a sharp endothermic peak at 75 °C having 
peak spectrum at temperature range of 35 °C to 100 °C. HPMC was found to be 
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more stable even over temperature of 800 °C. Above data clearly describes that 
formulation is more thermo-degradable than individual ingredient HPMC. 
DSC data of present study was in good agreement with DSC studies conducted 
somewhere else by Patitapabana and Subash in 2012 where they studied thermal 
stability of HPMC-co-AA hydrogel by TGA and DSC. They reported that HPMC 
and AA hydrogel are more thermostable as compared to individual component. 
Grafting g is noted to improve thermal stability of formulation. These results are in 
support with results of present study (Patitapabana and Subash, 2012). Osiris and 
Manal also reported increase thermal stability of HPMC after hydrogel preparation 
which was also in good support with present study (Osiris and Manal, 2012). 
5.2.3.3. HPMC-co-AA-co-HEMA hydrogels 
TGA graphs of HPMC-co-AA-co-HEMA hydrogels described its thermal stability as 
shown in figure 4.42. Cross linked HPMC-co-AA-co-HEMA hydrogels exhibited 
three step degradation starting at 200°C. Only 20% weight loss was observed in 
temperature range of 200°C to 300 °C which showed grafted copolymer was more 
thermostable as compared to individual components i.e. hydroxypropyl methyl 
cellulose, acrylic acid and HEMA. Significant weight loss i.e. 35% was observed at 
temperature range of 350 °C to 450 °C. In comparison AA and HEMA exhibited 
slight two-step decomposition at temperature range of 75 °C to 100 °C and 100 °C to 
175 °C respectively with almost 80% weight loss. This fact clearly showed that 
grafting has greatly improved thermal stability. 
In DSC thermogram of HPMC-co-AA-HEMA hydrogel cleared that formulation 
exhibited a broad exothermic peak transition peak at temperature range of 223 °C to 
545 °C as shown in figure 4.43. Thermal degradability of acrylic acid was showed by 
a sharp endothermic peak at 70 °C. HPMC behaved more stable over temperature of 
900 °C. Melting range of HEMA lied in temperature range of 100 °C to almost 225 
°C with an endothermic peak at 202 °C. Above data exhibited that formulation was 
more thermo-degradable than individual ingredient HPMC and more thermostable as 
compared to AA. 
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Podko also worked with TGA and DSC of various HEMA hydrogels. His work is in 
good support with present study (Podko et al., 2012). Results of study conducted by 
Monica et al. (2014) were also in good agreement with results of present study. 
5.2.3.4. CMC-co-MAA-co-AMPS hydrogels 
CMC-co-MAA-co-AMPS hydrogels were characterized by thermal analysis to find 
out percentage of weight loss of CMC-co-MAA-co-AMPS hydrogel as well as pure 
components. Pure hydrogel has four decomposition curves below 500°C as given in 
figure 4.44. While pure components MAA and AMPS have two distinct degradation 
steps below 15 °C and 375 °C respectively with almost 100% weight loss. This fact 
clearly depicts that thermal stability of hydrogel was increased by grafting as 
compared to pure ingredients. 
Chandra et al., in 2013 conducted same pattern of study in 2013 and reported that 
stability of hydrogel was increased as compared to individual ingredient. His results 
were in support with present study. 
In DSC thermogram AMPS showed a clear sharp endothermic peak at 200°C while 
melting range of hydroxyethylmethacrylate lies in temperature range of 75°C to 
almost 175°C with an endothermic peak at 125.4°C as given in figure 4.45. DSC 
thermogram of CMC displayed a broad exothermic peak transition peak over 
temperature range of 275°C to 335°C. DSC thermogram of formulated hydrogel had 
small endothermic peaks at 200°C and 300°C which was good indicative of cross 
linking as newer peaks justify formation of new bonds. Wang studied same pattern 
of study. Results of his studies of DSC were in good agreement with results of 
present work (Wang et al., 2011).  
5.2.4. XRD Analysis 
All formulations and drug were investigated for amorphous or crystalline nature by 
X-ray diffraction as shown in figure 4.46. In general at low intensities diffraction 
decreased and peaks become broader when angle was increased depicting partial 
crystallinity of substance. Diffractogram of XRD of formulations proved that graft 
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copolymerization enlarges amorphous regions resulting in decreased value of 
percentage crystallinity. Grafting was thought to be basic reason behind amorphous 
nature of hydrogels as grafting of monomer side chain on basic polymer back bone 
imparts amorphous regions to copolymer. Chandra also reported that hydrogel 
formulations did not have any peak on x-ray difractogram giving justification on its 
highly amorphous nature (Chandra et al., 2013). 
Diffractogram of drug Nicorandil showed diffraction at 2θ value about 20°, 22.5°, 
25°, 37.5°, 43.5° and 44.5°. As peak intensity represents crystallinity so values of 
these peaks showed that drug is moderately amorphous as no intense peak was 
found. 
Results of X-ray diffraction studies of Yonghyun were also in good support with 
results of present study. He studied X-ray diffraction patterns copolymeric hydrogel 
and copolymeric-silver nanocomposite. He reported that sharp and intense peaks 
representative of highly crystalline of any substance. According to his study pure 
copolymeric hydrogels did not have any peak because of amorphous nature of 
hydrogel (Yonghyun et al., 2011). Results of present study were well supported by a 
study conducted somewhere else by a researcher named Ray. Results of his x-ray 
studies clearly stated that only crystalline substances show intense peaks at x-ray 
diffractogram while amorphous substance show not any single peak at all ( Ray et 
al., 2010). 
5.2.5. In vitro drug release studies 
5.2.5.1. HEMA-co-AA hydrogels 
Results showed that release of nicorandil from F1 was increased up to 96.09 % by 
highest monomer AA concentration at pH 7.4 because of polymer chain relaxation or 
expansion of polymer network and thus increased water penetration and increased 
water holding capacity shown in table 4.26 and figure 4.47, while drug release 
profile was found to be minimal at acidic pH. Cross linker concentration also 
affected drug release profile. Moreover, increased cross linker concentration in 
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formulation F7 to F9 resulted in decreased drug release ranging from 77.34 % to 
70.99 % at pH 7.4 as shown in table 4.29 and figure 4.48. Mechanism behind this 
kind release can be batter explained by swelling of polymer ionic network. At low 
pH polymer ionizes resulting in formation of anionic centers which ultimately leads 
to domination of compact polymer interaction leading to compact network. This over 
all mechanism offered hindrance to water penetration resulting in decrease water 
holding capacity and thus ultimately lessen drug release. At lower pH 1.2, 
approximately no noticeable difference in release profile was observed. 
As cross linker concentration was increased ionization of carboxylic group and 
deprotonation of take place leading to creation of new cross linked sections by 
hydrogen bonding. These electrostatic interaction forces between functional groups 
caused compact arrangement and thus allow less chain relaxation leading to low 
swelling and release profile (Suseem et al., 2013). Sindhu et al. (2015) also 
conducted in vitro release studies of HEMA-co-AA and results of his studies were in 
good agreement with present study. 
5.2.5.2. HPMC-co-AA hydrogels 
Drug release basically depends upon to swelling mechanism of hydrogels which 
ultimately depends upon chemical architecture of hydrogels. All formulations of 
HPMC-co-AA hydrogels (F10-F18) were subjected to in vitro release study in both 
acidic and basic media at pH 1.2 and pH 7.4 to simulate conditions of gastric fluid 
(SGF) and intestinal fluid (SIF), respectively. Percentage drug release in acidic 
media at pH 1.2 was found to be less i.e. in range of 8.742 % to 17.239 % for 
varying polymer, monomer or cross linker concentrations. Reason for less drug 
release in acidic media can be better explained by less hydrogel swelling in acidic 
media as anionic regions form more compact arrangement result in low polymer 
chain relaxation or less water holding capacity thus ultimately leading to less drug 
release. Drug release at basic media was increased as function of time for different 
polymer, monomer or cross linker concentration ranging from 30.061 % to 92.878 % 
due to polymer chain relaxation increased leading to more water penetration and 
release. Drug release was noticed to increase with increasing concentration of acrylic 
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acid and hydroxypropyl methyl cellulose from 75.78 % to 84.93% and 89.817 % to 
92.878 % as shown in table 4.31 and 4.30 respectively as depicted by formulations 
F1 to F15. In formulations F16 to F18 drug release was also decreased with 
increasing cross linker concentration from 66.63 % to 56.26 % as shown in table 
4.32. Reason for less drug release by increasing cross linker concentration was 
increased crosslink density in polymeric structure.  Same pattern of study was 
conducted by Sindhu et al. (2015)  where he reported that drug release was greater in 
basic media s compare to acidic media, moreover drug release was decreased with 
increasing cross linker concentration while it was increased with increasing acrylic 
acid concentration. So his results supported well the results of present study. 
Kinetic evaluation of all formulations was also performed by applying various 
kinetic models. Selection of the best fit method depends upon value of regression 
coefficient (r). The model that best fits release data was evaluated by value of 
regression coefficient (r). As value of regression coefficient (r) approaches more 
close to 1 model is considered best fit for drug release mechanism for that 
formulation. Values of regression coefficient (r) for varying concentration of 
components range from 0.939 to 0.9756 for zero order and from 0.9522 to 0.9826 for 
Higuchi model. Values of regression co-efficient (r) were higher for zero order and 
Higuchi model than Corsmayer-Peppas model or first order release model. These 
values of regression coefficient (r) in Higuchi model designated that drug release 
followed diffusion mechanism as graph of drug released versus square root of time is 
linear suggesting diffusion controlled drug release. The value of release exponent „n‟ 
for different polymer/monomer concentrations were also calculated which fall 
between 0.5 and 1.0 suggesting non-Fickian or anomalous diffusion mechanism. 
Same pattern of studies were conducted by Nazar and Umbreen. Results of their 
studies are in very well agrrement with results of present study. They also found that 
drug release from HPMC-co-AA hydrogels followed non-fickian diffusion 
controlled mechanism (Nazar and Umbreen, 2014).  Sindhu another researcher also 
studied drug release mechanism of hydrogels of AA and he reported that release 
followed non-fickian diffusion controlled mechanism, a supportive reference to 
results of present study (Sindhu et al., 2015). 
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5.2.5.3. HPMC-co-AA-co-HEMA hydrogels 
In vitro drug release studies were conducted to find out percentage drug release and 
drug release mechanism. Analysis of in vitro release data was done by employing 
various kinetic models like Zero order release model, first order release model, 
Higuchi model and Korsmayer-Peppas model for better understanding of release 
mechanism. Value of regression coefficient (r) was used to decide upon best fit 
model for drug release. 
Drug release studies were carried out at acidic pH (i.e. pH 1.2) and basic pH (i.e. 
pH7.4). Drug release was found to be less at acidic pH as compared to basic pH 
following same mechanism as that of percent swelling. Percent drug release was 
found to be varied with varying concentrations of polymer or monomer. Percent drug 
release was decreased from 67.46 % to 59.64 % in formulations F19 to F21 by 
increasing concentration of HEMA from 0.5 to 1.5 (%w/w) as a result of more 
compact structure formation with less porosity as shown in table 4.34 and figure 
4.53. Percent release was increased from 69.29 % to 73.38 % and 75.80 % to 82.82 
% in formulations F22 to F27 with increasing concentration of HPMC and AA from 
5 to10 and 10 to 15 (%w/w) respectively as more polymer chain relaxation occur 
leading to more water absorbing and retention capacities as shown in tables 4.36 and 
4.35 and figures 4.55 and 4.54. 
These formulations were also subjected to kinetic evaluation by applying various 
kinetic models. Best fit method was decided upon value of regression coefficient (r) 
keeping in view the fact that as value of regression coefficient (r) approaches more 
close to 1 model is thought to be the best fit for drug release mechanism for that 
formulation. Values of regression coefficient (r) lie in range of 0.9673 to 0.988 for 
Higuchi model and from 0.949 to 0.9885 for Korsmayer-Peppas model and plot of 
drug released versus square root of time was linear justifying at diffusion controlled 
drug release. Value of release exponent “n” for increasing concentration of HEMA 
and crosslinker MBA lie in range of 0.3296 to 0.4186 and 0.2727 to 0.3352 
respectively indicating that drug release followed fickian diffusion mechanism as 
given in table 4.34. Value of release exponent “n” for acrylic acid was greater than 
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0.5 indicating that that drug release followed non-Fickian or anomalous mechanism. 
Sindhu et al., conducted same pattern of studies. Results of his studies were in good 
support to results of present studies as he stated that percent drug relase was 
increased by increasing concentration of acrylic acid and also release of acrylic acid 
hydrogels followed non-fickian diffusion controlled mechanism (Sindhu et al., 
2015). In vitro drug release profile HPMC and acrylic acid hydrogels was studied by 
Nazar and Umbreen with supportive results to present studies (Nazar and Umbreen, 
2014).  
5.2.5.4. CMC-co-MAA-co-AMPS hydrogels 
In vitro release profile of CMC-co-MAA-co-AMPS hydrogels with varying amount 
of MAA and AMPS in buffer solutions of pH 1.2 and pH 7.4 were studied as 
function of time. All formulations of CMC-co-MAA-co-AMPS hydrogels (F31-F42) 
were subjected to in vitro release study in both acidic and basic media at pH 1.2 and 
pH 7.4 to simulate conditions of gastric fluid (SGF) and intestinal fluid (SIF) 
respectively. Over all drug release was found greater at pH 7.4 as compared to pH 
1.2. Drug release basically follows same mechanism as that of swelling of hydrogels. 
Percentage drug release in acidic media at pH 1.2 was found to be less for varying 
polymer, monomer or cross linker concentrations. Reason for less drug release in 
acidic media can be better understand by less hydrogel swelling in acidic media as 
anionic regions form more compact arrangement leading to low polymer chain 
relaxation or less water holding capacity thus ultimately resulting in less drug 
release. Drug release at basic media was increased as function of time due to 
increased polymer chain relaxation leading to more water penetration and more drug 
release. 
It was found that cumulative % drug release gradually increased with increasing 
concentration of AMPS from 88.68 % to 94.76 % as given in table 4.40. Introduction 
of increasing concentration of monomer methacrylic acid increased cross linking 
density and increased porosity resulted in more water absorption leading to more 
drug release. More over increased concentration of AMPS causes repulsion among 
sulfonate groups resulting in improved hydrophilicity leading to increase in swelling 
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ratio and ultimate increased percent drug release (Yizhe et al., 2013). Cumulative % 
drug release was noted to decrease gradually with increasing MAA concentration 
from 57.441 % to 64.683 % given in table 4.39, as hydrophobic methyl group in 
methacrylic acid results in decreased water penetration. Moreover creation of 
compact network structure at higher content of MAA led to decreased swelling and 
ultimately decreased cumulative % drug release. Same kind of study was conducted 
by Das and Nirada with results that were supportive to results of in vitro release of 
present study (Das and Nirada, 2015). 
5.2.6. Pharmacokinetic Evaluation 
Desired drug delivery system with controlled release profile was achieved by 
formulating hydrogels of various components that delivered therapeutic agent at a 
desired rate for a specified period of time. Nicorandil was used as model drug to 
evaluate prepared hydrogels systems. For conventional immediate release dosage 
forms reported Cmax of nicorandil was 300 ng/mL approximately in humans for a 
dose of 20 mg b.i.d. Cmax is attained rapidly within 30 min after administration for 
immediate release dosage forms. Nicorandil show extensive metabolism and kidney 
is major route of elimination (Frydman, 1992). 
Various pharmacokinetic parameters like Cmax (ng/mL), Tmax  (Hrs), AUCtot 
(ng.h/mL), AUMCtot (ng.h
2
/mL), MRT (Hrs), Ke (Hr
-1
) and t1/2 el (Hrs) of model drug 
nicorandil were determined for HPMC-co-AA, HEMA-co-AA, HPMC-co-AA-co-
HEMA hydrogels and oral solution after administering  15 mg. 
From pharmacokinetic data obtained it was found that mean plasma concentrations 
were 60.60845 ± 2.816851 ng/mL, 108.3883 ± 2.338 ng/mL, 92.32212 ± 3.667 
ng/mL and 117.6613 ± 3.093 ng/mL for HEMA-co-AA (F1), HPMC-co-AA (F12), 
HPMC-co-AA-co-HEMA(F24) hydrogels and oral solution respectively. By 
comparison of plasma concentrations of these formulations it was noticed that 
difference between Cmax of these was highly significant as p value is less than 0.05. 
Cmax of HPMC-co-AA hydrogel was observed as 108.3883 ± 2.338 ng/mL which 
was found greater than other two combinations. Moreover, this value was found to 
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be closer to Cmax of pure solution even with desired controlled release profile. The 
reason behind this improved pharmacokinetic profile of HPMC-co-AA hydrogel was 
that have more cross linking density with greater porosity. It also had greater water 
retention and controlled release capacities (Sindhu et al., 2015). 
From pharmacokinetic data it was observed that the time taken to reach peak plasma 
concentration 𝑇max were 3 ± 0.365148 hrs, 3 ± 0.258 hrs, 3 ± 0.365 hrs and 1 ± 
0.017 hrs for HEMA-co-AA, HPMC-co-AA, HPMC-co-AA-co-HEMA hydrogels 
and oral solution respectively. Similarly mean elimination half-life 𝑡1/2 for HEMA-
co-AA, HPMC-co-AA, HPMC-co-AA-co-HEMA hydrogels and oral solution were 
0.087807 ± 0.003324 hr
-1
, 2.083081 ± 1.996 hr
-1
, 0.084933 ± 0.002 hr
-1 
and 0.487692 
± 0.009 hr
-1
, respectively. The mean AUCtot values were 1085.876 ± 38.02274 
(ng.h/mL), 2101.51 ± 40.014 (ng.h/mL), 1791.957 ± 29.630 (ng.h/mL) and 271.867 
± 7.546 (ng.h/mL) for HEMA-co-AA, HPMC-co-AA, HPMC-co-AA-co-HEMA 
hydrogels and oral solution, respectively. 
So on behalf of these stated results HPMC-co-AA hydrogels considered the best than 
other two formulations i.e. HEMA-co-AA and HPMC-co-AA-co-HEMA as it 
provided a prolonged and controlled in vivo delivery of model drug. 
Same pattern of in vivo studies were conducted by researchers named Hemant and 
Shivakumar on controlled release hydrogel formulations. He also made comparison 
of two different hydrogel formulations and found that one gave more sustained 
release profile so gave better results (Hemant and Shivakumar, 2012). 
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6.0 Conclusion 
The study was designed to develop an oral controlled release system to deliver drug at 
predetermined and reproducible rate over a prolong period of time. In this regard different 
crossed linked polymeric networks were designed and their capability of delivering drug at 
predefined rate over a period sufficient for once daily dose was evaluated. 
From this study following main conclusions were drawn: 
Free radical solution polymerization technique was used to prepare pH sensitive crosslink 
polymeric networks using different polymer, monomer and cross linker concentrations. 
Their responsiveness to buffer solutions of different pH i.e. pH 1.2, pH 5.8 and pH 7.4 was 
evaluated. Cross linking structure of all formulations were confirmed by FTIR, XRD and 
SEM. In-vitro drug release and in-vivo evaluation of the best formulations were also 
performed. 
a) HEMA-co-AA hydrogels were prepared by using MBA as cross linker. HEMA-co-
AA hydrogels showed good pH responsiveness as they showed maximum swelling at 
alkaline pH i.e pH 7.4 as compared to acidic pH i.e. pH 1.2. This property was used 
as a key factor to design sustained release drug delivery system that deliver drug in 
gastrointestinal tract in response of different pH environment. Among combination 
HEMA-co-AA hydrogels F1 was found to be the best as it showed maximum 
cumulative drug release i.e. 92.878% at pH 7.4. Desired release profile was noticed 
to be greatly affected by varying concentrations of polymer, monomer or cross 
linker.  
b) HPMC-co-AA hydrogels had good pH sensitivity as these showed better and 
maximum swelling at pH 7.4 and minimum swelling at pH 1.2. Among this 
combination F1 depicted better desired properties regarding pH sensitivity, greater 
swelling ratio and desired sustained drug release profile etc. Swelling ratio, gel 
fraction and cumulative percent drug release was decreased with increasing cross 
linker concentration i.e. MBA while these parameters were noted to be increased 
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with increasing AA and HPMC concentration. Desired sustained release profile 
could be attained by adjusting polymer, monomer and cross linker ratio. 
c) HPMC-co-AA-co-HEMA hydrogels were developed by free radical polymerization 
technique using MBA as cross linker. Formulations were subjected to swelling (at 
pH 1.2, pH 5.8 and pH 7.4) and in-vitro drug release studies (at pH 1.2 and pH 7.4). 
Swelling and percent drug release was noted to be decreased with increasing MBA 
and HEMA concentration while it was noted to be increased with increasing AA and 
HPMC concentration. More over swelling ratio and percent drug release was also 
increased gradually with increasing pH from acidic to alkaline i.e. pH 1.2 to pH 7.4. 
All formulations were noted to be stable and intact during swelling and in-vitro drug 
release studies. Among this combination F24 was found to be the best as it gave best 
results for swelling and cumulative percent drug release i.e. 82.820%. It also showed 
better pharmacokinetic profile as well. 
d) Developed CMC-co-MAA-co-AMPS showed less pH sensitivity as compared to all 
other three combinations as difference in swelling ratio and cumulative percent drug 
release at acidic and alkaline pH was negligible. Formulations were noted to be 
unstable and broken during swelling and in-vitro drug release studies. 
HEMA-co-AA (F1), HPMC-co-AA (F12) and HPMC-co-AA-co-HEMA (F24) hydrogels 
were subjected to in vivo evaluation using animal model rabbits as all these formulation give 
sustained release profile in in vitro studies. After oral administration of these formulations 
Cmax was noted to be 60.608 ± 2.816 ng/mL, 108.388 ± 2.338 ng/mL and 92.322 ± 3.667 
ng/mL respectively. MRT was noted to be 12.790 ± 0.310 hrs, 13.1786 ± 0.468 hrs and 
13.600 ± 0.245 hrs for HEMA-co-AA (F1), HPMC-co-AA (F12) and HPMC-co-AA-co-
HEMA (F24) hydrogels. On behalf of these in-vivo findings it can be concluded that these 
cross linked polymeric networks can be used as good sustain release drug delivery system. 
Overall it could be concluded that among formulated four different cross linked polymeric 
networks, HPMC-co-AA (F12) hydrogel could be regarded as superior or the best one as it 
gave better in-vitro in-vivo release profile and thus proven suitable for desired sustained 
release effect at predetermined rate over prolong period of time. However, these findings are 
preliminary and studies can proceed to further investigations. 
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7.0 Future Suggestions/Recommendations 
1. In this dissertation FTIR studies were performed on individual ingredients and on 
prepared formulations to check chemical interaction. In future these studies can further 
be extended for evaluation of drug and drug loaded formulations to check drug and 
excipients compatibility. 
2. In this work for surface morphological studies Scanning Electron Microscopy (SEM) 
was used. In future more advanced technique for study of structural morphology 
“Transition Electron Microscopy” (TEM) can also be included for clear structural 
elucidations. 
3. Drug loading was checked by gravimetric analysis after loading through absorption 
method. It could also be verified by extraction method or by percent content analysis. 
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